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ABSTRACT
Ovarian cancer (OC) is characterized by late stage discovery and low
survivability. However, when diagnosed early (Stages I or II) the 5-year survival rate is
92% up from 29%.5 The extreme dichotomy in survivability is what makes OC a prime
candidate for early diagnosis techniques. Exosomes, a subtype of extracellular vesicles,
may bridge the gap between early and late diagnosis, but are lacking consistent isolation
and detection technologies. Here poly(ethylene terephthalate) (PET) capillary channeled
polymer (C-CP) fibers employing an HIC protocol are investigated as a novel exosome
isolation method and a quick, inexpensive, and easy-to-use platform for OC diagnosis.
The cell model system, immunoaffinity protocols, and biomarker identification tools
developed here will aid in the refinement of a selective PET C-CP exosome isolation.
The exosome isolation and diagnostic technique developed as a result of these
investigations will allow for earlier and routine diagnosis of OC and save many women
from one of the deadliest cancers.

ii

DEDICATION
I would like to dedicate this dissertation to my parents, sister, family, and friends
who kept me motivated along this journey. In particular, this dissertation is dedicated to
the memory of my aunt Doris Logan who was impassioned by biology and taken from us
too soon by ovarian cancer.

iii

ACKNOWLEDGMENTS
First and foremost, I would like to thank my advisor, Dr. Terri Bruce, for guiding
me through this project, pushing me to produce high quality material, and providing
motivation and emotional support along the way. Your brilliant mind and crazy ideas are
what pushed this project forward and are what got me to where I am now.
I would like to thank my committee members, Dr. R Kenneth Marcus, Dr. Jeoung
Soo Lee, and Dr. Brian W. Booth for allowing me the privilege to present this research
and for guiding me during this project.
Thank you, Rhonda Powell, for being my unofficial second advisor. I would not
have survived graduate school without your guidance and expertise in the lab. You
deserve more credit than you’re officially given and I appreciate the hard work,
dedication, and many laughs you bring to the lab every day. Additional thanks to all the
interns at the Clemson Light Imaging Facility for helping me in the lab and always
bringing a positive attitude to our group.
Thank you, Dr. Larry Puls, Lorie Allen, and Tina Pettry of Prisma Health, for
providing guidance and supplying patient samples in the continued partnership with
Clemson University. Additional thanks to Dr. Brian Dean and Dr. Billy Bridges for
providing analysis guidance on this research project.

iv

Thank you to all my colleagues, Clay Morton, Sisi Huang, Lei Wang, Kaylan
Kelsey, and Paritra Mandal, that have worked alongside me on this project. I appreciate
every one of you and realize I could not have completed this journey without all of you.
Thank you to my parents, sister, and family who have supported me along this
journey. Thank you for giving me the confidence to complete this project and the
constant support during the process.
I would also like to thank Alissa Williams for her continual guidance and support.
You are a truly amazing friend that has been willing help me at a moment’s notice. A
special thanks to Justin Whitaker for being true to Atlanta, reviving and motivating me
during this project, and for always listening to Alissa and me, even if you didn’t
understand what we were talking about.
And last, but not least, I would like to thank the Gibbs Foundation for Cancer
Research, The Eppley Foundation for Research, the National Science Foundation and
Prisma health for continued funding and partnerships.

v

TABLE OF CONTENTS

Page
TITLE PAGE ................................................................................................ i
ABSTRACT ................................................................................................. ii
DEDICATION ............................................................................................ iii
ACKNOWLEDGMENTS .......................................................................... iv
LIST OF TABLES ...................................................................................... ix
LIST OF FIGURES ..................................................................................... x
LIST OF ABBREVIATIONS................................................................... xiv
CHAPTER
I.

LITERATURE REVIEW ............................................................. 1
Introduction ........................................................................................ 1
Exosome Biogenesis, Sorting, and Release ....................................... 5
Division of Extracellular Vesicles ..................................................... 9
Physiological Roles of Exosomes .................................................... 11
Exosome Medical Applications ....................................................... 16
Exosome Characterization and Biochemical Profile ....................... 22
Exosome Isolation Techniques ........................................................ 25
Exosome Loading Techniques ......................................................... 35
Liquid Chromatography ................................................................... 37
Ovarian Cancer Detection, Diagnosis, and Treatment..................... 41
Summary .......................................................................................... 48
References ........................................................................................ 50

II.

EXOSOME ISOLATION AND PURIFICATION VIA
HYDROPHOBIC INTERACTION CHROMATOGRAPHY
USING A POLYESTER, CAPILLARY-CHANNELED
POLYMER FIBER PHASE ....................................................... 67
vi

Table of Contents (Continued)

Page

Abstract ............................................................................................ 67
Introduction ...................................................................................... 69
Materials and Methods ..................................................................... 73
Results and Discussion .................................................................... 80
Conclusions ...................................................................................... 97
References ........................................................................................ 99

III.

A MODEL SYSTEM TO INVESTIGATE SELECTIVE
EXTRACELLULAR VESICLE CAPTURE ........................... 103
Abstract .......................................................................................... 103
Introduction .................................................................................... 105
Materials and Methods ................................................................... 111
Results ............................................................................................ 123
Discussion ...................................................................................... 152
References ...................................................................................... 168

IV.

POTENTIAL IMPACTS OF ISOLATION METHOD
AND SAMPLE SOURCE ON SMALL
EXTRACELLULAR VESICLE MORPHOLOGY AND
BIOMARKER PROFILING .................................................... 176
Abstract .......................................................................................... 176
Introduction .................................................................................... 177
Materials and Methods ................................................................... 183
Results ............................................................................................ 190
Discussion ...................................................................................... 209
References ...................................................................................... 224

V.

CONCLUSIONS ...................................................................... 233

vii

Table of Contents (Continued)

Page

APPENDICES ......................................................................................... 235
A. EXTRACELLULAR VESICLE CHARACTERIZATION
IN BUFFERS ........................................................................... 236
Materials and Methods ................................................................... 236
Results ............................................................................................ 238
Discussion ...................................................................................... 240
References ...................................................................................... 244

B.

EXOSOME UPTAKE EXPERIMENT ................................... 246
Materials and Methods ................................................................... 246
Results ............................................................................................ 249
Discussion ...................................................................................... 250

C.

EXTRACELLULAR VESICLE DRUG DELIVERY
PROPOSAL.............................................................................. 252
Hypothesis and Specific Aims ....................................................... 252
Research Strategy........................................................................... 255
Conclusion ..................................................................................... 281
Timeline ......................................................................................... 282
Vertebrate Animals ........................................................................ 283
Biohazards...................................................................................... 285
Resources and Environment .......................................................... 286
References ...................................................................................... 287

D. CURRICULUM VITAE .......................................................... 293
E.

LETTER OF PERMISSION .................................................... 294

viii

LIST OF TABLES
Table

Page

1.1

Potential exosome miRNA and protein markers for different types
of ovarian, lung, and breast cancer .................................................................... 25

1.2

A brief summary of extracellular vesicle separation strategies ......................... 34

2.1

Comparison of EV size population characteristics for the different
isolation procedures as determined by NTA ...................................................... 87

3.1

Description and catalog number of antibodies used in western blot
and immuno-affinity blot capture experiments. ............................................... 122

3.2

Relative fluorescence intensities (a.u.) of captured IHOE-CD81GFP and SKOV-3-CD9-RFP sEVS using multichannel widefield
fluorescence imaging with GFP filter set (450-490 nm
excitation/500-550 nm detection) and mCherry filter set (540-580
nm excitation/592-667 nm detection) .............................................................. 151

4.1

Average and maximum volumetric flow rates of C-CP film
wicking. ............................................................................................................ 194

4.2

Differentially expressed miRNAs of interest from benign (n=2) vs
cancerous (n=2) urine-derived sEVs (Pilot Study). ......................................... 202

4.3

Differentially expressed miRNAs of interest from benign (n=2) vs
cancerous (n=2) cervical mucus-derived sEVs (Pilot Study). ......................... 204

4.4

Differentially expressed miRNAs of interest from benign vs
cancerous cervical mucus-derived sEVs .......................................................... 208

ix

LIST OF FIGURES
Figure

Page

1.1

Diagram of exosome and microvesicle biogenesis .............................................. 6

1.2

Possible mechanisms of extracellular vesicle uptake in the
recipient cell ......................................................................................................... 8

1.3

Diagram of Isopycnic and Rate zonal density centrifugation ............................ 28

1.4

Demonstration of hydrophobic interaction chromatography
separation theory using a salt concentration gradient ........................................ 40

1.5

Various roles of exosomes released from primary cancer cells ......................... 45

2.1

Comparison of EV size population characteristics for the different
isolation procedures as determined by NTA ...................................................... 82

2.2

Comparison of NTA-determined particle population characteristics
following the various exosome isolation methodologies ................................... 86

2.3

Representative nanoparticle tracking analysis (NTA) size
distributions........................................................................................................ 89

2.4

TEM images of exosomes immobilized on copper grids................................... 90

2.5

SEM images of exosomes immobilized on PET C-CP fibers............................ 91

2.6

PET C-CP fiber HIC chromatograms of simulated urine matrix
spiked at 0.1 mg ml-1 concentration of model proteins and 50:50
mixture of simulated urine and DC-isolated exosomes ..................................... 94

2.7

Analytical response curves for separations of mixtures of 100 μL
of the test matrices (simulated urine and HL5 media) and the
designated volumes of DC-isolated exosomes .................................................. 96

x

List of Figures (Continued)
Figure

Page

3.1

Diagram of sEV immunoaffinity blot capture experimental setup .................. 118

3.2

Confocal Fluorescence and DIC Images of transduced cells fixed
and stained with DAPI ..................................................................................... 124

3.3

Confocal Fluorescence and DIC Images of transduced cells fixed
and stained with DAPI ..................................................................................... 126

3.4

Transmission electron microscopy of small extracellular vesicles .................. 127

3.5

GFP and RFP western blots of IHOE-CD81-GFP sEVs and cell
lysate and SKOV-3-CD9-RFP sEVs and cell lysate........................................ 129

3.6

Fluorescence images of GFP and RFP tagged vesicles dotted on
nitrocellulose membrane .................................................................................. 131

3.7

Relative fluorescence intensity per μg of protein of sEVs and cell
lysate imaged on nitrocellulose membranes .................................................... 133

3.8

Relative fluorescence intensity per μg of suspended protein ........................... 134

3.9

Scanning electron microscopy of small extracellular vesicles on
PET C-CP fibers .............................................................................................. 135

3.10

Super-resolution confocal fluorescence microscopy of IHOECD81-GFP and SKOV-3-CD9-RFP-expressing small extracellular
vesicles on PET C-CP fibers ............................................................................ 137

3.11

Super-resolution confocal fluorescence microscopy of IHOECD81-GFP and SKOV-3-CD9-RFP small extracellular vesicles on
PET C-CP fibers .............................................................................................. 139

3.12

Immunoaffinity blot capture using rabbit anti-tGFP and rabbit antiRFP antibodies ................................................................................................. 142

xi

List of Figures (Continued)
Figure

Page

3.13

IHOE-CD81-GFP sEVs immuno-captured on a nitrocellulose
membrane and imaged with multichannel microscopy ................................... 144

3.14

Normalized relative fluorescence intensities of IHOE-CD81-GFP
immuno-captured on a nitrocellulose membrane and imaged with
multichannel microscopy ................................................................................. 145

3.15

SKOV-3-CD9-RFP sEVs immuno-captured on a nitrocellulose
membrane and imaged with multichannel microscopy ................................... 146

3.16

Normalized relative fluorescence intensities of SKOV-3-CD9-RFP
sEVs immuno-captured on a nitrocellulose membrane and imaged
with multichannel microscopy ......................................................................... 147

3.17

IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs immuno-captured
on a nitrocellulose membrane and imaged with multichannel
widefield fluorescence microscopy.................................................................. 149

3.18

Normalized relative fluorescence intensities of mixed IHOECD81-GFP and SKOV-3-CD9-RFP sEVs captured by ovarian
cancer EV marker antibodies ........................................................................... 150

4.1

Scanning electron microscopy of C-CP films after wicking of
various media ................................................................................................... 191

4.2

Average volumetric flow rates of C-CP film wicking ..................................... 193

4.3

SEM of C-CP film cross-section...................................................................... 194

4.4

Patient urine C-CP fiber-based film wicking velocity and
stereoscopic image ........................................................................................... 195

4.5

Transmission electron microscopy of small extracellular vesicles
derived from urine and cervical mucus via UC or C-CP fiber HIC................. 197

xii

List of Figures (Continued)
Figure

Page

4.6

Principal Component Analysis (PCA) plot of benign and cancerous
cervical mucus- or urine-derived sEV miRNA expression (Pilot
Study) ............................................................................................................... 199

4.7

Volcano plot of miRNA differential expression of benign vs
cancerous urine-derived sEVs (Pilot Study) .................................................... 201

4.8

Volcano plot of miRNA differential expression of benign vs
cancerous cervical mucus-derived sEVs (Pilot Study) .................................... 203

4.9

Principal Component Analysis (PCA) plot of benign and cancerous
CM-derived sEV miRNA expression .............................................................. 205

4.10

Volcano plot of miRNA differential expression of benign vs
cancerous cervical mucus-derived sEVs.......................................................... 207

4.11

Re-clustering of cervical mucus miRNA expression data ............................... 208

A1

Scanning electron microscopy of Caov-3 small extracellular
vesicles isolated by UC and diluted in various buffers .................................... 239

B1

Exosome uptake experiment ............................................................................ 249

C1

Average exosome concentration and particle size distribution
measured by NTA. ........................................................................................... 263

C2

SEM and Fluorescent images of extracellular vesicles adhered to
C-CP fiber surfaces .......................................................................................... 264

xiii

LIST OF ABBREVIATIONS
OC

ovarian cancer

EV

extracellular vesicle

sEV

small extracellular vesicle

lEV

larger extracellular vesicle

PET

poly(ethylene terephthalate)

C-CP

capillary-channeled polymer

HIC

hydrophobic interaction chromatography

DNA

deoxyribonucleic acid

RNA

ribonucleic acid

GFP

green fluorescence protein

tGFP

turbo green fluorescence protein

copGFP

copepoda green fluorescence protein

RFP

red fluorescence protein

miRNA

micro ribonucleic acid

siRNA

small interfering ribonucleic acid

mRNA

messenger ribonucleic acid

MVB

multivesicular body

xiv

List of Abbreviations (Continued)

MVE

multivesicular endosome

ILV

intraluminal vesicle

ESCRT

endosomal sorting protein complexes required for transport

TSG101

tumor susceptibility gene 101

ALIX

programmed cell death 6-interacting protein

MHC

major histocompatibility complex

MSC

mesenchymal stem cell

ADSC

adipose tissue-derived stem cell

EpCAM

epithelial cell adhesion molecule

L1CAM

L1 cell adhesion molecule

EGFR

epidermal growth factor receptor

HER2

human epidermal growth factor receptor 2

CA-125

cancer antigen 125

CD

cluster of differentiation

DDS

drug delivery system

RVG

rabies-virus glycoprotein

IPSC

induced pluripotent stem cell
xv

List of Abbreviations (Continued)

EMT

epithelial-mesenchymal transition

MSA

multiple system atrophy

ALS

amyotrophic lateral sclerosis

MS

multiple sclerosis

ISEV

international society of extracellular vesicles

NTA

nanoparticle tracking analysis

DLS

dynamic light scattering

TEM

transmission electron microscopy

SEM

scanning electron microscopy

AFM

atomic force microscopy

STED

stimulated emission depletion

PALM

photoactivated localization microscopy

ELISA

enzyme-linked immunosorbent assay

FACS

flow cytometry

UC

ultracentrifugation

UF

ultrafiltration

SEC

size exclusion chromatography
xvi

List of Abbreviations (Continued)

PEG

polyethylene glycol

EXPLORS

exosomes for protein loading via optically reversible protein-protein
interaction

LC

liquid chromatography

HPLC

high performance liquid chromatography

VEGF

vascular endothelial growth factor

PARP

poly(adenosine diphosphate ribose) polymerase

ECM

extracellular matrix

IHOE

immortalized human ovarian epithelial

BSA

bovine serum albumin

Chimo

α-chymotrypsinogen A

CRM

certified reference material

DC

differential centrifugation

HMDS

hexamethyldisilazane

IMAC

immobilized metal affinity chromatography

RP

reversed-phase

LYSO

lysozyme

xvii

List of Abbreviations (Continued)

Myo

myoglobin

Ribo

ribonuclease A

SPE

solid phase extraction

SPR

surface plasmon resonance

PBS

phosphate buffered saline

UV

ultraviolet

MALS

multi-angle light scatter

CLDN3

claudin 3

CLDN4

claudin 4

PCNA

proliferating cell nuclear antigen

TGF-β1

transforming growth factor - β1

MAGE3/6

melanoma antigen gene 3/6

FASN

fatty acid synthase

ERBB2

receptor tyrosine-protein kinase

APOE

apolipoprotein E

DI

deionized

RIPA

radioimmunoprecipitation assay
xviii

List of Abbreviations (Continued)

PVDF

polyvinylidene difluoride

TBS

tris buffered saline

PEEK

polyether ether ketone

FE-SEM

field emission scanning electron microscopy

DAPI

4',6-Diamidino-2-Phenylindole, Dihydrochloride

DIC

differential interference contrast

CL

cell lysate

MOI

multiplicity of infection

CM

cervical mucus

THP

Tamm–Horsfall protein

EDTA

ethylenediaminetetraacetic acid

ACN

acetonitrile

STD EXO

standard exosome

PCA

principal component analysis

TMM

trimmed mean of M-values

CPM

counts per million

FC

fold change
xix

List of Abbreviations (Continued)

GMP

good manufacturing practices

BRCA

breast cancer gene

xx

CHAPTER 1
LITERATURE REVIEW
Introduction
Cell signaling is an encompassing term that covers a variety of complex processes
in which biological systems, collections of cells, and individual cells communicate
information, directives, and functions. Most methods of cellular communication involve
transmission of soluble molecules, neurotransmitters, hormones, or ligands followed by
signal reception, signal transduction, and cellular response. However, more recently,
exosomes have emerged as an accompanying and complex means of cell signaling.6
Exosomes are a class of lipid bilayer membrane vesicles, approximately 30-150 nm in
diameter, that play a variety of roles in autocrine and paracrine signaling. Prior to
investigation into exosomes’ role in cellular communication, the vesicles were assumed
to play a role in dissemination and disposal of intracellular waste.1, 7
Over the last several years, exosomes have generated immense excitement within
the biotech and scientific communities. As such, there has been an explosion of research,
with exponential growth in the number of articles published over the last 10 years.
Remarkably, exosomes may be involved in a variety of processes including stem cell
renewal, cancer metastasis, inflammation, coagulation, and chemotaxis.6-12 As more
information about the complex role of exosomes is discovered, further potential medical
and research applications are being examined. Exosome applications may include
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biomarker disease diagnostics, drug delivery, gene therapy, cancer therapy, and tissue
regeneration.1, 7, 10, 13-15
Exosomes contain transmembrane, cytosolic, intracellular proteins, and several
types of RNA that may be used as biomarkers for cancers and various disease states.13, 1618

Furthermore, since exosomes are derived directly from cells, there is little immune

response associated with inserting autologous exosomes back into the same human
system.19-22 Remarkably, Alvarez et al.23 have been able to manipulate the lipid bilayer
membrane content of exosomes to include a peptide that specifically targets neurons,
microglia, and oligodendrocytes in the brain. The versatility and applications of
exosomes seem endless and will surely impact the field of medicine in the future. Their
potential for disease diagnostics could alone eliminate the need for biopsies and more
invasive procedures. Simply put, with exosome biomarkers, a urine, blood, or
cerebrospinal sample may be used for early detection of diseases.
Despite the emerging popularity of exosome research, very little is known about
what happens to an exosome once it reaches and enters a target cell. There is an extensive
understanding of how an exosome is manufactured and released in the original cell, but
the mechanisms of transport in the target cell still remain in the dark.24 In the original
cell, exosomes do not simply bud off from the plasma membrane. In the 1980s, Harding
et al.25 and Pan et al.26 revealed a slightly more complex mechanism of exosome
formation and secretion. They showed that exosomes are formed by inward budding of
intracellular endosomes. The intracellular endosomes containing the exosomes then fuse
with the plasma membrane, thus releasing the exosomes outside of the cell. There are a
2

number of theorized mechanisms for exosome uptake, transport, and dissemination into
the target cell, none of which have gained widespread backing. In particular,
understanding of these mechanisms is crucial for developing the proper drugs for
exosome loading, determining how to manipulate exosome drug vector targeting
properly, and increasing the efficacy of loaded drugs. For instance, if the exosomes were
to follow the endocytic pathway and eventually come in contact with a lysosome, the
loaded drug could become deactivated or degraded. Greater understanding of the
biochemical makeup, biogenesis, transport, uptake, and dissemination mechanisms will
enhance our ability to capitalize on the natural properties of exosomes.
One of the largest problems preventing exosome technology from advancing into
the clinical setting is the lack of a quick, efficient, and reliable exosome isolation method.
Current exosome isolation techniques can be crude, often producing small yields and
damaging the exosomes. Before any potential applications of exosomes can be realized,
we need to learn how to better isolate exosomes. Furthermore, current methods of
studying exosomes can be expensive due to the cost of mammalian cells lines, cell media,
and equipment. The burgeoning amount of research being conducted on exosomes and
related vesicles calls for the development of new exosome isolation techniques that may
result in clinical translation. Our research group has proposed using hydrophobic
interaction chromatography and Polyethylene terephthalate (PET) Capillary-Channeled
Polymer (C-CP) fibers in order to achieve a lower cost, faster, and more effective
exosome isolation and ultimately develop an all-in-one exosome isolation and disease
diagnostic test for ovarian cancer. However, the testing of such a diagnostic technique
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will require expensive and time consuming marker detection. In this study, we detail the
development of two new cell lines, one cancerous and one normal, which express
fluorescent tags on exosome and extracellular vesicle-enriched proteins and demonstrate
the ability to differentiate between these two populations of vesicles using antibody
capture.
Our research has resulted in three primary outcomes. First, we have developed
and tested a poly(ethylene terephthalate) (PET) capillary-channeled polymer (C-CP) fiber
EV isolation method employing a hydrophobic interaction chromatography (HIC)
protocol. This new method will allow for faster, cheaper, and easier EV isolation for
diagnostic and therapeutic applications. Second we have developed and tested a model
system of cell lines, one normal ovarian cell line with green fluorescent protein (GFP)tagged CD81 and one ovarian cancer cell line with red fluorescent protein (RFP)-tagged
CD9. This model system will be used to investigate and refine a selective PET C-CP EV
isolation method. We have demonstrated that EV populations from these two cell lines
can be differentiated using antibody capture on nitrocellulose membranes and
fluorescence microscopy. The ability to differentiate cancerous and non-cancerous
vesicle populations is an important step in the development of a selective diagnostic test.
Third, we have shown the importance of sample selection for downstream analysis of
EVs through comparison of urine and cervical mucus and demonstrated the diagnostic
potential of miRNA expression patterns to compare ovarian cancer and non-cancerous
clinical samples. Continued analysis of the miRNA expression data and ongoing
proteomics will reveal biological pathways and connections that will identify novel
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biomarkers for OC. These biomarkers can be applied to a PET C-CP EV isolation method
for further refinement of EV selective capture. The achievements of these investigations
will ultimately aid in the development of a tool for earlier, routine OC diagnosis that will
save the lives of many women.
The following review covers the different topics investigated by this research
including the current understanding of exosome and extracellular vesicle mechanisms,
physiological responsibilities, techniques, and medical applications, the potential of
liquid chromatography to separate and isolate extracellular vesicles, an overview of
ovarian cancer and exosome involvement in tumorigenesis, and the use of antibody
capture to identify extracellular vesicles.

Exosome Biogenesis, Sorting, and Release
Exosome are a class of extracellular vesicles (EVs), approximately 30-150 nm in
diameter.8 Typically, the varying categories of extracellular vesicles are classified based
on size and method of biogenesis. Exosomes are formed by inward budding of
multivesicular bodies (MVBs, or multivesicular endosomes; MVEs) followed by
extracellular release by MVB fusion with the cell membrane (see Figure 1.1).2 The
membrane contents and interior contents are determined by a number of factors unique to
individual cell types and the function of the exosome being produced.

5

Figure 1.1. Diagram of exosome and microvesicle biogenesis. Adapted from
Raposo et al.2

Initially, intraluminal vesicles (ILVs) are formed by inward budding of the
endosomal membrane into MVBs. After maturing from late stage endosomes, MVBs
then either fuse with a lysosome to degrade any internal contents or fuse with the cell
membrane to release any contents into the extracellular environment. ILVs are referred to
as exosomes only after extracellular release. During the formation process, specific
proteins and RNAs are sorted into the cytosol and membranes of the ILVs.27 The very
complex protein sorting process, although still not fully understood, is thought to be
primarily guided by the endosomal sorting protein complexes required for transport
(ESCRTs).28 As such, most ILV sorting mechanisms are categorized as ESCRTdependent or ESCRT-independent mechanisms. During the sorting process, ILVs are
typically enriched in specific proteins including tetraspanins CD63, CD81, and CD9,
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cytosolic protein tumor susceptibility gene 101 (TSG101) and programmed cell death 6interacting protein (ALIX).28-33 Although not nearly as well understood as the protein
sorting mechanisms, RNA sorting mechanisms are now being discovered. RNA sorting is
often thought to be associated with special 4 nucleotide motifs. Specifically, the
nucleotide sequence GGAG may be involved in the sorting and management of
miRNA.32, 33 The proteins and RNAs enriched in exosomes are distinctive from the
original cell membrane and cytosolic RNAs, suggesting an advanced preferential means
of determining exosome content exists.34 However, despite the knowledge surrounding
the mechanisms, proteins, and RNAs involved in ILV formation and sorting, the means
of determining vesicle content and production are still shrouded in mystery.

Exosome release into the extracellular environment is mediated by fusion of
MVBs with the plasma membrane of the cell. However, depending on the cell type and
physiological state of the cell, the mechanisms by which the MVB fuses with the plasma
membrane can vary. Much like other endosomal and endocytic vesicles, the mechanisms
of MVB plasma membrane fusion are facilitated by a variety of membrane-trafficking
Rab GTPase or SNARE proteins including RAB7, RAB11, RAB27a, RAB31, RAB35,
YKT6, and VAMP7.1, 11, 28, 35-37 Often, each mechanism of MVB plasma membrane
fusion is associated with enrichment of certain proteins in the exosomes.

7

Exosome Uptake and Dissemination

Figure 1.2. Possible mechanisms of extracellular vesicle uptake in the recipient
cell. Adapted from Mulcahy et al.3

There are several known mechanisms that are likely involved in exosome target
cell uptake including clathrin-mediated endocytosis, caveolin-dependent endocytosis,
micropinocytosis, phagocytosis, lipid rafts, and cell surface membrane fusion.3, 38, 39
Mulcahy et al.3 describe the range of possibilities for each of these uptake mechanisms
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and suggest that certain mechanisms have greater involvement in extracellular vesicle
uptake than others depending on the cell type.
Exosomes are initially taken into the target cell by either plasma membrane fusion
or endocytosis. If the exosome fuses directly with the plasma membrane of the target cell,
then its contents are presumably delivered directly into the cytoplasm, but very little is
known of the whereabouts of the contents after entry into the cell. If the exosome is taken
up by endocytosis, the exosome would likely fuse with the endosomal plasma membrane
and release its contents into the cytoplasm (see Figure 1.2). However, it is unknown
where along the endocytic pathway the exosomes may fuse with the endosome. As the
endocytic pathway is designed to digest incoming material, there is the potential that
incoming exosomes will be destroyed by lysosome fusion as well. As exosomes are, by
nature, vehicles of transportation, it is important to understand the mode of transport and
location of delivery. Knowledge of the uptake and dissemination mechanisms of
exosomes could have large impacts on the development of many medical applications.

Division of Extracellular Vesicles
Exosomes
Exosomes are one of several types of EVs. There is some debate regarding the
actual divisions of EVs based on size, but by defining the vesicles based on size,
function, content, and mode of biogenesis, general divisions can be created.40, 41
However, when the vesicles cannot be identified as a specific division of extracellular
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vesicle, it is more appropriate to label samples as small EVs (sEVs), large EVs (lEVs),
or, more generally, EVs, based on the isolation method. Exosomes are generally accepted
to be approximately 30-150 nm in diameter, with wide ranging functions within cell
signaling including inflammation mediation, antigen presentation, coagulation, and
angiogenesis among others.14, 18, 42, 43 Furthermore, exosomes are formed through inward
budding of the endosomal membrane of MVBs and released into the extracellular
environment (see Figure 1.1).27
Microvesicles
Perhaps most often confused for exosomes, microvesicles are a distinct class of
EVs with vastly different size, function, content, and biogenesis than exosomes. With a
size range of 100-1000 nm 24, 34, microvesicles can be easily confused as exosomes when
solely looking at vesicle diameter, especially if larger microvesicles have been
eliminated. When defining and characterizing vesicles after EV isolation, it is important
to distinguish between these two EVs. Furthermore, when microvesicle roles are
compared to exosome roles, the functions look very similar. Microvesicles are involved
in a variety of processes including inflammation, coagulation, and stem cell renewal, but
are capable of carrying much larger cargo like circular DNA and loaded reporter
molecules.34, 44 The biogenesis of microvesicles involves outward budding and fission
from the plasma membrane of the cell (see Figure 1.1). Therefore, the membrane and
internal content composition tends to be very different than exosomes.
Apoptotic Bodies
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Lastly, apoptotic bodies, EVs approximately 500-4000 nm in diameter, only
appear when a cell begins undergoing apoptosis.24 Apoptotic bodies are not usually
confused with exosomes or microvesicles since their diameter, functions, content, and
biogenesis are distinct from smaller EVs. The formation of apoptotic bodies is likely a
means for dividing cell components for easier digestion by phagocytes.
Characteristically, apoptotic bodies will contain organelles, large cell components, and
genetic information. Most findings suggest that apoptotic bodies are used for cell
disposal, but some studies have found that they may be able to pass genetic information
upon uptake.45, 46
Physiological Roles of Exosomes
Exosomes are released by many cells in vivo and in vitro and have been found in
every biological fluid tested thus far, including urine, blood, saliva, breast milk, cervical
mucus, amniotic fluid, cerebrospinal fluid, and ascitic fluid.13, 27, 47 With such a large
presence in biological fluids, it makes sense that exosomes would have a variety of
important physiological roles. As carriers for cell communication, exosomes may play a
diverse regulatory role depending on the vesicle contents including, but not limited to,
immunomodulation and antigen presentation, wound healing and angiogenesis,
inflammation, drug resistance, disease propagation, regulation of the central nervous
system, synaptic plasticity, reproduction and embryonic development, and homeostasis.1,
7, 8, 14, 43, 48

Several aspects of exosomes have been extensively studied, but perhaps the most
well-characterized is their role in immunomodulation and antigen presentation. The
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adaptive immune response is an incredibly complex system in which exosomes may play
a regulatory role. In particular, exosomes derived from immune cells have demonstrated
antitumor effects and have been found to display class I and II major histocompatibility
complex (MHC) molecules involved in antigen presentation.49 However, tumor cells have
benefited from the same immunomodulatory properties of exosomes. Tumor cell-derived
exosomes have been shown to promote tumor development through a variety of
mechanisms.43, 50 These contradictory functions further demonstrate the versatility of
exosome communication and function under both normal and pathological physiological
conditions.
Immunomodulation and Antigen Presentation
Exosomes that contain MHC class I and II molecules play an important antigen
presentation role in the adaptive immune system.51 Dendritic cells and macrophages, two
types of antigen presenting cells, release exosomes with these MHC-peptide complexes,
which can have both stimulatory and suppressive effects on the immune system.52-54
Exosomes released by these cells can form an antigen-MHC complex which can be used
to directly present the antigen to T-cells, thereby leading to T-cell activation.
Additionally, exosomes containing this antigen-MHC complex can present the antigen to
other antigen presenting cells resulting in processing of the antigen and crosspresentation to T-cells.43, 54, 55 Pregnancy immune regulation presents a unique
immunomodulatory situation in which the fetus must be protected from the allogenic
immune response of the mother. The immunomodulatory effects of exosomes released by
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the placenta may play a role in this regulation.11, 56 In fact, exosome concentration in the
amniotic fluid increases over each pregnancy trimester.56
Wound Healing and Angiogenesis
Wound healing is a remarkable process that is regulated and controlled by a
complex network and cascade of growth factors, cytokines, and proteins. Through
homeostasis, inflammation, proliferation, and remodeling, damaged tissue is repaired and
reconstructed to restore tissue function.57-59 Exosomes may play a significant role in
regulating the intricate interactions of chronic and acute would healing developments. By
carrying gene influencing material, exosomes can initiate wound healing pathways
(PI3K/Akt, ERK, STAT3)57, 60, promote expression of growth factors (hepatocyte growth
factor, insulin-like growth factor-1, nerve growth factor, stromal-derived growth factor1), heat shock proteins, and other signaling molecules.57, 61, 62 Specifically, mesenchymal
stem cells (MSCs) and adipose tissue-derived stem cells (ADSCs) play an important role
in modifying and controlling wound healing. Likewise, exosomes derived from MSCs
and ADSCs play a significant role in communicating to fibroblasts, promoting cell
migration and proliferation, and promoting angiogenesis.60, 61 Exosomes may allow for
further paracrine signaling to aid in faster wound healing and angiogenesis. Furthermore,
several cell types have been revealed to release pro-angiogenic exosomes, including
endothelial cells, tumor-derived cells, hematopoietic stem cells, mesenchymal stem cells,
and cardiomyocyte- and myocardial progenitor cells.14, 63-67
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Inflammation
Inflammation is a normal physiological process that is used to defend against
generic foreign material and infection and to remove damaged tissue. It is characterized
by a large increase in inflammatory cell migration to the injury site.68 Although the
inflammatory process is closely tied to the adaptive and innate immune response, the
control mechanisms and processes are quite different. Depending on the type of injury or
reaction, inflammation is typically mediated by neutrophils, basophils, eosinophils,
macrophages, lymphocytes, and monocytes.69, 70 Exosomes, as mediators of
communication, are particularly involved in controlling the inflammatory response
through the use of miRNA and protein genetic modulatory molecules.18 Specifically,
exosomes released by lipopolysaccharide-injected macrophages have demonstrated
inflammatory modulating abilities, including NF-kappaB activation.53 Furthermore,
dendritic cell-derived exosomes have been shown to suppress inflammation in murine
collagen-induced arthritis.71, 72 However, other dendritic cell-derived exosomes have
shown the ability to induce inflammation in the spleen.73 Such vast and varying
responsibilities within inflammation alone suggest that exosome-mediated responses
depend heavily on the exosome content and the type and physiological state of the target
cell. As such, exosome makeup and content are determined by the original cell type and
its current physiological state.
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Drug Resistance
Drug resistance is a major combatant of many newly developed cancer drug
therapies and chemotherapies. Cancer cells, either by acquired or de novo mutations, can
obtain means to defend against drugs and promote cancer growth. Mutations in the
genome and epigenome ultimately result in a series of changes that may confer drug
resistance by drug metabolism, inactivation, efflux, or DNA damage repair.74, 75 Much
like other pathogens or microbes, cancer cells mutate quickly and thus may develop these
genetic and epigenetic changes quickly. As exosomes are mediators of genetic
expression, it makes sense that they may be involved in the complex network of changes
required to develop drug resistance. Specifically, exosomes may play a role in multiple
myeloma development of bortezomib resistance.74, 76 Exosomes may be able to aid in the
expulsion of drugs, counteract immunotherapy drugs, and aid in the spread of
resistance.77 Drug resistance is a developing problem for current and future cancer
therapies and requires further investigation. Although exosomes may only play a small
role in development of drug resistance, understanding the mechanisms behind exosome
dissemination, transport, and loading may prove useful in the effort to develop effective
cancer therapies and combat against drug resistance.
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Exosome Medical Applications
More and more frequently, studies are revealing the ever expansive roles that
exosomes may play in cell communication. Since cell communication is a universal
necessity for development of complex multicellular life, there is much speculation that
exosomes are involved in many more processes than currently known. Consequently,
exosomes have been given a great deal of contemplation with regards to potential
medical applications and functional biological understanding. As of now, many exosome
applications are being investigated including disease diagnostics, drug delivery, immune
system modulation, and other therapeutics. The theranostic potential for exosomes is
seemingly boundless, with patient-specific and personalized medicine at the core of these
applications.
Disease Diagnostics
Exosomes appear to be packaged in a very uniform and controlled manner so as to
preserve the accuracy and precision of the message to be delivered. However, the
exosome contents can actually vary greatly depending on the cell of origin and the
physiological state of the cell of origin. Fortunately, the consistency among identical cell
types and the variation of exosome components between distinct cell types may allow for
tracing of the cellular origins of exosomes. In other words, the lipid, protein, and RNA
signature of an exosome may provide enough clues to determine what type of cell
released the exosome. This unique feature of exosomes may allow for downstream
identification of abnormal cell types using only a body fluid sample. Specifically, several
types of cancer exosome markers, including ovarian, breast, prostate, pancreatic,
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glioblastoma, and colorectal, have been identified and may potentially be used for early
cancer diagnosis.78 Furthermore, exosome markers have been found for other
pathologies, including acute kidney injury, renal ischemia reperfusion, alcoholic liver
disease, and nephrotic syndrome.79 Cancer exosome marker identification is occurring at
a rapid pace and markers are quickly being translated into multiplexed marker diagnosis
protocols. For example, Zhao et al.80 have developed a microfluidics device that captures
and identifies ovarian cancer exosomes using the multiplexed ovarian cancer exosome
markers, epithelium cell adhesion molecule (EpCAM) and cancer antigen 125 (CA-125).
Although most other types of cancers are awaiting exosome marker identification and
cataloging, circulating exosomes have been identified in lung, ovary, and gastric cancer
patients, which bodes well for potential marker identification.37 New biochemical
exosome RNA, protein, and lipid information is being discovered and amassed, on such
online databases as ExoCarta, EVpedia, Vesiclepedia, and exoRBase, so as to aid in the
creation of diagnostic profiles and the advancement of exosome knowledge. Furthermore,
several groups are working on developing devices that will simultaneously isolate
exosomes and provide a diagnosis.80 For these reasons, exosome biomarker disease
diagnosis is perhaps the most promising and likely first attainable application of
exosomes.
Drug Delivery
When developing any pharmaceutical drug, it is important to keep in mind the
pathway that the designed drug will follow. The four processes of pharmacokinetics
(absorption, distribution, metabolism, and elimination) are critical to understand when
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developing any drug. Particularly, the drug must be able to reach the intended target in
the correct formation and concentration and must be capable of being eliminated or
excreted after achieving its intended function. One strategy to combat potential drug
degradation is to develop a drug delivery system (DDS) to deliver the drug to a location
where it can function appropriately. Many DDSs have been developed and implemented
in modern pharmaceuticals, including polymeric dendrimers and micelles, stimuliresponsive carriers, nanoparticles, and biological materials.81 Exosomes are being
investigated as a potential DDS due to their size, histocompatibility, natural targeting
ability, and ability to cross unique barriers, such as the placenta or blood brain barrier.8284

Although exosomes contain major histocompatibility complex (MHC) molecules, there

is very little immune reaction to the vesicles.54, 85, 86 However, to date, any exosome
clinical trials have been performed using autologous exosomes to avoid greater immune
reaction.87 Additionally, exosomes are very similar in basic composition to liposomes,
which have been used in various DDS applications. Liposomes and exosomes are made
up of a lipid bilayer enclosing internal media, however, exosomes are much smaller and
have a much more complex makeup of proteins, lipids, and RNAs.88 Several investigators
have explored different possibilities for loading drugs into exosomes, including
exogenous and endogenous techniques with varying success.33, 83, 89-91 Another important
factor in drug delivery, besides protecting the drug, is targeting the drug to a particular
location to increase drug bioavailability to a subset of cells. Natural exosomes, depending
on the source, may already target specific cell types, but may also be engineered to target
a number of desired cell types. For instance, Alvarez et al.23 have loaded exosomes with
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siRNA and inserted a rabies-virus glycoprotein (RVG) peptide into the surface membrane
of the exosomes that successfully targeted the exosomes to the central nervous system in
mice. In order to further engineer and manipulate exosomes for drug delivery purposes
and other applications, several groups are now working on developing synthetic and
semi-synthetic exosomes.91, 92 Given the unique exosome features, exosome drug delivery
is a real possibility that may provide a useful DDS for treatment or therapies for
cardiovascular diseases, neurodegenerative diseases, cancers, and countless ailments.
Immunotherapy
As discussed previously, exosomes are heavily involved in immune system
modulation, antigen presentation, and T-cell activation. Their involvement within the
immune system offers extensive opportunities and advantages for immunotherapy
applications. Engineering and manipulation of exosome contents and membranes may
allow for consistent activation or suppression of the immune system.93 In particular,
exosome cancer immunotherapy is being investigated as an alternative therapy for cancer
treatment. By artificially activating or suppressing the immune system, immune cells may
be specifically activated to target and destroy cancer cells. Similar to drug delivery
applications, liposomes, artificial lipid-membrane nanocarriers, have already been used in
cancer immunotherapy applications.88, 91 However, as immunotherapy nanocarriers,
exosomes may provide many advantages over liposomes including natural
histocompatibility, biocompatibility, targeting, and ability to cross biological barriers.23,
55, 94, 95

Among the most promising exosome-based immunotherapy applications is their

use in the generation of vaccines against diseased cells through immunization and antigen
19

presentation and immune system stimulation.19, 86, 96 However, the natural exosome
immune system suppressive properties may be particularly useful for avoiding transplant
rejection and treating autoimmune disorders such as rheumatoid arthritis, inflammatory
bowel disease, and multiple sclerosis.93, 97, 98 Exosome immunotherapy is an exciting
prospect, offering a strong alternative to artificial drug delivery for disease treatment.
Although in the early stages of research, exosome immunotherapy treatments may be
able to take advantage of the body’s natural defense system to combat internal disease.
Regenerative Medicine and Other Therapeutics
Given the extensive number of biological processes that may involve exosome
communication, therapeutics may be developed through manipulation of exosome
presence and content. In recent years, regenerative medicine has focused on development
of stem cell therapies to help regenerate or reform tissue. Stem cells are capable of
reproducing indefinitely and differentiating into other cell types, which makes them ideal
candidates for aiding in regeneration of tissues. Furthermore, in recent years, stem cell
research has overcome many controversial hurdles through development of induced
pluripotent stem cells (IPSCs) and use of adult stem cells like mesenchymal stem cells
(MSCs) and adipose tissue-derived stem cells (ADSCs). However, cell-based therapies
are often expensive and run into biocompatibility, histocompatibility, teratoma, and
ectopic tissue formation issues when introducing allogeneic or autologous cells as
therapeutic agents.97, 99 Exosomes derived from stem cells may offer an alternative
therapy to direct stem cell therapy, but without many of the concerns associated with
stem cell therapy. As much of the cellular changes that occur during tissue regeneration
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and reformation are enacted by stem cell-derived exosomes, standalone stem cell-derived
exosomes may be used to induce tissue regeneration instead.99 Thus far, exosome driven
tissue regeneration has been investigated in many tissues including, neural, myocardial,
hepatic, renal, cutaneous, skeletal, chondral, and muscular.99 However, despite the recent
advances in exosome understanding, particularly within tissue regeneration, it is still
uncertain whether exosomes will ultimately evolve into a reliable therapy for
regenerative medicine.
Several maladies, including cancers and neurodegenerative diseases, have been
found to be associated with an increased release of exosomes or exosome involvement in
disease progression.100-105 Therefore, several groups have theorized that inhibition of
exosome formation, release, or uptake or removal of particular exosomes or miRNAs
found in exosomes may help prevent or slow disease progression.1 Specifically,
exosomes have been found to aid in environmental preparation for cancer metastasis and
acquisition of cancer cell chemoresistance.77, 103 Filtration or elimination of cancer
exosomes may potentially slow progression of epithelial-mesenchymal transition (EMT)
in tumor cells and aid in chemotherapy of tumors.100, 102, 106, 107 Furthermore, exosomes
have been implicated in the prion-like propagation of neurodegenerative diseases
including Alzheimer’s disease, Parkinson’s disease, multiple system atrophy (MSA),
amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS)
through transfer of toxic proteins or miRNA.108 Similarly, filtration or elimination of
exosomes involved in the spread of neurodegenerative diseases may slow the progression
of their pathology. To this end, further understanding of pathology and the role of
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exosomes in cancer metastasis, cancer cell acquisition of chemoresistance, and
propagation of neurodegenerative diseases may ultimately aid in the development of
treatments for these maladies.
Exosome Characterization and Biochemical Profile
As exosomes are approximately 30-150 nm, it is often difficult to characterize
their defining properties. Furthermore, being derived from cellular components,
exosomes can be difficult to differentiate from other cellular debris and nanoparticles.
Therefore, the International Society for Extracellular Vesicles (ISEV) has defined several
basic requirements for defining and differentiating types of EVs.40, 41 The requirements
for EV definition primarily focus on two categories of characterization: Physical and
Chemical.
Physical Characterization
Physical characterization is used to evaluate individual vesicles based on size,
diameter, concentration, and morphology. ISEV recommends that at least two singlevesicle technologies be used to characterize EVs. Nanoparticle tracking analysis (NTA)
and dynamic light scattering (DLS) can be used to obtain vesicle size distributions and
vesicle concentrations. However, both NTA and DLS can be unreliable as no distinction
is made between vesicles and other particulate nanoparticles present in the sample.
Likewise, the limit of resolution of NTA and DLS (approximately 30 nm)109 may hinder
the ability to identify smaller vesicles and may lead to misidentification of other nonvesicle particles. Thus, sample purity can affect the dependability of both NTA and DLS.
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Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) can
be used to characterize size, diameter, and morphology of vesicles in solution or on a
surface. Both TEM and SEM have been used extensively to study biologics, materials,
and processes at a nanoscale level. However, the sample preparation process can be very
harsh and damaging, particularly toward biological samples and EVs. Despite these
challenges the morphology and structure of EVs viewed under TEM and SEM are
credible when consistently prepared, but the sample preparation methods employed
should be taken into account when making conclusions. Finally, several other techniques,
including atomic force microscopy (AFM) and super-resolution microscopy techniques,
such as stimulated emission depletion (STED) or photoactivated localization microscopy
(PALM), have been used to generate EV size distributions and morphology
characterizations.110-112 Although no single-vesicle technique can perfectly qualitatively
or quantitatively characterize EVs, when used in tandem, they can provide useful and
reliable information to study EVs.
Chemical Characterization and Profile
Chemical characterization of EVs involves identification of protein, RNA, and
lipid markers that are typically enriched in EVs. ISEV has laid out particular guidelines
for identification of EVs using typical EV-enriched proteins.40, 41 Membrane associated,
cytosolic, intracellular, and extracellular proteins have all been used to identify and
differentiate subtypes of EVs. Accordingly, ISEV recommends using at least 3 protein
markers to identify and characterize EVs. Proteins typically used to identify and
differentiate EVs include CD9, CD81, CD63, ALIX, TSG101, Grp94, Calnexin, and
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many disease specific markers (See Table 1.1).16, 18, 113-116 Protein analysis can be
completed using Western blot analysis, enzyme-linked immunosorbent assay (ELISA),
flow cytometry (FACS), or mass spectrometry. As with any method of chemical
profiling, positive and negative controls of cell lysate and culture medium should be
compared to the EV samples. Extensive sequencing and compilation of data has
identified different types of RNAs within EVs, including miRNA, mRNA, tRNA, rRNA,
piRNA, snRNA, snoRNA, and scaRNA.13 However, miRNA is perhaps the most
commonly used RNA for EV identification and study due to its function in gene
regulation.32 There is likely no single exosome marker that will provide an outright
positive or negative diagnosis for any disease. Therefore, many groups have focused on
developing a multiplexed diagnostic approach using miRNA or protein identification (see
Tables 1.1). Specifically, for ovarian cancer, Yokoi et al.117 developed an early stage
diagnosis technique using expression levels of 8 different miRNAs with an area under the
curve of 0.97. Furthermore, Zhao et al.80 have used 3 exosome ovarian cancer markers,
EpCAM, CA-125, and CD24, in conjunction to capture and identify ovarian cancerspecific exosomes. Lipids, which have been less frequently used to identify and
differentiate EVs, offer an alternative method to EV biomarker detection. In particular,
exosomes have been found to be enriched in particular lipids as compared to the parent
cell.118 For example, Skotland et al.118, 119 have identified 9 different lipids that were
differentially expressed in exosome membranes of prostate cancer patients. Chemical
characterization of EVs may reveal important data about the composition and origins of
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vesicles. Ultimately, a combination of exosome miRNA, protein, and lipid composition
may provide a characterizing profile to identify many maladies.
Table 1.1. Potential exosome miRNA and protein markers for different types of
Associated
Potential Exosome miRNA
Potential Exosome
ovarian, lung, and breast cancer.
Disease
Markers
Protein Markers
Ovarian Cancer miR-16, -21, -26a-5p, -93, -100, 126, -130b-3p -141, -142-3p, 200a-3p, -200b, -200c, -203, 205, -214, -223 -320, -328-3p, 374a-5p, -766-3p117, 120, 121

EpCAM, CA-125, CD24,
L1CAM, ADAM10,
EMMPRIN, TGFβ1,
MAGE3/6, Claudin-412,
80, 101, 122

Lung Cancer miR-17, -3p, -21, -20b, -223, CD91, CD317, EGFR,
301, -486, -181-5p, -30a-5p, -30e- LRG1, NY-ESO-130, 126128
3p, -361-5p, -10b-5p, -15b-5p, 320b, let-7d-5p, let-7f123-125
Breast Cancer miR-338-3p, -340-5p, and -1243p, -29b-3p, -20b-5p, -17-5p, 130a-3p, -18a-5p, -195-5p, -4865p, -93-5p, -1246, -373129-131

PKG1, RALGAPA2,
NFX1, TJP2, Glypican-1,
Her29, 132, 133

Exosome Isolation Techniques
In order to take advantage of any of the potential benefits of exosomes, they must
first be isolated from cell growth media or bodily fluids. Given that exosomes are
approximately 30 to 150 nanometers in size, this is no easy task. Current techniques for
isolating exosomes often involve a number of sequential centrifugation steps to eliminate
larger materials from the media. Many isolation strategies follow the protocol laid out by
Thery et al. that involves sequentially increasing ultracentrifugation of the media
containing the exosomes.134 Others elect to use filters to eliminate larger materials and
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then pellet the exosomes using ultracentrifugation. Both of these current techniques for
exosome isolation and other variations require the use of ultracentrifugation, which may
not always be available in medical settings. There are a number of exosome isolation kits
available commercially that have produced varying results. Importantly, the type of
exosome isolation can impact protein and RNA downstream analysis. As it stands now,
given the difficulty and varying effectiveness of these isolation techniques, it seems
unlikely that any of them will perform effectively, efficiently, and consistently in a
clinical setting. For these reasons, there is a need to refine or develop new techniques of
exosome isolation that may be more suitable for medical environments.

Differential Centrifugation
Differential Centrifugation exosome isolation takes advantage of the ability of a
centrifuge to separate out materials in solution based on the density and size of the
material. Higher weight objects will move faster through the solvent and will thus
sediment quicker from solution at lower centrifugation speeds. Lower weight objects will
begin to sediment faster from solution at much higher centrifugation speeds.135 Therefore,
the heavier objects in the cell growth media (e.g. cells, apoptotic bodies, and debris) will
sediment from solution and be removed in a primary centrifugation. A faster secondary
centrifugation will pull down lighter objects, including larger EVs and microvesicles, to
be removed, and finally a third and fastest centrifugation will sediment the desired
exosomes.136 Typical ultracentrifugation exosome isolations often require a final
centrifugation speed greater than 100,000Xg. The ultracentrifugation process requires
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upwards of 3 hours to complete depending on the number of centrifugation steps included
and experience level of the personnel performing the isolation. Furthermore, the
centrifuges and ultracentrifuges required for this method can very expensive (low speed
centrifuges – several thousand dollars; high speed centrifuges - $15,000-$100,000) and
may not be suitable for smaller labs and organizations. This exosome isolation method is
crude, results in highly variant samples, and can potentially damage the exosomes due to
the high speeds of centrifugation and the resuspension of the vesicles.136 By nature of
centrifugation, the final isolated exosome sample will contain anything from the original
cell growth media of similar or lighter weight than an exosome (for example, lipoproteins
and proteins)137 and may contain aggregate vesicles and proteins. Furthermore, any larger
particles that were not eliminated from the solvent may sediment along with the
exosomes. Differential centrifugation is relatively easy to perform with the proper
equipment and training, but often results in low purity samples with fairly low efficiency.
However, due to the relative ease with which this method can be performed, it is one of
the most common exosome isolation techniques used today.
Density Gradient Centrifugation
Density gradient centrifugation is very similar to differential centrifugation but
includes an extra medium that increases the viscosity of the solution. There are two types
of gradients, isopycnic and rate zonal, that have been used to isolate exosomes.137 During
isopycnic gradient centrifugation, samples are dispersed within the gradient medium and
separate components based on density, whereas during zonal gradient centrifugation
samples are layered as a narrow band at the top of the gradient medium and separate
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components based on size (Figure 1.3).135 Exosome density gradient centrifugation
typically uses a sucrose or iodixanol solution that is compatible with the lipid bilayer of
the exosomes and vesicles. By increasing the viscosity of the solution, objects of very
similar density can be differentiated and separated more easily. Therefore, this method of
exosome isolation can result in purer exosome samples with less debris. However, even
though the final sample can be purer than differential centrifugation, the range of
centrifugation speeds and range of centrifuge times must be more accurate to be in the
proper density range for exosomes. Monitoring the centrifugation times and speeds
makes this method more difficult than differential centrifugation alone due to the
increased density sensitivity of the solution. Variations of density gradient centrifugation
have been used to develop exosomes samples for use in clinical trials.21, 22, 138

Figure 1.3. Diagram of Isopycnic and Rate zonal density centrifugation.
Adapted from Sigma-Aldrich (St, Louis, MO).
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Size Exclusion Chromatography
Size exclusion chromatography (SEC) is used to separate molecules within a
solution based on the size of the molecule rather than the density or weight of the
molecule. The solution flows through a size exclusion column containing small stationary
phase beads with nanometer–sized pores. Smaller molecules in the solution will enter and
adsorb in the pores, thus slowing their rate of flow through the column and delaying the
time of elution. Larger molecules will flow through the column without entering the
adsorbent material pores and elute quicker. The same principle can be applied to isolate
exosomes from other components of the solution. Böing et al.139 use sepharose CL-2B
beads with 75 nm pores to separate out exosomes from solution. Furthermore, several
groups have used SEC in conjunction with other exosome purification or enrichment
techniques, such as ultrafiltration or ultracentrifugation, to achieve higher purity
samples.140-142 Size exclusion chromatography can very accurately separate exosomes
from solution based on size, but the final exosome eluate may also contain other
materials of similar size. Additionally, size exclusion chromatography limits any shear
force damage to the exosomes and prevents protein and vesicle aggregation. Despite its
efficiency and accuracy, size exclusion chromatography may be severely limited by the
amount of eluate obtained and the time it takes to flow through the column.140, 143, 144
However, recent improvements in this technique have led to faster and cheaper separation
of molecules. Böing et al.139 demonstrate that this technique can be used to isolate a
sample of exosomes in as little as 20 minutes.
Ultrafiltration
29

Much like SEC, ultrafiltration isolates exosomes based on size or molecular
weight using pore sizes ranging from 0.8 to 0.1µm.145 Ultrafiltration is much faster and
cheaper than ultracentrifugation, and does not require large, specialized machinery.146
Similar to SEC, ultrafiltration has been used in tandem with ultracentrifugation or SEC to
isolate exosomes.147, 148 Fluorescent imaging has revealed that ultrafiltration results in a
higher RNA yield compared to ultracentrifugation.149 Unfortunately, by the nature of
filtration, any molecules that are smaller than the pore size will pass through into the final
sample, resulting in particle contamination.145 In order to alleviate protein contamination
and remove molecules smaller than exosomes, a sequential ultrafiltration has been used
to purify the exosomes further. Sequential ultrafiltration of exosomes consists of an initial
“dead-end” filtration to remove cells and debris. A secondary tangential flow filtration is
used to remove proteins and molecules with a 500kDa filter. Finally, a filter with a pore
size of 100 nm is used to isolate the exosomes.137 Ultrafiltration has been used to isolate
exosomes from a variety of cell types and biological fluids, and has been used to isolate
exosomes from as little as 0.5 mL of urine.137, 145, 147, 150
Polymer-based Precipitation
Exosomes can be precipitated out of solution by manipulating the content of the
solvent. In phosphate buffered saline, exosomes will remain in solution, but altering the
solvent can change the solubility of the exosomes. By adding a polymer, such as
polyethylene glycol (PEG), exosomes will precipitate out of solution at low speed
centrifugation.146 This method requires either pre-centrifugation or pre-filtration to
remove cells and larger debris from solution. Polymer-based precipitation can be
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performed easily, inexpensively, effectively, and can be completed on a large scale.
However, the precipitate may contain polymers and other undesired molecules of similar
solubility.137, 151, 152 Further steps must be taken to fully purify the exosome sample
including pre-isolation of lipoproteins and post-isolation of polymeric materials.137
Several commercially available polymer-based precipitation EV isolation kits that
operate with minimal sample exist, including Total Exosome Isolation (Invitrogen,
Carlsbad, CA)), ExoQuick exosome precipitation solution (System Biosciences, Palo
Alto, CA).151 The availability and ease of use of polymer-based precipitation kits makes
them promising and convenient techniques for research and clinical purposes.
Immunological Separation
Immunoaffinity capture of exosomes is a promising exosome isolation technique
with high specificity.153 Since exosome lipid membranes are composed of proteins,
receptors, and transmembrane proteins, antibodies can be developed to specifically target,
capture, and isolate exosomes. Immunological separation requires understanding the
membrane content of exosomes from all sources and requires discovering a protein or
receptor that is common to all exosomes. However, a protein or receptor common to all
exosomes must not be common to other biological components of the cellular media. Due
to the high specificity of antibodies in immunological separation, exosomes can be
isolated at similar efficiency to ultracentrifugation, but with much smaller samples.113, 137,
154

Several variations of immunoaffinity capture, including modified ELISA exosome

isolation and magneto-immunocapture, have had success isolating exosomes with high
efficiency.29, 155-157 Despite the efficiency, effectiveness, quality, and speed of
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immunological separation of exosomes, there is still an incomplete understanding of
exosome membrane content. It is difficult to differentiate proteins specific to exosomes
when much of the content of the exosomal membrane is derived from the cellular
membrane. Currently, a common protein targeted is CD63, a tetraspanin membrane
protein common to many human exosomes. However, CD63, and other similar
tetraspanin proteins can also be found in apoptotic bodies and other extracellular
vesicles.30, 158, 159 Immunoaffinity-based separations using specific antibodies are
excellent techniques for isolating exosomes, especially for high quantity and quality RNA
extraction from exosomes. Even with a poor understanding of exosome membrane
composition, immunoseparation may produce high yields and generate subpopulations of
isolated exosomes and extracellular vesicles.137
Microfluidics Isolation techniques
Newer strategies involving microfluidics devices have begun to permeate the
realm of exosome isolation, as advancing fabrication processes have allowed for easier
manufacturing of microfluidics devices. Many of these new techniques use a device that
operate on one or more of the principle isolation strategies discussed above. For instance,
Lee et al.160 have developed an acoustic nanofilter that uses ultrasound to isolate
microvesicles based on size and density, while Wang161 et al. have developed ciliated
micropillars for selectively capturing lipid vesicles of 40-100nm in size. According to
Yang et al.162, microfluidic device exosome isolation techniques have the potential to be
faster and more effective than the current standard exosome isolation techniques.
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However, each individual microfluidics technique has drawbacks and many of the
devices are still early in development.
Although there are many strategies for isolating exosomes, there is no clear
method that stands above the rest. Each technique has its own benefits and downfalls
whether it be isolation efficiency, exosome purity, exosome integrity, RNA extraction,
cost, scalability or ease of use (see separation strategies summary in Table 1.2). With the
realization of the possibilities of exosome technology, there is clearly a need for a
solution to exosome isolation.
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Table 1.2. A brief summary of extracellular vesicle separation strategies
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Exosome Loading Techniques
There are a number of different ways to load exosomes with drugs or other
markers including electroporation, sonication, saponin incubation, extrusion, transfection,
and drug incubation.83, 89, 91, 94 In general, these and other exosome loading techniques can
be categorized as exogenous loading or endogenous loading. Exogenous loading
techniques are methods of loading exosomes after the exosomes have been isolated.
Conversely, endogenous loading techniques are methods of loading exosomes before the
exosomes have been released from the cell.
Exogenous loading
Separated exosomes can be prone to further damage after isolation that may limit
their viability and capability to perform functions. In order to load material into the
exosomes, exogenous techniques often employ potentially destructive and damaging
stimuli to open temporary holes in the exosomal membranes. These techniques, including
electroporation, saponin permeabilization, sonication, extrusion, transfection, and drug
incubation, while effective, destroy many vesicles in the process.23, 83, 89 Electroporation
is a method of shocking the plasma membrane with a relatively low voltage. The electric
shock temporarily makes the plasma membrane of the exosome more permeable and
allows for contents in the surrounding solution to enter the exosome. Alvarez et al.23 have
employed this technique to load siRNA into exosomes for drug delivery and treatment of
Alzheimer’s disease. Typical applications of electroporation involve transfecting genetic
material into cells of various types. Sonication, another potential exosome loading
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technique, also disrupts the stability of the plasma membrane, thus making the plasma
membrane more permeable to loading. According to Haney et al.83, saponin is a
surfactant that is thought to remove plasma membrane cholesterol, temporarily creating
holes in the plasma membrane allowing surrounding solution content to load into the
exosome. Much like sonication, extrusion and freeze/thaw methods disrupt the integrity
of the lipid bilayer and increase the permeability of the plasma membrane. All of these
methods have been shown to enable loading of exosomes, but with varying effectiveness
and stability. There are many advantages and disadvantages to these approaches, but
Haney et al. and Alvarez et al. have shown that exosomes loaded with these methods are
still effective for drug delivery.23, 83
Endogenous loading
Endogenous loading techniques are significantly less destructive to exosomes, but
can be significantly more difficult to accomplish. Loading of an exosome in this manner
could mean either modifying the membrane content of the vesicle or having the exosomeproducing cell automatically load the vesicles with the appropriate proteins or nucleic
acids for drug delivery. In exosomes, modifying membrane protein content is primarily
accomplished using genetically engineered plasmid vectors. The plasmids are encoded
with particular targeting proteins or peptides that will then be expressed in the cell and
inserted into the plasma membrane. Specifically, Alvarez et al.23, 163 inserted a modified
targeting peptide plasmid for Lamp2b, a known exosome membrane protein. They
verified the successful expression of the modified Lamp2b peptide using an exosome
protein pulldown assay. The modified Lamp2b exosomes primarily targeted neurons,
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microglia, and oligodendrocytes, as planned. Furthermore, the Lamp2b exosomes
successfully targeted and knocked down BACE1 expression in neurons, microglia and
oligodendrocytes by 60% and 62% using mRNA and protein respectively. BACE1 is a
gene involved in Alzheimer’s pathogenesis that could be knocked out for potential
therapy. Similarly, Monfared et al.164 have engineered exosomes to express membrane
miR-21 sponges in order to induce apoptosis in tumor cells. The ability to modify
exosome plasma membrane content is a vital step in targeted drug delivery and evidence
has thus far shown that specific targeting with exosomes is possible and effective. One
strategy for loading proteins or nucleic acids into the cytosol of exosomes is to engineer
the exosome-releasing cells to overexpress the molecule to be loaded.165 Alternatively,
Yim et al.165 have developed a more advanced method of selective drug loading during
biogenesis using exosomes for protein loading via optically reversible protein-protein
interaction (EXPLORs). EXPLORs uses engineered cell lines that express selective
membrane docking proteins that are photo-activated using blue light. This technique has
demonstrated very high loading efficiency in comparison to other loading techniques.
Endogenous engineering of vesicle membrane proteins and protein cargo may be used to
create a drug delivery system requiring only exosome isolation and administering to
patients.
Liquid Chromatography
Although most liquid chromatography (LC) techniques have been used to separate
proteins and other macromolecules, there is potential for LC isolation of more complex
bio-molecules, including extracellular vesicles and exosomes. LC is a chemical technique
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that allows for separation of molecules from solution. Modern LC, referred to as high
performance liquid chromatography (HPLC), can be used to separate, detect, and
quantify molecules and can isolate molecules based on hydrophobicity, charge, or size.166
Choice of solid and liquid phase components can determine which molecules can be
separated from solution and often vary depending on the specific application. HPLC has
been used to separate a variety of types of molecules including amino acids,
carbohydrates, lipids, nucleic acids, proteins, steroids, and biological substances.144
Depending on the physical properties being used, HPLC can be generally subdivided into
several categories including normal-phase, reversed-phase, ion-exchange, and sizeexclusion. Normal-phase describes liquid chromatography that uses a polar stationary
phase and hydrophobic mobile phase, whereas reversed-phase describes liquid
chromatography that uses a hydrophobic stationary phase and polar mobile phase.166
Furthermore, ion-exchange separates molecules based on charge properties and sizeexclusion typically uses columns packed with microbeads that slow down the flow of
molecules based on size.139, 144, 167 Although HPLC has typically been used to isolate
small or individual molecules, larger more complex biological components have been
separated as well. For example, Kasanović et al.167 have used ion-exchange
chromatography to separate EVs from amniotic fluid and An et al.142 have used sizeexclusion chromatography to separate exosomes from human serum. To this end, a
variety of combinations and expansive methods of HPLC exist beyond the standard
classification that have a diverse set of applications across chemical, material, and
biological fields.
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One particular type of LC, known as hydrophobic interaction chromatography
(HIC), is a variant of reversed-phase LC. HIC, like reversed-phase, uses a stationary
phase that is more hydrophobic than the mobile phase. Reversed-phase LC relies on
adjusting the polarity of the mobile phase using an organic solvent until the mobile phase
is more hydrophobic than the stationary phase.144 HIC, on the other hand, relies on
adjusting the salt concentration of the mobile phase from high concentration to low
concentration to change the polarity (see Figure 1.4).168, 169 Increased concentrations of
chaotropic ions can influence the solubility of hydrophobic molecules and cause
hydrophobic molecules to adsorb to the stationary phase. Molecule adherence to the
stationary phase can be explained by the “salting-out” phenomena, thermodynamics, and
van der Waals forces.4, 144, 168-171 In order to optimize the HIC separation gradient
steepness, salt concentration, volume of sample, pH, type of matrix, and flow rates can be
varied.172 HIC may be less damaging than reversed-phase LC and, thus, is often used to
separate more sensitive bio-molecules.168, 173 Most commonly, HIC is used to separate
proteins and large polypeptides, but many groups have used HIC for a variety of
applications including the separation and isolation of monoclonal antibodies.168, 169, 174
With this in mind, HIC may provide a method to isolate more complex and larger biomolecules under the appropriate conditions. In this case, our research group is
investigating whether HIC combined with poly(ethylene terephthalate) CapillaryChanneled fibers may be a suitable isolation method for exosomes and extracellular
vesicles.175
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Figure 1.4. Demonstration of hydrophobic interaction chromatography
separation theory using a salt concentration gradient. Adapted from McCue et
al.4
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Ovarian Cancer Detection, Diagnosis, and Treatment
Ovarian cancer (OC) is the 7th most diagnosed cancer in women and generally
reflects a very poor 5-year prognosis.5 OC consists of several different histological
subtypes that vary in genetic expression, origin, pathogenesis, prognosis, and treatments.
Of these subtypes, epithelial ovarian cancer accounts for about 90% of all diagnosed
benign and malignant tumors. Malignant epithelial OC can be further subdivided into
histotypes including high-grade serous, endometrioid, clear cell, mucinous, and lowgrade serous.5 The pathogenesis and development of OC is still very unclear, but many
types may originate from the fallopian tubes or peritoneum.176, 177 OC is typically
detected in late stage, with a 5-year relative survival rate of 29% with early stage 1
detection only occurring about 15% of the time. However, if OC is detected in stage 1,
the 5-year relative survival rate is 92%.5 Early detection of OC is very difficult and
effective means for early detection do not currently exist. However, genetic sequencing
now allows for detection of particular gene alleles that are correlated with a higher risk of
developing OC, including BRCA1/2, MMR, TP53, CHEK2, RAD51, BRIP1, and
PALB2 genes.178 Even with genetic marker testing and screening available, the hallmark
of OC remains late stage diagnosis and the corresponding stark prognosis and mortality
rates.179, 180
The most common methods for OC detection include a transvaginal ultrasound
and screening for CA-125 in serum.181 Combined, these methods are capable of detecting
OC and differentiating malignant and benign tumors in low-risk postmenopausal women,
but are not highly sensitive in many cases.182 Once a tumor is detected, biopsy and
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histopathological assessment can determine the type, stage, severity, prognosis, and
treatment options. New biomarkers in conjunction with CA-125 have been used to
increase screening sensitivity and specificity including HE4, CEA, VCAM-1,
transthyretin, apolipoprotein A1, β2-microglobulin, and transferrin. However,
multiplexed biomarker testing is not prevalent or proven yet.181 Earlier detection of OC,
once achieved, would likely improve prognosis and mortality rates, but current general
population screens are not standard.183
Regardless of the type and stage, OC, once diagnosed, is typically treated by
surgical removal of the tumor often combined with intraperitoneal and intravenous
chemotherapy.184, 185 Interval cytoreduction combined with chemotherapy has remained
the standard treatment for late stage treatment of OC, but has only seen a small reduction
in mortality over the last 25 years, likely due to preventative measures and accuracy of
surgical techniques. More recently, cytoreduction has been paired with neoadjuvant
chemotherapy and hyperthermic intraperitoneal chemotherapy, but there is some debate
whether or not these techniques are more effective.185 Indeed, there is a clear need for
new strategies and therapies to treat and eradicate OC growth, metastasis, and recurrence.
High-grade serous OC is associated with hypoxic angiogenesis, over-production
of vascular endothelial growth factor (VEGF), and the subsequent development of
ascites.186 Therefore, one new therapy strategy is to use anti-angiogenic drugs to combat
OC growth and recurrence. Bevacizumab, a VEGF antagonist, has shown promise in
reducing recurrence, but its use is controversial due to differences in regulatory approval,
varying strategies of use, and lack of improvement over other therapies.185, 186 Other anti42

angiogenic drugs under investigation include cediranib, pazopanib, nintedanib, and
angiopoietin inhibitor.185 Treatment with Poly(ADP-ribose) Polymerase (PARP)
inhibitors are also being investigated as inducers of synthetic lethality in OC and other
cancers through disruption of DNA repair.187 PARP inhibitors, including olaparib,
niraparib, rucaparib, have shown promise as primary and post primary treatment,
particularly in OC patients with BRCA mutations.185 Other therapies for OC under
investigation include epidermal growth factor receptor tyrosine kinase inhibitors, folate
receptor α inhibitors, and immunotherapy.185 Treatment options for OC are quickly
advancing and have demonstrated improvement in survival rates and reduction of
recurrence. Even so, OC remains one of the most lethal gynecological maladies, likely
due to the asymptomatic nature of early stages leading to late stage detection.186
Role of Exosomes in Cancer Metastasis
Tumor invasion, metastasis, and the formation of secondary tumors is the primary
reason for high mortality in most cancers.188 Metastatic tumors are characterized by
invasion, intravasation and extravasation into distant tissues, often having very poor
outcomes.189 The stages of tumor epithelial-mesenchymal transition and eventual tumor
metastasis are controlled by a number of cascading biological pathways involving many
cell types, cytokines, growth factors, chemokines, and small molecule mediators
delivered by exosomes.77, 190, 191 In fact, tumors have been found to release a higher
number of exosomes into the microenvironment compared to healthy cells.192 Typically,
exosomes involved in tumor metastasis will influence the microenvironment and
surrounding cells to prepare the area for tumor growth and create a pre-metastatic
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niche.193 Such preparations may include promotion of angiogenesis, adaptation to
hypoxic environments, immune evasion, and promotion of inflammation (see Figure
1.5).1, 104, 105, 194-199 Specifically, exosomes can recruit bone-marrow derived cells to
mediate vascular permissiveness and inflammation, ultimately leading to pre-metastatic
preparation of the extracellular matrix.50, 77, 200 Additionally, pro-angiogenic factors
transmitted by tumor-derived exosomes can boost vascular development which may aid
in the development of the pre-metastatic niche and minimize the lethal effects of a
hypoxic environment. Furthermore, tumor-derived exosomes may escape immune
surveillance by inducing cytotoxic T-cell apoptosis, decreasing natural killer cell activity,
and pushing T-helper cells to differentiate into T-regulatory cells that promote
inflammation.1, 197, 198, 201 In short, exosomes are intricately involved in the growth and
spread of tumors and new pathways and functions are frequently being unveiled. Greater
understanding of the role of exosomes in tumor metastasis and any corresponding
pathways will enhance the ability to develop therapies or treatments to prevent or stop
tumor proliferation.
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Figure 1.5. Various roles of exosomes released from primary cancer cells.
Adapted from Rashed et al.1
Role of Exosomes in Ovarian Cancer Diagnosis
As they are carriers of proteins and nucleic acids and are heavily involved in
tumor metastasis, exosomes are thought to be potential biomarkers for cancerous cells
and tumor progression. By capturing exosomes from circulating fluids, the signal-tonoise ratio of cancer-related molecules can be greatly improved when screening for tumor
markers. In recent years, exosome marker identification has yielded an array of common
exosome markers that may be useful for capturing and identifying specific types of
exosomes and their origins. Identification of an exosome’s cell of origin, the molecular
cargo carried inside, and potential target cell reveals valuable information about
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objectives of the exosomes, the physiological state of the original cell, and potential
diagnostic information from diseased cells. Particularly, exosomes are being investigated
as potential early stage biomarkers for OC as a remedy for late stage diagnosis. Both
protein and miRNA exosome marker profiles are being developed to aid in the diagnosis
of OC. Zhao et al.80 have developed a microfluidics device that captures and identifies
OC-specific exosomes using CA-125, EpCAM, and CD24 markers with potential
diagnostic ability. Further advances in protein marker profiles for OC will likely enhance
diagnostic sensitivity and specificity using multiplexed protein approaches. Similarly,
Yokoi et al.117 have used a combination of 8 different OC-associated exosome miRNA
molecules to achieve an area under the curve of 0.97, a sensitivity of 0.92 and a
specificity of 0.91 for OC diagnosis. Interestingly, when capturing EpCAM positive
exosomes, Taylor et al.120 found that exosome miRNA profiles had a high correlation
with miRNA profiles from the associated biopsy and that miRNA profiles tended to
differ between benign and cancerous tumors. This suggests that exosome miRNA profiles
may vary enough to differentiate between tumor types and physiological states.
Multiplexed exosome biomarker approaches offer promising early diagnostic capabilities
for OC and other cancers. In particular, OC stands to benefit greatly from early stage
diagnosis as stage 1 detection results in a 92% 5-year relative survival rate.5
SKOV-3 and Immortalized Human Ovarian Epithelial Cells
Cell lines are important tools that can be used as models to be able to study
biological phenomena. Several cell lines, including SKOV-3, OVCAR-2, OVCAR-3,
OVCAR-433, OVCAR-5, IGROV1, and BG-1 have all been used for exosome research
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in relation to ovarian cancer.38, 122, 202, 203 In particular, the SKOV-3 line, a high-grade
adenocarcinoma cell line, is among the most popular and commonly used cell lines in
publications reporting on OC. It is one of two cell lines that make up 60% of publications
relating to OC and one of five cell lines that make up 90% of publications relating to
OC.204 Their popularity and high-grade serous derivations, fast growth rate, and abundant
production of extracellular vesicles are some of the main reasons SKOV-3 cells have
emerged as popular cells for exosome study. Despite their popularity, many cells lines,
including SKOV-3 cells, have come under scrutiny over representative accuracy or how
well the cell line genetically and physically represents the original parent carcinoma.204,
205

Even so, with little in the way of other available options (primary cells are not feasible

in most research settings), cell lines remain very popular and widespread and, for the
most part, still provide insightful and accurate results.
Most cell lines, by their very nature, are derived from diseased primary cells.
Often, the disease is the purveyor of the immortality required to become an endlessly
replicating cell line. As with any experiment, it is important to maintain a control, but
control cells lines of normal, non-diseased cells, can be difficult to find and maintain.
Primary cell lines, which can be used as controls, do not replicate indefinitely invitro and
are considerably less hardy. Fortunately, immortalized primary cells have emerged as
viable alternatives to normal primary cells.206-208 Through genetic modification of tumor
suppressor and cell cycle controller genes, more genetic variance is introduced into the
cell environment. Although these are major changes to the cell cycle, immortalized cells
are considered more genetically and physically similar to primary cells than carcinoma-
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derived cell lines and thus have been used as control cell lines in research.209 In the case
of OC, Immortalized Human Ovarian Epithelial cells, created through simian virus
transduction, can be used as a viable control cell line in extracellular vesicle and exosome
research
Summary
The mechanisms and roles of exosomes are incredibly complex and evidence thus
far has demonstrated the intricate involvement of exosomes in a number of processes,
including cell-cell communication and tumorigenesis.8, 104, 210 Increased understanding of
exosomes and their roles in the body will undoubtedly result in fundamental insights that
may lead to breakthroughs in such areas as liquid biopsy-based diagnostics,
understanding of disease progression and development of new medical treatments.
However, to date, exosome isolation presents a number of fundamental challenges that
must be overcome before academic research can progress to the point of translational
medical applications. An exosome isolation methodology that is practical for use in a
clinical setting is greatly needed.
In the following research, we have a developed an EV isolation method and
model systems that will support earlier and routine OC diagnosis. The three specific aims
of this project are:
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1. To develop and investigate a novel poly(ethylene terephthalate)(PET) capillarychanneled polymer (C-CP) fiber-based extracellular vesicle isolation method using
Dictyostelium discoideum as a model organism.
2.

To create fluorescent Immortalized Human Ovarian Epithelial (IHOE)-CD81-

GFP (non-cancerous) and SKOV-3-CD9-RFP (cancerous) cell lines to produce green
and red small extracellular vesicles, respectively, for use as model sEVs to investigate
PET C-CP fiber-based selective EV capture.
3. To investigate urine and cervical mucus as EV sample sources and explore EV
miRNA expression data as a tool for distinguishing between ovarian cancer and noncancer patient samples and discovering novel ovarian cancer biomarkers for use in
diagnostics.
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CHAPTER 2
EXOSOME ISOLATION AND PURIFICATION VIA HYDROPHOBIC
INTERACTION CHROMATOGRAPHY USING A POLYESTER,
CAPILLARY-CHANNELED POLYMER FIBER PHASE

Abstract
Extracellular vesicles, including microvesicles and exosomes, are lipidic
membrane-derived vesicles that are secreted by most cell types. Exosomes, one class of
these vesicles that are 30-100 nm in diameter, hold a great deal of promise in disease
diagnostics, as they display the same protein biomarkers as their originating cell. For
exosomes to become useful in disease diagnostics, and as burgeoning drug delivery
platforms, they must be isolated efficiently and effectively without compromising their
structure. Most current exosome isolation methods have practical problems including
being too time-consuming and labor intensive, destructive to the exosomes, or too costly
for use in clinical settings. To this end, this study examines the use of poly(ethylene
terephthalate) (PET) capillary-channeled polymer (C-CP) fibers in a hydrophobic
interaction chromatography (HIC) protocol to isolate exosomes from diverse matrices of
practical concern. Results demonstrate the ability to isolate extracellular vesicles
enriched in exosomes with comparable yields and size distributions on a much faster time
scale when compared to traditional isolation methods. As a demonstration of the
potential analytical utility of the approach, extracellular vesicle recoveries from cell
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culture milieu and a mock urine matrix are presented. Scalable separations covering submilliliter spin-down columns to the preparative scale are projected.
It should be noted that this is collaborative work that has been published as a
peer-reviewed article and was performed with Dr. Ken Marcus of the Clemson University
Chemistry Department. Of note, the hydrophobic interaction chromatography work
outlined in this chapter was primarily performed by Dr. Lei Wang and Ms. Sisi Huang.
This chapter appears here directly as published (with minimal additions) for
completeness.
Terri F. Bruce, Tyler J. Slonecki, Lei Wang, Sisi Huang, Rhonda P. Powell, R.
Kenneth Marcus, Exosome isolation and purification via hydrophobic interaction
chromatography
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Introduction
Exosomes are tiny lipid-bound vesicles, approximately 30-100 nm in diameter,
that are secreted by most types of cells, including both normal and disease-state cells.
They carry internal “cargo” molecules, such as nucleic acids and proteins, which are
derived from their cell of origin. These biomarkers make exosomes a promising means of
minimally-invasive early disease diagnosis 1-4. Once considered cellular debris, research
has demonstrated that exosomes have multiple biological roles. Exosomes may be
involved in a myriad of normal physiological processes including cross-placental
communication between the mother and fetus, fetal development, and bone calcification,
as well as disease processes including metastasis, pathogenesis of thrombosis, diabetes,
atherosclerosis, tumor growth, arthritis, and progression of neurodegenerative diseases 4,
5

. Exosomes can be found in most body fluids, including urine, saliva, amniotic fluid,

semen, breast milk, plasma, and blood, making them a promising basis for the
development of liquid biopsies 6, 7. Exosomes have been shown to have unique
microRNA (miRNA) signatures that could soon open the door for clinical and therapeutic
applications 8. Exosomes are being exploited for disease diagnostics 7, 9, 10, including
cancer 11, 12, with potential biomarkers identified relative to a number of different types of
cancers, including ovarian, lung, breast, prostate, and pancreatic cancer 11-14.
Despite these promising attributes, the analysis of exosomes is currently limited
by the processes required to isolate them from body fluids 15-17. In most cases, exosomes
are isolated by differential centrifugation (DC), requiring the use of a high-speed
centrifuge over several hours, including the sedimentation of other particulate debris and
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potentially impacting the integrity of the lipid bilayer membrane of the exosome. Other
emerging exosome isolation techniques include density gradient centrifugation, size
exclusion chromatography, ultrafiltration, polymer-based precipitation, immunological
separation, and microfluidics techniques 13, 18-23. Some of these methods are generic with
respect to the specific types of exosomes which can be isolated, while others solely
capture vesicles originating from specific cell types. Each of these exosome isolation
techniques has benefits, but the aforementioned shortcomings are fairly universal 17, 18, 24.
Thus, none are currently sufficient for use in clinical diagnostics or for isolation of larger
lots from cell culture media as would be required for drug delivery applications.
Exosome isolation methods are generally based on the size/hydrodynamic radii of
the vesicles, i.e, centrifugation, filtration, and sieve-based approaches, or their affinity
towards capture surfaces used in spin-down formats. However, methods relying on
chemical separation and processing platforms, such as those employed in HPLC, have not
been fully explored; yet, they may have many attractive features. Most of the common
LC stationary phases used for chemical separations, such as porous silica beads, would
not be practical, as exosomes would likely be excluded from the internal pore structures,
and clogging would be a major operational problem. This study describes the use of
capillary-channeled polymer (C-CP) fibers as stationary phases for the isolation and
recovery of exosome-enriched populations of extracellular vesicles (referred to as
“exosomes” from here forward) from culture media, buffer, and urine. C-CP fibers have
been employed by Marcus and co-workers as stationary phases for protein separations via
reversed phase, ion exchange, hydrophobic interaction, and affinity chromatographies 25-
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31

. These fibers are melt-extruded from commodity polymers (nylon 6, polypropylene,

and poly(ethylene terephthalate) (polyester,PET)), having a unique cross-sectional
profile consisting of eight “legs” on the periphery. When packed in column formats, the
fibers inter-digitate to create massive numbers of 1-4 µm-wide channels that provide high
permeability to fluid flow. The non-porous nature of the fiber surfaces (at least on the
size scale of proteins) means that intra-phase diffusion of solutes is prohibited. This
combination of macro and micro characteristics results in the ability to affect protein
separations at exceedingly high linear velocities (>50 mm sec-1) without the mass transfer
limitations common to porous phases. These hydrodynamic advantages are
complemented by a high degree of chemical separation diversity. In addition to the range
modalities of separation that can be affected using different base polymers, an extensive
tool box of simple surface modification approaches has also been developed. The fiber
surfaces may be modified to affect high ligand densities for ion exchange (cationic and
anionic) and affinity chromatography 30-32. Affinity separations include the use of
protein A for IgG purification and quantification, biotin-streptavidin interactions, and
chelates for immobilized metal affinity chromatography (IMAC) 33-35. In total, these
attributes make the utilization of the C-CP fibers for exosome isolation a promising
alternative to traditional isolation methodologies.
This study describes the first successful use of the PET C-CP fibers to isolate and
elute exosomes via a hydrophobic interaction chromatography (HIC) protocol. The
procedure, first developed for protein separations 27, is readily implemented to isolate
exosomes from from host cell proteins and concomitant components present in cell
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culture media, phosphate buffer, and urine. The hydrophobic exosome surfaces adhere to
the weakly-ionized surfaces of the PET fibers, making HIC a selective method of
exosome isolation. Use of an HIC approach, involving an inverse salt gradient for
elution, is much preferred over a common reversed-phase (RP) method as organic
solvents employed in RP might result in the loss of important species (e.g. proteins)
adhered to the exosome surfaces. It is important to note that while hydrophobic
substrates have been used in previous exosome assay methods such as the Qiagen
exoEasy Kit, use of a truly chromatographic method holds the promise for higher
throughput and sampling/analysis of other matrix components such as host cell proteins
as retentates can be selectively eluted. Such advantages would be the same as argued in
any case of solid phase extraction versus liquid chromatography.
In order to investigate the ability of the C-CP fibers to isolate exosomes,
Dictyostelium discoideum cells were used to generate generic exosomes. D.discoideum is
not only simple and inexpensive to culture in the lab, but it is also a model organism used
for studying cell signaling, the endocytic pathway, and generation of extracellular
vesicles and exosomes 36, 37. Under normal conditions, it is a common single-cell, soildwelling amoeba; however, under environmental stress, such as lack of water and
nutrients, its cells can form multi-cellular aggregates, the formation of which require
direct cell-to-cell communication 37. The ease with which Dictyostelium discoideum can
be cultured, the prominent role of cellular communication in its life cycle, and its use as a
model organism for exosome research, make it a useful organism for generating
exosomes needed to investigate isolation techniques.
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In this demonstration study, the efficacy and efficiency of the new HIC C-CP
fiber exosome isolation methodology are compared to two commonly utilized exosome
isolation methods, standard differential centrifugation (DC), as it is the most widely used
isolation method, and the exoEasy Maxi Kit (QIAGEN), as it is the most similar
commercially-available method to the proposed HIC C-CP fiber approach 38. The kit
method uses post-centrifugation, spin-down processing and a membrane-based stationary
phase to affect an “affinity” (presumably a hydrophobic interaction) binding step to
isolate exosomes and other EVs from serum and plasma, or cell culture supernatants.
There is no selectivity with regards to size or cellular origin of the EVs. It relies on
generic characterstics of the vesicle surfaces to capture all forms of EVs in the sample.
The implementation of a chromatographic (flow through) approach versus the spin-down,
solid phase extraction (SPE) approach, would seem to present a number of potential
advantages. These attributes are highlighted herein. The utility of the C-CP fiber HPLC
separation is further demonstrated by investigation of recovery of exosomes from
simulated urine and standard cell culture media.

Materials and methods
Exosome Expression by Dictyostelium discoideum
Dictyostelium discoideum AX2 cells (provided by L. Temesvari, Clemson
University) were grown and maintained axenically in HL5 medium supplemented with
100 µg mL-1 ampicillin at room temperature in 25 mL culture flasks 39. Cells were
passaged at 70-90% confluency.
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For exosome expression, AX2 cells were used to inoculate 50 mL of HL5 media
supplemented with 100 µg mL-1 ampicillin at a starting cell concentration of 5 – 10 x 105
cells mL-1 in a 250 mL Erlenmeyer flask. After inoculation, the flask was covered in
aluminum foil to block out light and placed on a shaker (150 RPM, 22˚C) for 48 hours 37.
Isolation of exosomes via differential centrifugation and Qiagen exoEasy Kit
Two widely accepted methods of exosome isolation, differential centrifugation and
the Qiagen exoEasy Maxi Kit, were chosen as benchmarks for comparison to the
proposed PET C-CP HIC isolation method. These specific methods were chosen because
differential centrifugation is one of the most widely used methods for exosome isolation
and the exoEasy Maxi Kit is most like the PET C-CP HIC isolation method in terms of
being an exosome/surface adhesion process. While differential centrifugation is the most
utilized method of exosome isolation, it can sediment host cell proteins along with
exosomes. The process is also time consuming, and requires expensive equipment 18-20, 24.
The Qiagen exoEasy Maxi kit uses a membrane-based affinity column to separate
exosomes and other extracellular vesicles from solutions, in much less time in
comparison to differential centrifugation; however, the process still takes up to 30
minutes to complete and costs approximately $32 per sample 40. Another shortcoming of
the exoEasy method is the high carryover of host cell proteins along with the derived
exosomes.
All resulting differential centrifugation and exoEasy kit exosome isolations were
resuspended in either PBS or Qiagen elution buffer and subsequently divided into two
aliquots. One aliquot of each sample was used for nanoparticle tracking analysis (NTA)
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for the determination of exosome concentration and size distribution, while the other was
used as a concentrated exosome sample during the initial testing of the HIC C-CP fiber
isolation method.
Differential centrifugation
Differential centrifugation retrieval of D. discoideum derived exosomes was
conducted as previously described by Tatischeff et al., with slight modifications 41. Due
to the novelty of D. discoideum in exosome research, all centrifugation steps followed
previous research completed by Tatischeff et al., rather than standard mammalian cell
exosome isolation ultracentrifugation protocols. All centrifugation steps performed
below 12,000Xg were performed using an Eppendorf Centrifuge 5430R (Eppendorf,
Hamburg, Germany). Centrifugations of 12,000Xg or more were performed using a
Beckman Coulter Avanti J-26S XPI Centrifuge with a JA-25.50 rotor (Beckman Coulter,
Brea, CA). The first centrifugation step was performed at 700Xg (5 min., 22˚C) in a 50
mL conical centrifuge tube. After centrifugation, 45 mL of the supernatant was
transferred to a new 50 mL conical centrifuge tube for further centrifugation, with the
remaining 5 mL of supernatant saved for exosome isolation via the C-CP HIC method.
The second centrifugation was performed at 2,000Xg (10 min., 22oC.) The final
centrifugation step was performed at 12,000Xg (30 min., 4oC.) The supernatant was
carefully removed and the final pellet was re-suspended in 400 µL of PBS and stored at
4oC.
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Qiagen exoEasy Maxi Kit
The QIAGEN exoEasy Maxi kit (QIAGEN, Hilden, Germany) isolations were
accomplished per the manufacturer’s instructions. All of the centrifugation steps required
by the kit were performed using an Eppendorf Centrifuge 5430R. Briefly, 10 mL of the
D. discoideum cell growth media prepared for exosome isolation were filtered using a 0.8
µm syringe filter. An additional 1 mL of the remaining media was filtered using a 0.8
µm syringe filter and set aside for exosome isolation via the C-CP HIC method. The
resulting exosomes were eluted using 400 µL of the Qiagen XE elution buffer and stored
at 4oC.
Hydrophobic interaction chromatography (HIC) method
The poly(ethylene terephthalate) (PET) C-CP fibers were produced by the
Materials Science and Engineering Department, Clemson University. All solvents were
purchased from EMD (EMD Millipore, Billerica, MA). Ammonium sulfate ((NH4)2SO4)
and all other chemicals and proteins were purchased from Sigma-Aldrich (St. Louis,
MO). Deionized water (DI-H2O) was secured from a Milli-Q water system. The
chromatographic exosome separations were performed on a Dionex Ultimate 3000 HPLC
system, LPG-3400SD Quaternary pump, and MWD-3000 UV–vis absorbance detector
(Thermo Fisher Scientific, Waltham, MA). A Rheodyne model 8125 low dispersion
injector with 20 and 60 μL injection loops was used for exosome sample injections.
The PET C-CP fiber microbore columns (column length: 200 mm, i.d., 0.762 mm
PEEK, 450 fibers) prepared as described previously 28, were used for the exosome
separations. After flushing the column with Buffer C (10 mM potassium phosphate
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buffer; pH = 7.4), it was equilibrated with Buffer A (1.8 M (NH4)2SO4 solution dissolved
in PBS; pH = 7.4). As previously described in research regarding antibody purification
using HIC, appropriate amounts of organic additives (such as methanol and acetonitrile)
in the elution buffer demonstrate improved protein recovery 42-44. As such, 30%
acetonitrile (v/v) dissolved in PBS was employed as buffer B. A mobile phase flow rate
of 0.5 mL min-1 and a 20 min gradient from 100% buffer A to 100% buffer B was used
for exosome separation. Briefly, exosome samples were injected onto the column during
the high-salt (buffer A) mobile phase. Under these conditions, latent HCPs and exosomes
are adsorbed to the PET fiber media, with the gradient subsequently eluting species of
increasingly greater hydrophobicity. UV absorbance at 216 nm was monitored as a
means of detecting the eluting species (proteins and exosomes). Based on the detector
response reflecting their elution, purified exosomes were collected post-column.
HIC elution and isolation of exosomes from simulated urine and standard cell culture
media
In order to demonstrate the HIC C-CP column isolation of exosomes from body
fluids, and to assess the potential quantitative aspects of the exosome isolation method,
previously isolated exosomes were spiked into a simulated urine matrix (194 g urea, 6 g
CaCl2, 11 g Mg2SO4, and 80 g NaCl in 1 L of DI-H2O), spiked with myoglobin (Myo), αchymotrypsinogen A (Chymo), ribonuclease A (Ribo), bovine serum albumin (BSA), and
lysozyme (Lyso) (0.1 mg mL-1 each), as simple representatives of the variety of proteins
present in urine. HIC isolation of the vesicles from the simulated urine was followed by
quantification based on the integrated peak areas of the eluted exosomes. The gradient
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baseline absorbance, obtained by running the gradient with no exosomes injected, was
subtracted from the exosome-spiked separation chromatograms.
Exosome characterization via Nanoparticle Tracking Analysis (NTA)
Nanoparticle tracking analysis (NTA) was performed using a Nanosight
(Malvern, Worcestershire, UK) NS500 with a 532 nm laser and 565 nm long pass cut off
fluorescent filter (Center for Nanotechnology in Drug Delivery, UNC Eshelman School
of Pharmacy). Samples were diluted to a concentration between 1x108 and 5x108
particles mL-1 with 20 nm filtered PBS. For each sample, particles moving under
Brownian motion were recorded on video five times for 40 seconds each. Hydrodynamic
diameters were calculated using the Stokes-Einstein equation.
Transmission Electron Microscopy Fixation, Staining, and Imaging
Transmission electron microscopy (TEM) imaging was used to verify the physical
size of single vesicles. D. discoideum differential centrifugation extracellular vesicles and
human urine standard exosomes (Galan Laboratory Supplies, North Haven, CT) were
fixed in 4% paraformaldehyde for 1 hour. Immediately following fixation, 5 µl of each
sample was applied to 200 mesh formvar carbon coated copper grids (Electron
Microscopy Sciences, Hatfield, PA) and allowed to adsorb for 5 minutes. Each sample
grid was negatively stained with 5 µl of 2% Uranyl Acetate for 5 minutes. Grids were
then washed 3 times in 10 µl of distilled water for 5 minutes each and allowed to dry for
imaging. All TEM images were obtained using a Hitachi H-7600 TEM (Hitachi, Tokyo,
Japan) in the Clemson Electron Microscopy Lab.
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Scanning Electron Microscope Fixation and Imaging
The capture of intact exosomes onto the C-CP fiber surfaces was confirmed by
scanning electron microscopy (SEM) imaging. Proprietary PET C-CP fiber-packed tips
were produced according to a previously described method 45. The fiber surfaces were
wetted by flushing with 1 mL of H2O, and then rinsed in 2M (NH4)2SO4 in PBS. 100 µL
of each sample (DC-derived exosomes, milieu or 2M (NH4)2SO4) were mixed with 2M
(NH4)2SO4, followed by flushing through the tip (300Xg for 5 min). The prepared fibers
were fixed in 1% osmium tetroxide for 1 hour and washed 3 times for 3 minutes each in
distilled water to remove any excess osmium tetroxide. Next, each sample was washed in
a 6 step gradient of ethanol-distilled water solutions starting at 50% ethanol and ending at
100% ethanol for 3 minutes each. An additional 100% ethanol wash step was performed
to ensure that all water had been removed from the sample. Finally, each sample was
washed in a 50-50 hexamethyldisilazane (HMDS)-ethanol solution for 3 minutes and
dried in 100% HMDS overnight. Samples were sputter-coated with platinum at 70
millitorr argon for 2 minutes using a Hummer 6.2 Sputtering system (Anatech USA,
Union City, CA). SEM imaging was performed on a Hitachi S-4800 at 5.0 kV (Hitachi,
Tokyo, Japan).
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Results and Discussion
HIC isolation of exosomes
In order to determine whether or not exosomes could be isolated via HIC using the
PET C-CP fibers, aliquots of the D. discoideum-derived exosomes that had been
previously isolated using the benchmark techniques were run on the PET C-CP columns
with a mobile phase flow rate of 0.5 mL min-1 and a 20 minute gradient from 100%
buffer A (1.8 M (NH4)2SO4 in PBS) to 100% buffer B (30% v/v acetonitrile in PBS).
Figure 2.1 shows the resulting chromatograms derived from pristine HL5 media and four
different exosome isolation lots. In Fig. 2.1a, pristine HL5 was injected in order to
establish a baseline chromatogram of the media components. The detector response
shows a broadly eluting peak from ~2 – 10 minutes, composed of a myriad of proteins
derived from yeast extract and peptone, various salts, and sugars. In Fig. 2.1b, exosomes
previously isolated via differential centrifugation were injected onto the fiber column.
The resulting HIC chromatogram displays two major peaks, a very broad band between 2
– 11 minutes, and a fairly sharp feature reflecting more strongly retained (hydrophobic)
species with an elution time of ~13 – 13.5 mins. In Fig. 2.1c, exosomes previously
isolated via the exoEasy kit were injected for HIC separation. The resulting
chromatogram displays four prominent peaks. In this case, the first three broad peaks
eluting within the same same time frame of 2 – 11 minutes bands in Figs. 2.1a and b. As
in Fig. 2.1b, a discrete feature eluting in the ~13 – 13.5 min window is seen. Based on
the structure of the respective chromatograms (Figs. 2.1a-c), it is not unreasonable to
suggest that the peaks eluting between 2 – 11 minutes represent remaining HL5 media
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components, host cell (D. discoideum) proteinaceous and genetic material, salts, and
other small molecules left behind during the previous isolation procedures, with the later
eluting (13 – 13.5 min) smaller, sharper peak representing exosomes. One cannot rule
out that there may be some EV-related material in the broad elution band, but one would
expect that such species would be very hydrophobic in comparison to other media and
cellular byproducts.
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Figure 2.1. Representative HIC chromatograms of exosome isolation using
using PET C-CP fibers. Separations were performed with a mobile phase flow
rate of 0.5 mL min-1, 60 µL aliquot injections, and a 20 min gradient from 100%
buffer A (1.8 M (NH4)2SO4 solution dissolved in PBS; pH = 7.4) to 100% buffer
B (30% acetonitrile (v/v) dissolved in PBS). a) Baseline chromatogram of pristine
HL5 media. b) D. discoideum-derived exosomes previously isolated via
differential centrifugation. c) D. discoideum-derived exosomes previously
isolated via the Qiagen exoEasy Maxi Kit. d) D. discoideum-derived exosomes
following centrifugation to remove cells and large debris. e) D. discoideumderived exosomes following filtration through a 0.8 µm filter to remove cells
and large debris. f) Abbreviated gradient program (injection at A (0.8 M
(NH4)2SO4 solution dissolved in PBS; pH = 7.4), gradient initiated at t= 2 min.,
gradient to 100% buffer B (30% acetonitrile (v/v) dissolved in PBS) in 10 min.
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Indeed, simple Bradford assays revealed very high protein/amino acid content in
these bands. Further confirmation of the latter assignment is presented in particle
tracking data and SEM images presented in subsequent sections. These results suggest
that the PET C-CP HIC method is effective at separating the population of exosomes
from other chemical species inherent in the spent cell media. Indeed, the presence of the
broad concomitant elution bands in the HIC chromatograms reflects the non-specificity
and carryover towards proteins, etc. that exists in the DC and exoEasy isolates. It is
believed that the far greater abundance of such species (based on the integrated
absorbance of the bands) for the exoEasy case versus the DC is due to non-specific
binding to the hydrophobic matrix versus the differential centrifugation where proteins
and exosomes are more discretely segregated. HIC results prove that the exosome
fractions can indeed be readily isolated from those otherwise undesirable components, as
in the protein carryover in the exoEasy. Removal of such proteins would require further
processing for both the DC and exoEasy isolation methods. The eluted exosome
fractions from these isolations were collected and saved for NTA.
To more realistically compare the efficiencies of the C-CP fiber method with the
benchmark methods, D. discoideum cell cultures were processed in similar fashions in
terms of removing whole cells and cellular debris. In the case of DC, simple
centrifugation is the first step, while macroscale debris is filter-removed prior to exoEasy
Kit isolation. The resulting culture milieu solutions, having the exosomes in their native
(relatively dilute) concentrations, were then subjected to HIC on the PET C-CP fiber
columns using the previous gradient. The chromatogram of the centrifuged D.
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discoideum cell culture milieu (Fig. 2.1d), displays two prominent peaks at elution times
of 2 - 11 and approximately 13 minutes, respectively. The differences in retention time
(<5 % relative) and shapes among the exosome eluents may be due to slight differences
in the surface chemistries of the exosomes based on how they were processed prior to the
HIC separation, especially solvent composition. This is certainly a point for further
investigation. As before, the broader peak is attributed to various media components and
cellular metabolites and debris, with the smaller second peak attributed to more
hydrophobic species, likely exosomes. The relative responses for the concomitant
species and the exosomes make sense as there is apt to be more debris and proteinaceous
material, and lower exosome concentrations, in the milieu sample than the DC isolate
suspended in PBS. The exosome peak from the milieu reflects their more dilute
concentration in this stage of media processing. The corresponding HIC chromatogram
taken of the filtered cell culture media is structurally the same as those seen in Figs. 2.1bd, though with a lower relative exosome yield versus the other media components. This
suggests that there may be some exosome loss in the initial filtration process in the
exoEasy kit protocol, which is not unreasonable as the filter material itself is composed
of both hydrophobic and hydrophilic layers.
As in any new chromatographic method, there are many aspects of the separation
that can be optimized. The ability to improve the HIC method throughput is illustrated in
Fig. 2.1f, where the initial DC milieu sample was injected at a reduced salt concentration
of 0.8 M ammonium sulfate. In this way, the components making up the broad elution
peak are not retained on the column. Following passage of the injection peak, the reverse
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salt gradient was then initiated, with clean elution of the exosomes. A simple
comparison to the analogous full gradient (Fig. 2.1b) reveals that there is little or no
difference in the exosome recovery for the abbreviated gradient method. Thus, there is
an expectation that further improvements in throughput may be realized. Certainly,
larger column formats would also improve processing speeds.
Comparison of exosome recoveries for the different isolation methodologies
NTA is a widely-accepted method for the evaluation of exosome concentration
and size distribution, and so was used to characterize the exosome isolation from the DC
and exoEasy kit procedures and those of the exosome fractions from the HIC isolations.
Figure 2.2 provides a graphic overview of the procedural steps and NTA-determined
exosome concentrations for each exosome isolation protocol. The initial entrees into the
flow charts (starting milieu volumes) were chosen based on previous experience in the
use of DC and exoEasy methods, with the ultimate particle densities normalized to a
common 50 mL volume sample.
Since all particles counted during the NTA may not be exosomes (protein
aggregates, other classes of extracellular vesicles, including microvesicles, and other
cellular debris would also be counted), the resulting values (presented as particles-permL) in Fig. 2.2 should be compared to one another on an order-of-magnitude basis as
opposed to absolute values. When compared in this manner, it can be seen that the
differential centrifugation (Fig. 2.2a) and exoEasy kit (Fig. 2.2b) yield comparable
exosome/particle recoveries. Figure 2.2 also shows that the PET C-CP HIC exosome
isolation method, regardless of whether the cell culture was first centrifuged (Fig. 2.2c) or
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a) Differential
Centrifugation

b) Qiagen exoEasy
Maxi Kit

c) Centrifuged Milieu
+ C-CP fiber HIC

d) Filtered Milieu +
C-CP fiber HIC

Initial Media
Volume

50 mL

10 mL

50 mL

50 mL

Working
volume

400 µL of
exosomes in
PBS

400 µL of
exosomes in
Buffer XE

1000 µL in HL5

1000 µL in HL5

4x80 µL injections
and 1000-1200 µL
collection
(4x dilution)

4x80 µL injections
and 1000-1200 µL
collection
(4x dilution)

NTA

6.5x1011
particles mL-1

3.3x1011
particles mL-1

1.4x1009

5.3x1008

particles mL-1

particles mL-1

Density in 50 mL
original cell media

2.6x1011

6.6x1011

2.9x1011

1.1x1011

particles

particles

particles

particles

Process time

2+ hours

30 minutes

8 minutes

8 minutes

Determined density

Figure 2.2. Comparison of NTA-determined particle population
characteristics following the various exosome isolation methodologies. All
values were normalized to number of particles (exosomes) derived from 50 mL
of starting cell culture. Reported values are averages from triplicate isolations.
a) Exosomes isolated via differential centrifugation. b) Exosomes isolated via
Qiagen exoEasy Maxi Kit. c) Cell culture media cleared of cells and large
debris via centrifugation, followed by exosome isolation via PET C-CP HIC. d)
Cell culture media cleared of cells and large debris via filtration, followed by
exosome isolation via PET C-CP HIC.
filtered (Fig. 2.2d) to remove cells and large debris, yields the same order of magnitude
values as the benchmark methods following the initial debris removal steps.
The particle size distributions, as measured by NTA, were also very similar across
all of the isolated exosome samples, regardless of the isolation method (Table 2.1). In
general, the D. discoideum exosome size distributions were very similar to those
previously reported by Tatischeff et al.41 Histograms of the NTA size distributions (Fig.
2.3) each contained a prominant high concentration peak on the lower range of the size
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distribution scale ranging from ~90 to 160 nm, typically representing ~70 % of the total
population. Beyond this, a minor, larger-sized fraction is also seen in each distribution,
most prominently in the DC-generated populations. These populations reflect protein and
exosome agglomerates, as well as other classes of extracellular vesicles, including
microvesicles, which would be most expected in the case of differential centrifugation.

Such populations would also reflect the time-lag associated with sampling, packaging,
and shipping of the materials for NTA characterization. Performing NTA/SEM/TEM
measurements immediately following exosome isolation may help remediate the level of
potential exosome or protein aggregation. Collectively, the NTA results demonstrate that
the PET C-CP fiber exosome isolation method does not adversely bias exosome
population recoveries (density or sizing) versus the benchmark isolation methods.
As a final point of comparison, Fig. 2.2 also demonstrates the isolation time
Table 1. Comparison of exosome size population characteristics for the different isolation

procedures
as determined
represent
averages forfor
triplicate
isolations.
Table
2.1 Comparison
of by
EVNTA.
size Values
population
characteristics
the different

isolation procedures as determined by NTA

Standard
10th
Deviation Percentile
(nm)
(nm)

90th
Percentile
(nm)

Exosome Isolation Method

Mean
(nm)

Mode
(nm)

Differential centrifugation

183

143

66.3

119

257

Qiagen exoEasy Maxi kit

154

97.1

80.2

87.6

263

Centrifuged milieu +
PET C-CP fibers

155

121

60.1

106

228

Filtered milieu +
PET C-CP fibers

142

108

60.4

87.6

206
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required for each of the processes. Differential centrifugation is the most timeconsuming method, requiring more than 2 hours to perform (Figs. 2.2a). In comparison,
the exoEasy kit requires approximately 30 minutes (Figs. 2.2b), while the PET C-CP HIC
method can be affected in only 8 minutes (Figs. 2.2 c,d). The C-CP fiber-based method
is appreciably faster than either benchmark method, a major asset with regards to its
potential usefulness for exosome isolation in a clinical setting. Indeed, the HIC method
could be easilly affected in less than 3 minutes with the use of a step-gradient program as
suggested in simple terms in Fig. 2.1f.
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a

b

c

d

Figure 2.3. Representative nanoparticle tracking analysis (NTA) size
distributions. a) differential centrifugation, b) Qiagen exoEasy Maxi kit, c)
centrifuged milieu + PET C-CP fibers, and d) filtered Milieu + PET C-CP
fibers.
Imaging of exosomes adsorbed onto C-CP fibers
While the size distributions of the D. discoideum EVs were very similar to those
previously reported by Tatischeff et al. 38, the standard method of verifying the presence
of EVs or exosomes generally includes NTA size distribution results in conjunction with
Western Blot verification of the presence of known exosomal protein markers, and a
TEM micrograph to visualize and verify sizes of individual vesicles. However, this trio of
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Figure 2.4. TEM images of exosomes immobilized on copper grids. (Left)
Standard exosomes derived from human urine (Right) D. discoideum-derived
exosomes previously isolated via differential centrifugation.
verification methodologies is for mammalian cell‐derived exosomes, where exosomal
marker proteins have been verified and antibodies to these proteins are commercially
available. To this end, no commercial antibodies exist for D. discoideum EV surface
proteins. Therefore, we rely herein upon the resultant NTA data in combination with
TEM micrographs of the commercially available exosome standards as compared to D.
discoideum EVs resulting from the differential centrifugation method employed for
isolation throughout this study (Fig. 2.4).
The resulting micrographs show that the sizes and general morphology of the
standard exosomes and those exosomes derived from D. discoideum are very similar.
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a

b

c

Figure 2.5. SEM images of exosomes immobilized on PET C-CP fibers. a) 2M
ammonium sulfate control (no exosomes exposed). b) D. discoideum-derived
exosomes previously isolated via differential centrifugation. c) Higher
magnification image of exosomes depicted in micrograph b, showing detail of
exosome interactions with each other and the fiber surface.
Therefore, we contend that the differential centrifugation method employed resulted in
the isolation of D. discoideum exosomes. These purified exosomes were subsequently
utilized to produce SEM images of the exosomes on the experimental columns as
outlined below.
SEM images were collected to verify the presence and integrity of the exosomes
and to investigate how they interact with the PET C-CP fiber channels. Exosomes that
had been isolated from D. discoideum cell culture media via differential centrifugation
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and re-suspended in PBS were added to 2M ammonium sulfate chromatographic mobile
phase and then each spun through PET C-CP fiber micropipette tips using the described
solid phase extraction technique.33, 45 In addition, 2M ammonium sulfate was spun
through a separate tip as a non-exosome control.
In each case, an aqueous wash step was employed following exposure to remove
any accumulated media particulates. As seen in Fig. 2.5a, the fibers exposed only to the
salt media show a very smooth surface, with multiple channels of the same fiber seen at
this 10 µm-scale micrograph. Passage of the DC–derived media through the fibers
results in the adsorption of vesicle material as seen in Fig. 2.5b (2.0 µm-scale). A large
number of vesicles are present as individual entities, but some appear as aggregates. It
remains to be confirmed whether or not the agglomerates were formed on the fiber
surface or originated in the milieu. Further magnification of the DC-derived aliquot (Fig.
2.5c, 500 nm scale) shows exquisite detail of individual exosomes, with diameters of 100
nm or less, on the PET fiber surfaces with some neighboring exosomes touching one
another, perhaps stretching or elongating as they adhere to the fiber. This morphology
could be early signs of aggregation or exosome fusion. While the SEM imaging
demonstrates the phenomenon of the immobilization of the exosomes on the fiber
surfaces, it also suggests that the fiber platform might be a valuable means of studying
exosome agglomeration or other phenomena.
Isolation of exosomes via HIC from a simulated urine matrix
Following verification that exosomes could be isolated directly from D. discoideum
culture milieu, the ability to isolate exosomes from synthetic urine (an ability needed for
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diagnostic applications) was investigated. For this experiment, exosomes that had been
previously isolated via differential centrifugation were spiked into a simulated urine
matrix which was also spiked with the model proteins Myo, Chymo, Ribo, BSA and
Lyso, each at a concentration of 0.1 mg mL-1. In this way, isolation from both urine
matrix components and concomitant proteins is demonstrated using the same HIC
gradient as employed in the Fig. 2.1 separations. Figure 2.6 shows the HIC
chromatogram of the simulated urine matrix to establish baseline elution times for the
matrix components and the spiked proteins. The five proteins are very well resolved in
this case, with the other matrix species eluting as a band over the 8 – 10 min elution
window. As seen in Fig. 2.6, when the simulated urine was spiked 50:50 with DCisolated exosomes and subsequently run on the C-CP columns, HIC revealed the
expected peaks for the spiked proteins along with an additional, later-eluting prominent
peak attributed to the exosomes. Importantly, the added proteins appear as discrete peaks
superimposed on a broader peak previously attributed to remnant proteins and debris
associated with the spiked exosomes following their DC-isolation (Fig. 2.1b). (The 0.1
mg mL-1 concentrations spiked here are clearly higher than those present from the spiked,
equal-volume, milieu isolate.) The ability to cleanly separate exosomes from other
species in a urine matrix suggests that C-CP fiber HIC (or simple solid phase
extraction45) may be a promising method of isolation in a clinical setting.
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Figure 2.6. PET C-CP fiber HIC chromatograms of simulated urine matrix
spiked at 0.1 mg ml-1 concentration of model proteins and 50:50 mixture of
simulated urine and DC-isolated exosomes. Separations were performed with
a mobile phase flow rate of 0.5 mL min-1, 20 µL aliquot injections, and a 20 min
gradient from 100% buffer A (1.8 M (NH4)2SO4 solution dissolved in PBS; pH =
7.4) to 100% buffer B (30% acetonitrile (v/v) dissolved in PBS).
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Potential for Exosome Quantification
In order to make exosome retrieval easier to verify and potentially quantify, a
simple measure of recovery is needed. In the context of the HPLC isolation step, UV-vis
absorbance at 216 nm is a viable approach. This is a common wavelength used in protein
chromatography, and fortuitously, the exosomes absorb at this wavelength. It is most
common to quantify exosomes based on lysing the vesicles and quantifying the total
protein content via Western blot separations or a Bradford-type assay, or counting/sizing
particles via NTA. Of course, this assumes no protein carryover in the isolation step, the
protein content in each exosome is the same, and no extraneous cellular debris is present.
Hook and co-workers have employed a surface plasmon resonance (SPR) approach to
quantification 46, wherein target proteins are captured onto a gold substrate through a
surface immobilized antibody. Solution concentrations were extrapolated from first
principles relationships, but not verified by any external standards. To establish a
quantitative relationship between exosome concentration and absorbance, increasingly
larger aliquots of exosomes (previously isolated via DC) were added to 100 µL aliquots
of the simulated urine and the culture milieu (HL5) matrices, and the integrated
absorbance values for the peaks eluting between 13 - 14 minutes were recorded. As
shown in Fig. 2.7, a direct proportionality exists, suggesting quantitative recovery of
exosomes from the C-CP fiber separation method. While the robustness of the method as
employed here requires far greater evaluation, the results plotted in Fig. 2.7 represent a
total of 24 and 15 injections of the respective samples (urine and media), each on a single
column, without showing deleterious effects
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Figure 2.7. Analytical response curves for separations of mixtures of 100
µL of the test matrices (simulated urine and HL5 media) and the
designated volumes of DC-isolated exosomes. Separations were performed
with a mobile phase flow rate of 0.5 mL min-1, 20 µL aliquot injections, and a
20 min gradient from 100% buffer A to 100% buffer B. Error bars reflect the
standard deviation across n=3 injections.
regarding the analytical precision. This suggests insignificant carryover or irreversible
binding of the exosome solutes. The number of cycles that milieu-derived samples might
be run is a more stringent and practical metric which is currently under review.
Importantly, the slopes of the two response curves are virtually identical,
implying that the purity of the isolated fractions is very consistent between the two matrix
forms. Note, we are in no position to place firm concentration values on the results of
these experiments, as no appropriate certified reference materials (CRMs) exists.
Sources of quantified exosomes will be investigated to provide more definitive figures of
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metrics. Based on the NTA values presented in Table 2.1, the working range presented in
Fig. 2.7 is ~0.1 – 7 X109 particles for the 20 µL injections. Accordingly, it is not difficult
to imagine limits of detection for this method to be approximately 5 X107 particles. Of
course, UV-vis absorbance post-column quantification could also be applied for
preparative purposes. One could also envision other LC-compatible detection methods,
for example, multi-angle light scatter (MALS), which would also provide size
information for the eluting particles.
Conclusions
In order for basic research and potential application of exosomes to continue to
grow, lower cost, more time-efficient methods of exosome isolation are needed. This
report introduces a promising new isolation platform using PET C-CP fibers as stationary
phases for HIC isolation of exosomes. The method isolates exosome populations of
similar number density and size distribution as currently accepted isolation methods
involving advanced centrifugation or solid phase extraction. The fiber platform is
inexpensive ($5 USD per column which can be used >20 times on the analytical scale),
while providing comparatively high throughput. Additionally, the versatility of the C-CP
fibers will allow for the addition of antibodies, surface chemistries, and other isolation
modalities to transform the generic (hydrophobic interaction) exosome isolation method
demonstrated here into a type-specific method. In an alternative approach, the fibers may
be used in spin-down column format (i.e., micropipette tips) to isolate exosomes from
body fluids such as urine 47, providing high purity, high throughput, and cost-effective
exosome isolation for potential clinical use. Selective capture can be augmented with
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spectroscopic or visual imaging as means of verifying the presence of target exosome
species on the fiber surfaces.
Much fundamental work remains towards realizing the practical utility of the
method on the clinical, analytical, and preparative scales. Each of these areas will pose
challenges and require evaluation regarding selectivity, robustness, loading capacity,
throughput, and column structure/operation parameters. Many basic challenges towards
this end remain. For example, there exist no reference materials which contain
quantitative amounts (either mass or number) of exosomes in defined media. Ultimately,
the potential impact of exosomes in modern medicine is a tremendous driving force for
these continued efforts.
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CHAPTER 3
A MODEL SYSTEM TO INVESTIGATE SELECTIVE
EXTRACELLULAR VESICLE CAPTURE
Abstract
Ovarian cancer (OC) is one of the deadliest cancers for women, in part due to its
often late stage discovery. Given current advanced treatment options, earlier diagnosis of
OC could greatly improve overall survival rates. Presently, there are no routinely
administered early OC screening techniques for non-symptomatic women. This is crucial,
as there is no symptomology associated with early stage, and late stage OC
symptomology is generally vague, including abdominal bloating, gastrointestinal upset,
nausea and fatigue. Exosomes are a subpopulation of extracellular vesicles (EVs)
approximately 30-150 nm in diameter that may hold promise for the development of
early OC diagnostics. However, despite promising studies, exosome diagnosis has been
mainly limited to research laboratories primarily due to inconsistencies in isolation and
characterization methodologies. The poly(ethylene terephthalate) (PET) capillary‐
channeled polymer (C‐CP) fiber-based EV isolation platform, discussed in Chapter 2,
may result in quicker, cheaper, and easier exosome isolations, but requires refinement to
improve the selectivity, specificity, and diagnostic accuracy required for clinical OC
diagnostics. The model system of cancerous and non-cancerous fluorescent EVs and the
immunoaffinity capture protocol developed and analyzed here will allow for quicker and
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easier development and optimization of a selective PET C-CP EV isolation platform for
use in OC diagnostics.
These investigations include collaborative work with Dr. Ken Marcus of the
Clemson University Chemistry Department.
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Introduction
Late stage diagnosis of severe maladies, particularly cancers, has led to poor
outcomes and high mortality among patients.1-3 Early diagnosis of these diseases,
regardless of treatment strategies, can greatly increase survival and outcome for patients.
For example, patients with melanomas, if diagnosed early, have an average 5-year
survival rate of 98%. However, when the patient is diagnosed late and melanoma reaches
the lymph nodes or metastasizes to other organs during later stages, the 5-year survival
rate drops to 64% and 23%, respectively.4 Likewise, pancreas, lung, ovarian, and breast
cancer, among others, demonstrate similar 5-year survival patterns.3, 5-13 Improvements in
early diagnosis and standardization of preventative screening are crucial components in
improving cancer survival rates.
Exosomes, a type of extracellular vesicle (EV), have recently garnered attention
as diagnostic tools and have several unique properties that make them ideal candidates as
biomarkers for early cancer diagnostics. First, as exosomes appear to be selectively
packaged with particular contents, including exosomal protein, lipid, and RNA markers,
they may be identified and traced back to the originating cell.14, 15 In particular, protein
marker identification and miRNA expression pattern recognition through advanced data
analysis may help develop exosome marker profiles for particular diseased cell-derived
exosomes.5, 16, 17 Second, exosomes are released by nearly all types of cells and are found
in nearly all types of body fluids.18 The ability to identify the same category of biomarker
from nearly all cell types may allow for development of a universal test to screen for a
multitude of diseases. Furthermore, a wide variety of body fluids from which to isolate
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EVs provides flexibility with regards to the types of exosome isolation methods that may
be utilized. Finally, exosomes are very stable and can protect protein and RNA contents
from protease and RNase degradation.19-21 This high exosome stability may allow for the
use of more severe isolation methods to enhance the speed and lower the cost of exosome
isolations. In addition, this quality makes them a more reliable species for use in liquid
biopsies than free DNA and RNA species that may be easily degraded.22
To date, the full potential of exosome-based diagnostics has yet to be realized in
clinical trials. However, several groups have developed promising exosome-based
diagnostic platforms using protein and miRNA markers. For example, Zhao et al. have
developed a microfluidics device that uses microbeads to capture and identify ovarian
cancer (OC) exosomal protein markers.23 Similarly, Yokoi et al. have developed an
analytical method to better diagnose OC using a combination of 8 exosome miRNAs with
a sensitivity of 0.92 and a specificity of 0.91.16 As evidenced by these studies, OC has
emerged as a desirable exosome diagnostic target due to its morbidity and the diagnostic
difficulties associated with the disease. OC, when diagnosed in stage 3 or 4, has a 5 year
survival rate of 29%. However, when OC is diagnosed and treated in stage 1, the 5 year
survival rate is 92%.24 Unfortunately, due to lack of effective diagnostic technologies and
indistinct early symptomology, most OC cases are diagnosed in stage 3 or 4.25, 26
Exosome-based diagnostics may provide an opportunity for early stage OC detection,
allowing treatments to be started earlier and potentially increasing the overall survival
rate of OC patients.
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There is now an ongoing effort to identify the patterns of protein and miRNA
expression within malignant tumor-derived exosomes to establish biological pathways
and discover new potential cancer biomarkers. By utilizing mass spectroscopy-based
proteomics and miRNA sequencing analysis in conjunction with machine learning and
pattern recognition algorithms, exosome expression patterns are being identified and
categorized by cancer type, stage, malignancy, origin, and pathology.5, 27-39 As the
available data continues to amass, more patterns that can be used for diagnosis will
emerge. However, the quickly changing classifications, isolations, and terminologies
surrounding exosomes and EVs may require that these analyses be revisited. Despite
these early challenges, it is anticipated that the differentiation of cancerous and noncancerous exosome expression patterns from this data will ultimately be an important
step in the development of quick, easy, and non-invasive exosome-based cancer
diagnostics.
Complete exosome proteomes and miRNA profiles are excellent for identification
of proteins and miRNAs enriched in cancerous exosomes, but not realistic for affordable
and efficient clinical diagnostics. Development of comprehensive proteomes and miRNA
profiles is expensive, time consuming, and would require extensive data analysis
amounting to long time periods passing between sample collection and diagnosis. A
much simpler, cheaper, and faster strategy has been to utilize identified enriched protein
and miRNA exosomal biomarkers to capture subpopulations to determine the origins of
the exosomes.18, 22, 36, 37, 40-43 Through these kinds of efforts, OC tumor cells have been
found to release exosomes enriched in protein biomarkers including, EpCAM (epithelial
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adhesion molecule), CA-125 (cancer antigen 125), CD24 (cluster of differentiation 24),
HER-2 (human epidermal growth factor receptor 2), CLDN3 (claudin 3), CLDN4
(claudin 4), L1CAM (L1 cell adhesion molecule), EGFR (epidermal growth factor
receptor), PCNA (proliferating cell nuclear antigen), TGF-β1 (transforming growth factor
- β1) , MAGE3/6 (melanoma antigen gene 3/6), FASN (fatty acid synthase), ERBB2
(receptor tyrosine-protein kinase), and APOE (apolipoprotein E).43-47 Furthermore,
antibodies to these biomarker proteins have demonstrated the ability to specifically
capture and/or identify subpopulations of exosomes for potential disease diagnostics.
Despite the promising medical applications and biomarker discovery underway,
reliable exosome isolation remains a large hurdle for their use in diagnostics.18, 48-52 Slight
variations in exosome isolation methods can greatly alter both the exosome proteome and
miRNA profile40, 52-54, making comparisons across datasets difficult. Additionally,
different exosome isolations may alter the integrity of the vesicles and their contents,
further contributing to alterations in proteome and miRNA signatures.22, 36, 55 Although
the EV community is working to create standards to increase consistency across the field,
there remains a need for an improved exosome isolation method that can become a
dominant protocol within the field. Current standards and commercially available
isolation methods are often expensive, slow, inefficient, or retain non-exosomal
impurities, making them unreliable in a clinical setting. A diagnostic test for early OC
needs to be quick, easy, and cost effective so that it can be performed routinely as a
preventative screening tool for women. Additionally, diagnostic accuracy has yet to be
verified for each type of exosome isolation. Developing an improved exosome isolation
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method that preserves exosome stability and integrity for downstream analysis is not only
critical for clinical translation but will also improve the accuracy, speed, and cost of
research laboratory protocols.
To increase the signal to noise ratio inherent in discovery of exosomal markers
and further improve diagnostic accuracy, it will be essential to efficiently separate
exosomes from healthy and diseased sources. Immunoaffinity capture will almost
certainly play a large role in this; however, differentiating capture of healthy and diseased
exosome populations may prove difficult. The separation will likely require time
consuming, costly protein assays to verify the results of each test and involve variable
and costly patient samples. Alternatively, model systems are frequently used to speed up
the protocol optimization process and reduce costs for early research. In this case, a
model system of cancerous and non-cancerous cell lines capable of producing
fluorescently-labeled exosomes would enable efficient optimization of the poly(ethylene
terephthalate)(PET) capillary-channeled polymer (C-CP) fiber-based EV isolation
platform, developed by Bruce et al.56, for use in OC diagnostics. This study details the
development and analysis of two new cells lines, one cancerous and one non-cancerous,
that constitutively express fluorescently-tagged exosomal marker proteins that allow for
simple, colorimetric-based differentiation between their individually released exosomes.
As there are several known exosomal OC protein biomarkers and OC is a prime
target for exosome-based diagnostics, cancerous (SKOV-3) and non-cancerous (IHOE)
ovarian cell lines were selected for the development of a model system for the production
of fluorescently-labeled exosomes. Each cell line was genetically transduced to express
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known exosomal markers, CD81 and CD9, with fluorescent tags of different excitation
and emission wavelengths (GFP and RFP, respectively). Exosomes isolated from each of
the resulting cell lines, IHOE-CD81-GFP and SKOV-3-CD9-RFP, express fluorescent
markers that allow for easier differentiation, separation, and detection of cancerous and
non-cancerous ovarian cell-derived exosome populations. To test the ability of PET C-CP
fibers to capture the model vesicles and to check for any potential adverse effects of the
fluorescent tags on the binding of the exosomes to the fibers, IHOE-CD81-GFP and
SKOV-3-CD9-RFP exosomes were used to evaluate adherence to the surface of the PET
C-CP fibers and fluorescence images were collected. Finally, in a proof-of-concept
investigation aimed at future efforts for the direct translation to OC diagnostics based
upon the new PET C-CP fiber-based EV isolation platform, antibodies to known
universal exosomal biomarkers and exosomal OC biomarkers were used to capture preenriched IHOE-CD81-GFP and SKOV-3-CD9-RFP exosomes on nitrocellulose
membranes to demonstrate the specific capture of the cancerous and non-cancerous
fluorescent exosomes. By utilizing these model cancer and non-cancer cell-derived
exosomes, the accuracy, selectivity, and specificity of the new PET C-CP EV isolation
platform may be studied without the need for more costly and difficult to obtain patient
samples. With improvements as a result of the fluorescent exosome model system
developed here, this diagnostic platform may be optimized for the identification of early
stage ovarian cancer and hopefully provide a quick, easy-to-use, and inexpensive tool for
routine and early ovarian cancer screening in the future.
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As the EV research field expands, experts have expressed a growing concern that
vesicles referred to generically as exosomes may actually be a mix of EV subtypes. Due
to the complex debate surrounding EV classification and nomenclature currently
underway, all EVs discussed herein will be referred to as small EVs (sEVs) rather than
exosomes specifically.

Materials and Methods
Cell and culture conditions
Immortalized Human Ovarian Epithelial (IHOE) cells (Applied Biological
Materials, Richmond, BC, Canada) were maintained in Prigrow I medium (Applied
Biological Materials, Richmond, BC, Canada) supplemented with 10% exosome-depleted
fetal bovine serum (FBS) (A2720801, Thermo Fisher Scientific, Waltham, MA), 100
IU/mL penicillin and 100 µg/mL streptomycin at 37˚C and 5% CO2. Human ovarian
adenocarcinoma epithelial SKOV-3 cells (ATCC, Manassas, VA) were maintained in
McCoy’s 5a Medium Modified supplemented with 10% exosome-depleted fetal bovine
serum (FBS), 100 IU/mL penicillin and 100 µg/mL streptomycin at 37˚C and 5% CO2.
Additionally, IHOE-CD81-GFP and SKOV-3-CD9-RFP cells were supplemented with
puromycin at a concentration of 2.5 µg/mL to maintain selection. All cells were passaged
at 70-90% confluency.
SKOV-3 and IHOE plasmid transduction and clone development
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Approximately 9x104 SKOV-3 and IHOE cells were seeded in each well of a 96
well plate and incubated in media supplemented with 10% exosome-depleted FBS for 1018 hours before transduction. IHOE cells were transduced using an HIV lentivector
system pre-packaged with either pCT-CD81-GFP or pCT-Cyto-GFP plasmid (CYTO124VA-1, CYTO118-VA-1, System Biosciences, Palo Alto, CA). SKOV-3 cells were
transduced using an HIV lentivector system pre-packaged with either pCT-CD9-RFP or
pCT-Cyto-RFP plasmid (CYTO123-VA-1, CYTO119-VA-1, System Biosciences, Palo
Alto, CA). Both cell lines were transduced at a multiplicity of infections (MOI) of 1, 2, 5,
and 10 using the TransDux MAX Lentivirus Transduction Reagent (LV860A-1, System
Biosciences, Palo Alto, CA). After 72 hours of incubation at 37˚C and 5% CO2, cells
were screened for fluorescence using a GE INCell Analyzer 2500HS (General Electric,
Boston, MA), and cell culture media was replaced and supplemented with 2.5 µg/mL
puromycin for selection. All cells were incubated for 7-14 days until stable transduction
produced confluent polyclonal cultures. Afterward, dilution cloning was used to obtain
single cells for the development of monoclonal stable cell lines.
Small extracellular vesicle isolation using ultracentrifugation
All SKOV-3 and IHOE cells were cultured in Falcon 75 cm2 cell culture flasks
with vented caps (Corning, Corning, NY) to approximately 80% confluency and
replenished with fresh media. Cultures were incubated for 3 days and then conditioned
media was collected for sEV isolation. sEV isolation was performed in a series of
differential centrifugation steps starting with 45 mL of conditioned cell culture media.
Using an Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, Germany), the conditioned
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media was centrifuged at 700 x g for 5 minutes at 22˚C. The resulting supernatant was
then centrifuged at 2,000 x g for 10 minutes at 22˚C. Next, the resulting supernatant was
centrifuged at 10,000 x g for 30 minutes at 4˚C using a Beckman Coulter Avanti J-26S
XPI Centrifuge equipped with a JA-25.50 rotor (Beckman Coulter, Brea, CA) and the
supernatant was collected. Finally, the collected supernatant was centrifuged at 120,000 x
g for 60 minutes at 4˚C using a Beckman Coulter Optima XPN-80 Ultracentrifuge
equipped with a Type 45 Ti rotor (Beckman Coulter, Brea, CA) and the supernatant was
discarded. The final pellet was then resuspended in 400 µL of phosphate buffered saline
(PBS).
Fixation and staining of samples for transmission electron microscopy
Samples being prepared for transmission electron microscopy (TEM) were first
fixed in 4% paraformaldehyde for 30 minutes on ice. Grid adhesion, staining, and
washing steps were performed on parafilm by moving 200 mesh copper formvar grids
(Electron Microscopy Sciences, Hatfield, PA) from drop to drop. Following fixation,
grids were placed on 5 µL drops of each sample for 5 minutes. Grids were washed 3
times with DI water for 4 minutes each, stained with 2% Uranyl Acetate for 5 minutes,
and then washed 3 times with DI water for 4 minutes each. Grids were air dried in a lowhumidity environment and then imaged using a Hitachi H7600 TEM (Hitachi, Tokyo,
Japan).
Production of cell lysate
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Approximately 2.5 – 5 x 105 cells were resuspended in 1 mL of ice-cold 1X
radioimmunoprecipitation assay (RIPA) lysis buffer (50672585, Thermo Fisher
Scientific, Waltham, MA) and incubated with agitation for 30 minutes. Samples were
then centrifuged at 13,000 x g for 20 minutes at 22˚C using an Eppendorf Centrifuge
5424 (Eppendorf, Hamburg, Germany). The resulting supernatant (lysate) was collected
and saved for subsequent analysis.
Protein Quantification
All sEV and cell lysate samples were quantified using a NanoVue Plus UV-Vis
spectrophotometer (GE Healthcare, Chicago, IL). The spectrophotometer was blanked
between each sample using phosphate buffered saline and samples were quantified at 280
nm absorbance according to the manufacturer’s instructions.
SDS-PAGE and western blot analysis of extracellular vesicles and cell lysates
All samples were separated using a 12% gel and NuPAGE XCell SureLock MiniCell electrophoresis system (Thermo Fisher Scientific, Waltham, MA) under reduced or
non-reduced conditions. Cell lysate, recombinant TurboGFP protein (EVN-FP552,
Axxora, Farmingdale, NY), and purified RFP protein (NBP199583, Fisher Scientific,
Hampton, NH) were used as positive controls. All gels were run at 170 mV for
approximately 45 minutes. Wet transfer was performed using a Genie Electrophoretic
transfer system (Idea Scientific Co, Minneapolis, MN) with a polyvinylidene difluoride
(PVDF) membrane in 1X Towbin buffer run at 12 V for approximately 90 minutes.
PVDF membranes were blocked in 5% non-fat milk in 1X Tris buffered saline
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supplemented with 0.5% Tween 20 (TBS-Tween) for 40 minutes at 37°C. Blocked
membranes were rinsed with 0.5%Tween 20/TBS, and incubated overnight at 4oC with
primary antibody (1:2000 rabbit anti-TurboGFP (PIPA522688, Fisher Scientific,
Hampton, NH) or 1:1000 rabbit anti-RFP (600-401-379, Rockland Immunochemicals,
Inc., Pottstown, PA)). After washing in TBS-Tween for 1 hour at 22°C with 6 buffer
changes, membranes were incubated with secondary 1:5000 goat anti-mouse IgG
horseradish peroxidase (1:5000; GTXMU004DHRPX, Immunoreagents, Inc., Raleigh,
NC) or 1:10,000 goat anti-rabbit IgG horseradish peroxidase (GTXRB003FHRPX,
Immunoreagents, Inc., Raleigh, NC) antibody for 1 hour at room temperature. Probed
membranes were then washed in high salt tris buffered saline supplemented with 0.05%
Tween (TS-Tween) for 1 hour at 22°C with 6 buffer changes. Finally, protein was
detected using the Pierce ECL Western blotting substrate kit (32106, Thermo Fisher
Scientific, Waltham, MA) following the manufacturer’s instructions. Western blot gels
were loaded according to the following scheme. IHOE-CD81-GFP, SKOV-3-CD9-RFP,
IHOE, and SKOV-3 cell lysate lanes were loaded with 150 µg of protein each. IHOECD81-GFP, SKOV-3-CD9-RFP, IHOE, and SKOV-3 sEV lanes were loaded with 10 µg
of protein each. Differences in cell lysate and sEV loading amounts are to account for
differences in concentration of the protein of interest. Finally, the purified, control tGFP
protein lane was loaded with 50 ng of protein and the purified, control RFP protein lane
was loaded with 40 ng of protein.

115

C-CP fiber tip assembly
Polymer extruded polyethylene terephthalate capillary-channeled fibers (C-CP),
produced by the Material Science and Engineering Department at Clemson University,
were wound on a circular frame 8 times (450 fibers) then rinsed with hot water,
acetonitrile, isopropanol, and ultra-pure water. Wound fibers were pulled through a 30
cm length, 0.762 mm internal diameter polyether ether ketone (PEEK)(IDEX Health &
Science LLC, Oak Harbor, WA) tubing using a plastic monofilament. Packed tubing
sections were attached to the end of 200 µl micropipette tips and subsequently inserted
through pierced centrifuge tube caps for sample spin-down and wash collection.
sEV capture and isolation on C-CP tips
Following C-CP tip assembly, sEV or PBS samples of 100 µl were loaded into
the tips and spun down at 300 x g for 1 minute using an Eppendorf Centrifuge 5430R
(Eppendorf, Hamburg, Germany). Afterward, the loaded tubing was prepared for either
SEM or fluorescence imaging.
C-CP Fiber sample preparation for scanning electron microscopy
C-CP fiber samples being prepared for SEM were fixed in 1% osmium tetroxide
for 1 hour with shaking. After removing the osmium tetroxide, samples were washed in
deionized water 3 times for 3-5 minutes. Next, the samples were washed in an ethanolwater mixture of the following ethanol percentages for 3 minutes each: 50%, 70%, 80%,
90%, 95%, 100%, 100%. The samples were then washed in a 50:50
hexamethyldisilazane(HMDS) –ethanol mixture for 3 minutes and then washed in 100%
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HMDS and left to dry for 2-3 days. After drying, samples were attached to a metal stage
using adhesive and platinum coated using the Hummer 6.2 Sputtering system (Anatech,
Battle Creek, MI) at 70 millitorr for 2 minutes. A Hitachi SU5000 Field Emission
Scanning Electron Microscope (FE-SEM) (Hitachi, Tokyo, Japan) was used to capture
SEM images.
Immunoaffinity blot capture technique
Antibodies for turboGFP, RFP, CD63, CD24, Her2, L1CAM, and EGFR (Table
3.1) were used to capture sEVs on nitrocellulose membranes (See Figure 3.1 for visual
experimental setup). To prepare the membranes, 0.25 µL of each primary antibody at a
concentration of 1 mg/mL was applied to the nitrocellulose membrane and allowed to dry
for 1 hour. Prepared membranes were blocked with 0.5% bovine serum albumin (BSA) in
tris buffered saline supplemented with 0.5% Tween (TBS-Tween) for 30 minutes at 37˚ C
to prevent non-specific binding. Blocked membranes were then exposed to IHOE-CD81GFP and/or SKOV-3-CD9-RFP sEVs in TBS-Tween at a concentration of 125 µg/mL for
2 hours at room temperature with shaking. Finally, membranes were washed in TBSTween for 1 hour with 6 buffer changes to remove any excess sample and decrease
background signal. Fluorescent images of membranes were captured immediately while
wetted with TBS-Tween to minimize variation in background signal.
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Figure 3.1. Diagram of sEV immunoaffinity blot capture experimental setup.
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were incubated in solution with
antibody-dotted nitrocellulose membranes. Capture studies were performed with
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples in a) independent
experiments and b) mixed sample experiments. Capture antibodies used in the
complete experiment are detailed in Table 3.1.
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Fluorescence Intensity, Super-Resolution Confocal Imaging, and Image Analysis
Confocal fluorescent and differential interference contrast (DIC) images
were captured using a Leica SP8 confocal microscope with Hyvolution super-resolution
(Leica, Wetzlar, Germany). IHOE, IHOE-Cyto-GFP, IHOE-CD81-GFP, SKOV-3,
SKOV-3-cyto-RFP, and SKOV-3-CD9-RFP cells were seeded in 8-well, coverslip
bottom imaging plates at a concentration of 1 – 5 x 104 cells/mL. Cells were fixed in 4%
paraformaldehyde (EMS, Hatfield, PA) for 15 minutes at 22˚C and washed 3 times in 1X
PBS. Cells were then stained with 300 nM DAPI (4',6-Diamidino-2-Phenylindole,
Dihydrochloride) for 5 minutes at 22˚C and washed 3 times in PBS prior to imaging. All
images were captured using an HC PL APO CS2 63x/1.40 oil immersion objective. DAPI
images were obtained using 405 nm excitation (15% power; gain=50), and a gateable
HyD detector (411-449 nm detection; time gate = 8.5-12 ns). GFP images were obtained
using 488 nm excitation (15% power; gain=100), and a gateable HyD detector (512-564
nm detection, time gate = 0.01-6 ns). RFP images were obtained using 558 nm excitation
(25% power; gain=300), and a gateable HyD detector (575-650 nm detection, timegate =
0.08-3.58 ns).
Relative fluorescence intensity measurements of IHOE-CD81-GFP and SKOV-3CD9-RFP sEVs isolated by UC and resuspended in PBS were obtained using a Biotek
Synergy H1 Hybrid Reader (Biotek, Winooski, VT) with a 100 ms exposure time for all
samples. The suspended IHOE-CD81-GFP sEVs were excited at 488 nm with
fluorescence measured at 525 nm and suspended SKOV-3-CD9-RFP sEVs were excited
at 550 nm with fluorescence measured at 590 nm.
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All fluorescent C-CP fiber images were captured using a Leica SP8 HyVolution
confocal microscope (Leica, Wetzlar, Germany). PET C-CP fibers prepared with samples
were removed from the packed columns and spread evenly across a slide prior to
imaging. All green fluorescent protein (GFP) images were obtained using a 488 nm
excitation laser line at 25% intensity, an emission detection range from 500-541 nm, with
a detector gain of 300, and a time gate from 0.08-3.58 ns. All red fluorescent protein
(RFP) images were obtained using a 558 nm excitation laser line at 25% intensity, an
emission detection range from 564-628 nm, with a detector gain of 300, and a time gate
from 0.3-6 ns.
Relative fluorescence intensity measurements of the dot blots on nitrocellulose
membranes, prepared as described in the immunoaffinity blot capture technique above,
were obtained using a Leica Thunder- Model Organism imaging system (Leica, Wetzlar,
Germany). Single-channel images for GFP and RFP were captured using a Plan APO
1.0X objective (0.09 numeral aperture, no immersion) with a 5x zoom for a total of 50x
magnification (GFP - 100 ms exposure; ET GFP filter set (450-490 nm excitation/500550 nm detection); RFP- 2s exposure; ET mCherry filter set (540-580 nm excitation/592667 nm detection). Following image capture, average relative fluorescence intensity was
measured using ImageJ version 1.48 software (NIH, Bethesda, MD). Relative
fluorescence intensity values were normalized to the average intensities of UC isolated
sEVs from IHOE CD81-GFP and SKOV-3-CD9-RFP cells dotted (3 µl) on a
nitrocellulose membrane at a protein concentration of 2,500 µg/mL and imaged under the
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same conditions. All intensity values were adjusted using appropriate background
subtractions.
Statistical Analysis
All numeric values are presented as sample means ± 1 standard deviation. Data
were analyzed using a one-tailed t-test (α=0.05) in Microsoft Excel’s data analysis
software (Microsoft, Redmond, WA). All tests with p<0.05 were considered statistically
significant.
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Table 3.1. Description and catalog number of antibodies used in western
blot and immuno-affinity blot capture experiments.
Antibody
Rabbit antiTurboGFP
Rabbit antiRFP
Mouse antiCD81

Antigen Description
Brighter variant of the traditional green
fluorescent protein – a commonly used
fluorescent marker.
Red fluorescent protein – a commonly
used fluorescent marker.

Mouse antiCD9

Tetraspanin involved in signal
transduction and trafficking. Common
sEV marker.89
Tetraspanin involved in cell adhesion and
migration. Common sEV marker.89

Rabbit antiCD63

Tetraspanin involved in cell signaling
cascades. Common sEV marker.89

Mouse antiCD24

Sialoglycoprotein associated with
development, invasion, and metastasis of
cancer cells. Overexpressed in ovarian
cancer sEVs.90
Human Epidermal Growth Factor
Receptor 2 - Tyrosine kinase receptor
involved in cell proliferation and tumor
cell metastasis. Associated with poor
outcomes in ovarian cancer.65
Cell adhesion molecule involved in cell
proliferation, adhesion, migration, and
chemoresistance. Associated with poor
prognosis in various carcinomas and
ovarian cancer.91
Epidermal Growth Factor Receptor –
Tyrosine kinase receptor involved in cell
proliferation, migration, and invasion.
Highly expressed in ovarian tumors.92

Mouse antiHER-2

Mouse antiL1CAM

Mouse antiEGFR
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Catalog Number
AB513 (Evrogen,
Moscow, Russia)
600-401-379 (Rockland
Immunochemicals Inc.,
Limerick, PA)
sc-166029 (Santa Cruz
Biotechnology, Dallas,
TX)
sc-13118 (Santa Cruz
Biotechnology, Dallas,
TX)
11271-r142 (Sino
Biological Inc.,
Beijing, China)
14-0247-82 (Thermo
Fisher Scientific,
Waltham, MA)
BMS120
(ThermoFisher
Scientific, Waltham,
MA)
L4543 (Sigma-Aldrich,
St. Louis, MO)

555996 (BD
Biosciences, San Jose,
CA)

Results
Establishment and verification of IHOE-CD81-GFP and SKOV-3-CD9-RFP model
system
Initial lentiviral-mediated transduction of IHOE and SKOV-3 cells with pCTCyto-GFP (CYTO118-VA-1, SBI, Palo Alto, CA) and pCT-Cyto-RFP (CYTO119-VA-1,
SBI, Palo Alto, CA), respectively, revealed an optimal transduction efficiency of 10 pCTCyto-GFP virus particles per IHOE cell and 5 pCT-Cyto-RFP virus particles per SKOV-3
cell. Transduction of IHOE cells with pCT-CD81-GFP or the pCT-Cyto-GFP control
plasmid resulted in production of IHOE-CD81-GFP and IHOE-Cyto-GFP control cells,
respectively. Transduction of SKOV-3 cells resulted in production of SKOV-3-CD9-RFP
and SKOV-3-Cyto-RFP control cells, respectively. Confocal imaging of IHOE-CD81GFP cells, stained with DAPI (see Figure 3.2), revealed punctate expression of GFP
throughout the cytoplasm of the cell. Under the same imaging conditions, IHOE-CytoGFP control cells (see Figure 3.2) demonstrated even GFP distribution throughout the
entire cell, including potential expression within the nucleus. Non-transduced control
IHOE cells (see Figure 3.2) demonstrated no GFP expression while none of the samples
demonstrated RFP expression (see Figure 3.2)
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Figure 3.2. Confocal Fluorescence and DIC Images of transduced cells fixed
and stained with DAPI. Fluorescence and DIC images of IHOE-CD81-GFP;
IHOE-Cyto-GFP; and IHOE cells. Blue emission spectra (425-500 nm), green
emission spectra (510-590 nm), and red emission spectra (575-650 nm) were
captured in single channels and overlaid in confocal images.
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Similarly, confocal imaging of SKOV-3-CD9-RFP cells, stained with DAPI (see
Figure 3.3), showed punctate expression of RFP throughout the cytoplasm with little
evidence of RFP expression in the nucleus. Imaging of the SKOV-3-Cyto-RFP control
cells (see Figure 3.3) revealed even RFP expression throughout the entire cell, including
strong expression overlapping the nucleus. Non-transduced control SKOV-3 cells
displayed no evidence of RFP expression under the same imaging conditions (Figure
3.3). Additionally, none of the samples demonstrated GFP expression (see Figure 3.3)
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Figure 3.3. Confocal Fluorescence and DIC Images of transduced cells
fixed and stained with DAPI. Fluorescence and DIC images of SKOV-3CD9-RFP; SKOV-3-Cyto-RFP; and SKOV-3 cells. Blue emission spectra
(425-500 nm), green emission spectra (510-590 nm), and red emission spectra
(575-650 nm) were captured in single channels and overlaid in confocal
images.
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TEM of sEV samples isolated from IHOE-CD81-GFP and SKOV-3-CD9-RFP
cells revealed the presence of single vesicles of approximately 80-140 nm in diameter
(see Figure 3.4). Observed vesicles from both IHOE-CD81-GFP and SKOV-3-CD9-RFP
cells demonstrated a slight “dimpled” morphology as well as darker staining around the
exterior of the vesicle. The vesicles appeared intact and demonstrated no signs of damage
such as deformation, cracks, or debris.

Figure 3.4. Transmission electron microscopy of small extracellular
vesicles. TEM of sEVs isolated from (a) IHOE-CD81-GFP and (b) SKOV3-RFP cells by ultracentrifugation.
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Upon western blot analysis, GFP normally expresses a protein band size of ~26
kDa57, 58, as does CD8159, while RFP normally expresses a protein band size of ~ 27
kDa60 and CD9 a protein band size of ~ 25 kDa.61 As such, CD81-GFP should express a
protein band size of ~ 52 kDa, as should CD9-RFP. Western blot analysis of IHOECD81-GFP sEVs and cell lysate using rabbit anti-turboGFP (tGFP) (see Figure 3.5a)
revealed multiple bands at approximately 24 kDa (Band I), 41 kDa (Band II), 55 kDa
(Band III), and > 62 kDa (Band IV), while non-transduced control IHOE sEVs and cell
lysate showed no bands. Purified, control tGFP protein displayed bands at approximately
26 kDa and 43 kDa. SKOV-3-CD9-RFP sEVs and cell lysate probed with rabbit anti-RFP
showed bands at ~ 45 kDa (Band V) and ~54 kDa (Band VI) (see Figure 3.5b), while
non-transduced control SKOV-3 sEVs and cell lysate showed no bands. Purified, control
RFP protein displayed a single band at ~28 kDa.
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Figure 3.5. GFP and RFP western blots of IHOE-CD81-GFP sEVs and cell
lysate and SKOV-3-CD9-RFP sEVs and cell lysate. a) Rabbit anti-tGFP and b)
rabbit anti-RFP primary antibody probing. Arrows and Roman numeral indicate
regions of interest.
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The dotting of isolated, enriched IHOE-CD81-GFP sEVs and SKOV-3-CD9-RFP
sEVs on a nitrocellulose membrane with protein concentrations of 2500 µg/mL revealed
visibly greater relative fluorescence intensity for both sEV samples compared to the
vesicle-free PBS controls (see Figure 3.6). The sample images (Figures 3.6a,c) also
demonstrated distinct puncta. Average fluorescence intensities of these images (Figures
3.6a,c) were subsequently used for normalization of further nitrocellulose dotting and
capture experiments.
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Figure 3.6. Fluorescence images of GFP and RFP tagged vesicles dotted on
nitrocellulose membrane. (a) Immortalized Human Ovarian Epithelial (IHOE)derived CD81-GFP tagged, (b) IHOE-derived, (d) SKOV-3-derived CD9-RFP
tagged, and (d) SKOV-3-derived sEVs were isolated by ultracentrifugation and
dotted on a nitrocellulose membrane. Extracellular vesicle isolations were dotted
at a concentration of 2500 µg/mL of protein. (e, f) PBS controls dotted on
nitrocellulose. Images were obtained using both a GFP filter with a 100 ms
exposure (a,b,c) and an mCherry filter with a 2 s exposure (d,e,f).
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Following imaging of the IHOE-CD81-GFP and SKOV-3-CD81-RFP sEVs on
nitrocellulose (see Figure 3.7), average relative fluorescence intensity per µg of total
protein of the IHOE-CD81-GFP and SKOV-3-CD81-RFP sEVs was compared to normal
IHOE and SKOV-3 sEVs as well as to IHOE-CD81-GFP, SKOV-3-CD9-RFP, IHOE,
and SKOV-3 cell lysates. Relative fluorescence intensities per µg of protein of IHOECD81-GFP and SKOV-3-CD9-RFP sEVs (see Figure 3.7) were significantly higher than
those of their respective cell lysates and non-transduced control cell sEVs. Additionally,
relative fluorescence intensities of IHOE-CD81-GFP and SKOV-3-CD9-RFP cell lysates
were significantly higher than non-transduced IHOE and SKOV-3 cell lysates. It should
be noted that while the relative fluorescence intensities of the fluorescent cell lysate
samples were much higher than the corresponding fluorescent sEV samples, the total
protein in the fluorescent cell lysate samples were much higher. Thus, relative
fluorescence per g of protein was much higher in the fluorescent sEV samples.

132

Figure 3.7. Relative fluorescence intensity per µg of protein of sEVs and cell
lysate imaged on nitrocellulose membranes. Green bars represent samples derived
from IHOE cells and red bars represent samples derived from SKOV-3 cells.
Fluorescent sEVs and cell lysate were derived from IHOE-CD81-GFP and SKOV-3CD9-RFP cells. Normal sEVs and cell lysate were derived from non-transduced
IHOE and SKOV-3 control cells. Corresponding samples were subjected to a
student’s t-test ( ** - significantly different from corresponding sample and control,
p<0.05) ( * - significantly different from control alone, p<0.05); error bars
demonstrate one standard deviation, n=3.
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The relative fluorescence intensity of IHOE-CD81-GFP sEVs in solution
measured at 525 nm over varied protein concentrations (see Figure 3.8a) demonstrated
consistent intensities and a coefficient of determination (R2) of 0.9805. Similarly, the
relative fluorescence intensity of SKOV-3-CD9-RFP sEVs in solution measured at 590
nm over varied protein concentrations (see Figure 8b) demonstrated consistent intensities
and a coefficient of determination (R2) of 0.9190.

Figure 3.8. Relative fluorescence intensity per µg of suspended protein. a)
IHOE-CD81-GFP sEVs excited at 488 nm with fluorescence measured at 525
nm and b) SKOV-3-CD9-RFP sEVs excited at 550 nm with fluorescence
measured at 590 nm. Relative fluorescence intensity was measured with a 100
ms exposure time for all samples. Calculated coefficient of determination (R2)
represents the level of explained variability within the sample group. Coefficient
of determination values: a) 0.9805 and b) 0.919.
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PET C-CP fiber sEV capture
Following cell line establishment and verification, IHOE-CD81-GFP and SKOV3-CD9-RFP sEVs, initially isolated and concentrated via UC, were spun down onto C-CP
fibers in a micropipette tip format. Observation of the fibers under SEM revealed
significant vesicle capture along the surfaces of the PET C-CP fibers loaded with the
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples, while no vesicles were seen on
the PET C-CP fiber surfaces exposed to the sEV-free PBS control (see Figure 3.9).
IHOE-CD81-GFP vesicles on the fiber surface appeared more evenly distributed, while
SKOV-3-CD9-RFP vesicles on the fiber surface appeared to have greater amounts of
vesicle aggregation. Neither sample demonstrated significant vesicle damage.

Figure 3.9. Scanning electron microscopy of small extracellular vesicles on
PET C-CP fibers. SEM of sEVs isolated from (a) IHOE-CD81-GFP and (b)
SKOV-3-CD9-RFP cells by ultracentrifugation and (c) an sEV-free PBS control
spun down onto PET C-CP fibers in a micropipette tip format.
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Super-resolution confocal microscopy of IHOE-CD81-GFP sEVs (see Figure
3.10a) revealed small fluorescent particles, approximately 0.2-1 µm in diameter, scattered
across the surface of the PET C-CP fibers. While the fibers emitted significant
autofluorescence in the observed GFP emission range (500-541 nm; see PBS control in
Figure 3.10c), fluorescent puncta remained observable in micrographs of the IHOECD81-GFP samples. Non-transduced IHOE sEVs (non-fluorescent) captured on the fiber
surfaces appeared no different than the PBS control-treated fibers (see Figure 3.10b).
Similarly, super-resolution confocal microscopy of SKOV-3-CD9-RFP sEVs (see Figure
3.10d) revealed small fluorescent particles, approximately 0.2-1 µm in diameter,
scattered across the surface of the PET C-CP fibers. While the fibers emitted significant
autofluorescence in the observed RFP emission range (564-628 nm; see PBS control in
Figure 13f), additional fluorescent puncta were visible in the micrographs of the SKOV3-CD9-RFP samples. Non-transduced SKOV-3 sEVs (non-fluorescent) captured on the
fiber surfaces appeared no different than the PBS control-treated fiber (see Figure 3.10e).
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Figure 3.10. Super-resolution confocal fluorescence microscopy of
IHOE-CD81-GFP and SKOV-3-CD9-RFP-expressing small extracellular
vesicles on PET C-CP fibers. Super-resolution confocal fluorescence
microscopy of (a) IHOE-CD81-GFP sEVs, (b) non-transduced IHOE sEVs
(non-fluorescent), (c) PBS (d) SKOV-3-CD9-RFP sEVs, (e) non-transduced
SKOV-3 sEVs (non-fluorescent) and (f) PBS spun down onto PET C-CP
fibers in a micropipette tip format. Images a, b, and c were captured under
GFP imaging conditions (see Materials and Methods) and images d, e, and f
were captured under RFP imaging conditions. Arrows indicate distinct
exosomal adherence regions along the fibers.
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IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV mixed samples spun onto PET CCP fibers demonstrated similar patterns to the IHOE-CD81-GFP and SKOV-3-CD9-RFP
samples alone (see Figure 3.11). The mixed samples demonstrated fluorescent particles
within both the green emission range (500-541 nm, see Figure 3.11a) and red emission
range (564-628 nm, see Figure 3.11b). An overlaid image of the green and red emission
channels (see Figure 3.11c), revealed the presence of green and red fluorescent particles
in both overlapping and distinct locations along the fibers (see arrows on Figure 3.11).
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Figure 3.11. Super-resolution confocal fluorescence microscopy of IHOECD81-GFP and SKOV-3-CD9-RFP small extracellular vesicles on PET C-CP
fibers. Super-resolution confocal fluorescence microscopy of IHOE-CD81-GFP
and SKOV-3-CD9-RFP sEVs mixed prior to being spun down onto PET C-CP
fibers in a micropipette format. Observations in (a) green and (b) red channels were
(c) overlaid showing distinct exosomal adherence locations along the fibers
(arrows)
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Selective immunoaffinity capture of sEVs
Following determination of average fluorescence values for the sample area of the
controls for normalization (Figure 3.6), immunoaffinity capture experiments were set up
as described in Figure 3.1 using nitrocellulose strips dotted with the antibodies listed in
Table 3.1. IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples were added to
separate nitrocellulose antibody-dotted capture strips (see Figure 3.1a and Table 3.1) and
imaged with multichannel widefield fluorescence microscopy (see Figures 3.12-3.16,
Table 3.2). In a separate experiment, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs
were mixed prior to addition to a single nitrocellulose antibody-dotted capture strip (see
Figure 3.1b and Table 3.1) and imaged with multichannel widefield fluorescence
microscopy (see Figures 3.17-3.18, Table 3.2). The positive control capture antibody
against tGFP (rabbit anti-tGFP) demonstrated significant GFP fluorescence intensity
when incubated with IHOE-CD81-GFP sEVs alone (see Figure 3.12a) or with a sample
containing both IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (see Figure 3.12c), as
compared to the negative PBS controls (no antibody, IHOE-CD81-GFP or SKOV-3CD9-RFP sEV samples; see Figure 3.12e,f). Similarly, the positive control capture
antibody against RFP (rabbit anti-RFP) demonstrated significant mCherry fluorescence
intensity when incubated with SKOV-3-CD9-RFP sEVs alone (see Figure 3.12h) or with
a sample containing both IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs(see Figure
3.12j), as compared to the negative PBS controls (no antibody, IHOE-CD81-GFP or
SKOV-3-CD9-RFP sEV samples; see Figure 3.12k,l). No spectral crossover was
observed between the red and green channels (see Figure 3.12g,i,b,d) Fluorescence of the
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captured IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs appeared to be more
homogeneous as opposed to punctate in nature as compared to IHOE-CD81-GFP and
SKOV-3-CD9-RFP sEV samples dotted directly onto a nitrocellulose surface without
specific capture antibodies (Figure 3.6).
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Figure 3.12. Immunoaffinity blot capture using rabbit anti-tGFP and
rabbit anti-RFP antibodies. IHOE-CD81-GFP and/or SKOV-3-CD9-RFP
sEVs were isolated by UC and captured on a nitrocellulose membrane using
rabbit anti-tGFP or rabbit anti-RFP antibodies. Each type of sEV was exposed
to antibody-dotted nitrocellulose for 2 hours at a protein concentration of 125
µg/mL followed by a 1 hour wash in TBS-Tween. GFP images were obtained
using a 100 ms exposure and mCherry images were obtained using a 2 s
exposure.
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CD63 is a generic exosomal marker protein. When rabbit anti-CD63 antibodies
were used to capture IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs, there was
significant relative fluorescence intensity for IHOE-CD81-GFP sEVs (Figures 3.13-3.14,
Table 3.2) and mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (Figures 3.173.18, Table 3.2) in the green channel. Rabbit anti-CD63 dots also demonstrated
significant relative fluorescence intensity for SKOV-3-CD9-RFP sEVs (Figures 3.153.16, Table 3.2) and mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (Figures
3.17-3.18, Table 3.2) in the red channel. The rabbit anti-CD63 normalized relative
fluorescence intensity for IHOE-CD81-GFP sEVs in the green channel and the
normalized relative fluorescence intensity for SKOV-3-CD9-RFP sEVs in the red
channel were not significantly different (see Figures 3.13-3.16). Likewise, the rabbit antiCD63 normalized relative fluorescence intensities in both the green and red channels for
mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were not significantly different
(see Figures 3.17-3.18).
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Figure 3.13. IHOE-CD81-GFP sEVs immuno-captured on a nitrocellulose
membrane and imaged with multichannel microscopy. IHOE-CD81-GFP
sEVs were exposed to antibody-dotted nitrocellulose for 2 hours at a protein
concentration of 125 µg/mL followed by a 1 hour wash in TBS-Tween. GFP
images were obtained using a 100 ms exposure and mCherry images were
obtained using a 2 s exposure.
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Figure 3.14. Normalized relative fluorescence intensities of IHOE-CD81-GFP
immuno-captured on a nitrocellulose membrane and imaged with multichannel
microscopy. IHOE-CD81-GFP sEVs were captured and imaged on a nitrocellulose
test strips. sEVs were exposed to the multiple antibody-dotted nitrocellulose test
strip for 2 hours at a protein concentration of 125 µg/mL followed by a 1 hour wash
in TBS-Tween. GFP (green bar) images were obtained using a 100 ms exposure and
mCherry (red bar) images were obtained using a 2 s exposure. (* - Significantly
different from PBS control and corresponding fluorescence channel data based on a
one-tailed t-test)
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Figure 3.15. SKOV-3-CD9-RFP sEVs immuno-captured on a nitrocellulose
membrane and imaged with multichannel microscopy. SKOV-3-CD9-RFP
sEVs were exposed to antibody-dotted nitrocellulose for 2 hours at a protein
concentration of 125 µg/mL followed by a 1 hour wash in TBS-Tween. GFP
images were obtained using a 100 ms exposure and mCherry images were
obtained using a 2 s exposure.

146

Figure 3.16. Normalized relative fluorescence intensities of SKOV-3-CD9RFP sEVs immuno-captured on a nitrocellulose membrane and imaged with
multichannel microscopy. SKOV-3-CD9-RFP sEVs were captured and imaged
on nitrocellulose test strips. sEVs were exposed to multiple antibody-dotted
nitrocellulose test strips for 2 hours at a protein concentration of 125 µg/mL
followed by a 1 hour wash in TBS-Tween. GFP (green bar) images were obtained
using a 100 ms exposure and mCherry (red bar) images were obtained using a 2 s
exposure. (* - Significantly different from the PBS control, based on a one-tailed
t-test; **- Significantly different from PBS control and corresponding
fluorescence channel data based on a one-tailed t-test)
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Dot blots with antibodies against the ovarian cancer sEV marker proteins, CD24,
Her2, L1CAM, and EGFR, demonstrated significantly greater red relative fluorescence
intensities when incubated with the SKOV-3-CD9-RFP sEVs than green relative
fluorescence intensity when incubated with IHOE-CD81-GFP sEVs (see Figures 3.133.16, Table 3.2). Similarly, the dot blots demonstrated significantly greater red relative
fluorescence intensity than green relative fluorescence intensities when incubated with
mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs (see Figures 3.17-3.18, Table
3.2). Dot blots with mouse anti-L1CAM antibody did not show significantly greater red
relative fluorescence intensity than green fluorescent intensity when incubated with
mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs. However, the mouse antiL1CAM dot blots did show slightly lower mean red relative fluorescence intensity with
higher variance when incubated with mixed IHOE-CD81-GFP and SKOV-3-CD9-RFP
sEVs compared to dot blots with mouse anti-Her2 and mouse anti-EGFR (see Figure
3.17-3.18, Table 3.2). Dot blots using ovarian cancer sEV marker antibodies
demonstrating significant relative fluorescence intensities following sEV incubations had
normalized relative fluorescence intensities ranging from approximately 0.10 to 0.24
(a.u.) (see Figures 3.15-3.18, Table 3.2).
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Figure 3.17. IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs immunocaptured on a nitrocellulose membrane and imaged with multichannel
widefield fluorescence microscopy. IHOE-CD81-GFP and SKOV-3-CD9-RFP
sEVs were mixed prior to capture on a single test strip. Mixed sEVs were exposed
to multiple antibody-dotted nitrocellulose for 2 hours at a protein concentration of
125 µg/mL followed by a 1 hour wash in TBS-Tween. GFP images were obtained
using a 100 ms exposure and mCherry images were obtained using a 2 s exposure.
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Figure 3.18. Normalized relative fluorescence intensities of mixed IHOE-CD81GFP and SKOV-3-CD9-RFP sEVs captured by ovarian cancer EV marker
antibodies. IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were mixed prior to
capture on a single test strip. Mixed sEVs were exposed to antibody-dotted
nitrocellulose for 2 hours at a protein concentration of 125 µg/mL followed by a 1
hour wash in TBS-Tween and then imaged using multichannel widefield
fluorescence microscopy. GFP (green bar) images were obtained using a 100 ms
exposure and mCherry (red bar) images were obtained using a 2 s exposure. (* Significantly different from the PBS control, based on a one-tailed t-test; **Significantly different from PBS control and corresponding fluorescence channel
data based on a one-tailed t-test)
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Table 3.2. Relative fluorescence intensities (a.u.) of captured IHOE-CD81-GFP
and SKOV-3-CD9-RFP sEVS using multichannel widefield fluorescence
imaging with GFP filter set (450-490 nm excitation/500-550 nm detection) and
mCherry filter set (540-580 nm excitation/592-667 nm detection)
Sample Type
GFP Filter Set

Rabbit anti-tGFP

1.082

IHOE-CD81GFP
+
SKOV-3CD9-RFP
1.592

Rabbit anti-RFP

-0.005

Rabbit anti-CD63

mCherry Filter Set

0.001

IHOE-CD81GFP
+
SKOV-3CD9-RFP
0.007

-0.002

0.843

1.109

0.061

0.075

0.119

0.101

Mouse anti-CD24

0.012

0.020

0.174

0.241

Mouse anti-Her2

0.009

0.011

0.125

0.139

Mouse anti-L1CAM

0.003

-0.004

0.154

0.100

Mouse anti-EGFR

0.006

0.010

0.108

0.144

PBS

0.004

0.004

0.009

-0.002

Capture Antibody

IHOE-CD81GFP
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SKOV-3CD9-RFP

Discussion
Although there is currently no agreement or official guidelines on the
classification of EV populations, there is consensus on the need for new EV isolation
methods, particularly those with greater specificity, selectivity, purity, and yield. In
response, immunoaffinity sEV isolation techniques have emerged as promising methods
with respect to sEV specificity and selectivity and have demonstrated results similar to or
better than those of ultracentrifugation.50 Thus far, immunoaffinity capture techniques
have largely been dominated by magnetic bead and microfluidics approaches. Magnetic
bead approaches have demonstrated high capture efficiency and sensitivity due the to
enhanced surface area available for capture and mixture homogeneity.62 Microfluidics
devices employing immunoaffinity approaches in tandem with other separation factors,
including size, density, hydrophobicity, and biochemical profile, may allow for the
greatest specificity and selectivity and may prove ideal for diagnostic purposes. Strategies
employed in these methods include generic capture of sEVs using tetraspanin marker
antibodies followed by tumor-specific marker identification, as well as sEV capture using
tetraspanin and tumor-specific markers simultaneously. While both strategies have
certain advantages, recent studies appear to primarily focus on tetraspanin capture alone
prior to tumor-specific sEV marker identification. This workflow is likely due to low
overall sEV yield values.
As new EV isolation and quantification methods are designed, they will require
more systematic comparison protocols for overall efficacy evaluation. The overall goal of
this study was to develop a model system (IHOE-CD81-GFP- and SKOV-3-CD9-RFP-
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expressing cells) to produce fluorescent sEVs for use in optimization of the newly
developed PET C-CP EV isolation platform. Specifically, this model system, by
distinguishing between cancerous and non-cancerous cell-derived sEVs via fluorescence,
will be used to develop the selective capture component of the PET C-CP EV isolation
platform in a quick and cost-effective manner prior to patient sample investigation. Once
refined, selective OC-specific capture antibodies coupled to the isolation platform may be
able to streamline EV capture and be employed for early OC diagnosis. The aims of this
work included establishment and verification of the IHOE-CD81-GFP- and SKOV-3CD9-RFP-expressing cell lines for production of fluorescently-labelled sEVs,
demonstration of the ability of PET C-CP fibers to capture IHOE-CD81-GFP and SKOV3-CD9-RFP sEVs effectively, and demonstration of OC-specific antibody capture and
discrimination of IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs, thus demonstrating
the ability to distinguish between non-cancerous and cancerous cell-derived sEVs. This
study details the development of a model system that can be used to further develop the
PET C-CP EV isolation platform by improving selectivity and specificity and allowing
for its optimization prior to testing with highly variable and costly patient samples.
Development and analysis of the cell line model system
In order to engineer non-cancerous (IHOE) and cancerous (SKOV-3) cell lines to
release fluorescent sEVs for downstream selective capture, generic endosomal proteins
were identified as candidates for addition of fluorescent tags. Both CD81 and CD9 are
tetraspanin proteins that, due to their involvement in endosomal vesicle transport, are
expressed on plasma membrane components of cells. They are both reported sEV

153

markers, are typically highly expressed in populations of sEVs, and are often used as
protein controls in sEV experiments.63, 64 Specifically, IHOE cell sEVs contain high
amounts of CD81 and SKOV-3 cell sEVs are highly enriched in CD9.65 Therefore, to
create fluorescent sEVs from IHOE and SKOV-3 cells, IHOE and SKOV-3 cells were
transduced with commercially obtained pCT-CD81-GFP (CYTO124-VA-1, System
Biosciences, Palo Alto, CA) or pCT-CD9-RFP (CYTO125-VA-1, System Biosciences,
Palo Alto, CA) plasmids, respectively. The plasmids were designed by System
Biosciences to add fluorescent tags to the C-terminus, intracellular domains of the
specific tetraspanin proteins (CD81 and CD9).66 Each plasmid was independently
prepackaged into an HIV lentiviral construct purchased from System Biosciences to be
used for transduction of the appropriate cell line. To assess the optimal multiplicity of
infection (MOI, the ratio of virus particles to cells) required, transduction efficiency was
calculated using the pre-packaged control plasmids, pCT-Cyto-GFP (CYTO118-VA-1,
SBI, Palo Alto, CA) and pCT-Cyto-RFP (CYTO119-VA-1, SBI, Palo Alto, CA) for the
IHOE and SKOV-3 cells, respectively. pCT-Cyto-GFP showed an optimal transduction
efficiency at an MOI of 5 and pCT-Cyto-RFP showed optimal and maximum
transduction efficiency at an MOI of 10. Given these results, an MOI of 5 for pCT-CD81GFP and IHOE cells and a MOI of 10 for pCT-CD9-RFP and SKOV-3 cells were chosen
for future experiments.
IHOE cells and SKOV-3 cells were successfully transduced with either pCTCD81-GFP or pCT-CD9-RFP, respectively, selected for plasmid expression with
puromycin, and subjected to limited dilution cloning. Clones with the highest cell lysate

154

fluorescence intensities, as measured using a Biotek Synergy H1 Hybrid Reader (Biotek,
Winooski, VT), from identical cell densities were chosen for use in subsequent
experiments. Laser scanning confocal images of IHOE-CD81-GFP and SKOV-3-CD9RFP cells, as seen in Figures 3.2 and 3.3, demonstrate the successful cell transductions
and expression patterns of fluorescently-labelled CD81 and CD9 in the IHOE and
SKOV-3 cell lines. As the CD81 and CD9 transmembrane proteins are typically enriched
in extracellular vesicles, they would be expected to be expressed in many small, punctate
transport vesicles across the cell, resulting in scattered, intense fluorescence spots as
opposed to uniform fluorescence expression throughout the cytoplasm. The micrographs
of the IHOE-CD81-GFP and SKOV-3-CD9-RFP expressing cells (see Figures 3.2 and
3.3) as compared to the micrographs of the IHOE-Cyto-GFP and SKOV-3-Cyto-RFP
expressing control cells (general cytoplasm expression; see Figures 3.2 and 3.3)
demonstrate these expected localization patterns. TEM imaging (see Figure 3.4) of sEVs
isolated from IHOE-CD81-GFP and SKOV-3-CD9-RFP cells demonstrated typical
“dimpled” EV morphology and maintenance of EV structure. Additionally, IHOE-CD81GFP and SKOV-3-CD9-RFP sEV samples demonstrated higher relative fluorescence
intensity per µg of protein than cell lysates from the corresponding cell types (see Figure
3.7), further indicating that the expressed CD81-GFP and CD9-RFP proteins are
localized to extracellular vesicles, rather than generically expressed throughout the
cytoplasm.
An important step in the development of a new cell line is to verify that the
engineered cell line expresses the correct recombinant proteins using semi-quantitative
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methods. However, there are several factors that make this challenging for sEV specific
recombinant proteins. First, sEVs can be difficult to quantify due to their size and
heterogeneous makeup and, to date, there is no reliable method for accurate
quantification.67 Thus, obtaining a correct measure of protein concentration per vesicle is
difficult. Furthermore, it can be problematic to normalize protein data against standard
loading controls when dealing with sEVs, as there is significant variation in sEV protein
expression and enrichment, which can also be influenced by different sEV isolation
methods.68 Even when populations of sEVs are isolated from the same cell type, there can
be considerable variation between resulting isolate densities due to the crude, and
sometimes difficult, isolation processes often employed. While antibodies against
standard loading control proteins, such as IgG or GAPDH, can be used in certain
situations, the replication of samples is not always reliable or trustworthy for semiquantification via western blot analysis.40, 64, 69-71 Despite these issues, in an effort to
move forward with fundamental research, the EV community has deemed certain sEV
markers, such as CD81 and CD9, as suitable loading controls for sEV research.72
However, when using these loading controls, it is important to understand that they are
quite limited as they are only reliable when comparing sEVs from the same source or cell
type. With this in mind, any attempt to normalize or quantify this data based on western
blot band intensity would be unreliable. Therefore, there was no attempt to quantify or
statistically compare intensity values among western blot results. All western blot results
were evaluated only for specific protein presence or absence with limited relative
comparison based on amount of total protein loaded in each well.

156

To verify the recombinant protein expression of CD81-GFP and CD9-RFP in the
IHOE-CD81-GFP and SKOV-3-CD9-RFP cells and sEVs, western blots using primary
antibodies against tGFP or RFP (see Figure 3.5) were performed. As seen in Figure 3.5a,
probing IHOE-CD81-GFP sEVs with rabbit anti-tGFP reveals bands at approximately 24
kDa, 41 kDa, 55 kDa, and > 62 kDa as compared to the non-transduced control IHOE
sEVs and cell lysate controls. The copGFP tag is a monomer with a molecular weight of
26 kDa and the CD81 protein has a molecular weight of 26 kDa.57, 59 Thus, CD81 with
the addition of a GFP molecule should have a molecular weight of ~52 kDa. According
to the manufacturer’s instructions, rabbit anti-tGFP antibody only detects copGFP under
non-reduced conditions. During western blots, reduced conditions are used to break the
disulfide bridges that maintain protein tertiary structure73 but, in some cases, they may
restrict antibody access to the protein epitope. Therefore, the western blot was run under
non-reduced conditions to preserve protein disulfide bridges and maintain antibody
access to the epitope. This can change the migration properties of the recombinant CD81GFP protein as the two disulfide bonds of the CD81 portion do not unfold properly,
causing an uneven charge distribution across the entire molecule.59 A change in the
migration properties can lead to a slightly higher indicated size than expected (~55kDa),
as was observed. The IHOE-CD81-GFP cell lysate sample displayed a similar, albeit less
intense band at ~55 kDa, representative of CD81-GFP as well. As non-transduced control
IHOE sEVs and cell lysate did not display any bands, western blot evidence suggests that
the CD81-GFP recombinant protein is being successfully expressed in the IHOE-CD81GFP cells. Furthermore, GFP fluorescence is detected in the IHOE-CD81-GFP cell
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micrographs (see Figure 3.2) and IHOE-CD81-GFP sEVs and cell lysate dotted on
nitrocellulose (see Figure 3.6 and 3.7), suggesting CD81-GFP is being expressed in the
IHOE-CD81-GFP cells.
The RFP tag used in this experiment has a molecular weight of approximately 27
kDa and CD9 molecules have a molecular weight of approximately 25 kDa.17, 60, 61
Therefore, CD9-RFP molecules should have a theoretical molecular weight of ~52 kDa.
SKOV-3-CD9-RFP sEVs and cell lysate probed with rabbit anti-RFP show a band at
approximately 54 kDa (see Figure 3.5b, band VI), suggesting that CD9-RFP molecules
are present in the sEV and cell lysate samples. Moreover, RFP fluorescence is also
detected in SKOV-3-CD9-RFP cell images (see Figure 3.3) and in micrographs of
SKOV-3-CD9-RFP sEVs and cell lysate (see Figure 3.6 and 3.7) dotted on nitrocellulose,
further suggesting that CD9-RFP is being expressed in the SKOV-3-CD9-RFP cells.
To investigate the potential additional feature of using IHOE-CD81-GFP and
SKOV-3-CD9-RFP sEVs for testing the PET C-CP EV isolation platform, protein
concentrations were compared to relative fluorescence intensities as a means for simple
sEV quantification. The fluorescently-labeled IHOE-CD81-GFP and SKOV-3-CD9-RFP
sEVs demonstrated a high correlation between protein content and relative fluorescence
compared to non-fluorescent IHOE and SKOV-3 sEV controls (see Figure 3.8),
suggesting that the relative fluorescence of IHOE-CD81-GFP and SKOV-3-CD9-RFP
sEVs may be an alternative means of sEV quantification. Although protein concentration
is by no means considered an accurate method of sEV quantification, it does provide an
sEV concentration approximation and is widely reported in literature. With the use of
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fluorescence detectors (which are already incorporated into the PET C-CP fiber HIC
isolation platform reported in Chapter 2), sEV fluorescence protein correlation may hold
value as a simple method of sEV quantification approximation during PET C-CP fiberbased EV isolation.
Taken together, these results demonstrate that IHOE-CD81-GFP and SKOV-3CD9-RFP cells were successfully established and verified to express the fluorescent tags
on the appropriate proteins (CD81-GFP and CD9-RFP). Therefore, IHOE-CD81-GFP
and SKOV-3-CD9-RFP cells may assist in the development of the PET C-CP EV
isolation platform through EV binding verification via fluorescence imaging and EV
quantitative analysis through fluorescence detection. However, in order for the sEVs
derived from the IHOE-CD81-GFP and SKOV-3-CD9-RFP cells to be utilized for
evaluation of PET C-CP fibers, they must first be captured on the fiber surfaces.
PET C-CP fiber-based sEV capture
To evaluate the PET C-CP fiber utility for EV separation of and compatibility
with IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs, IHOE-CD81-GFP and SKOV-3CD9-RFP sEVs were isolated by UC and spun down through PET C-CP fibers in a
micropipette tip format (see Materials and Methods). Under SEM observation, IHOECD81-GFP (see Figure 3.9a) and SKOV-3-CD9-RFP (see Figure 3.9b) sEVs demonstrate
capture without significant morphological damage. Some vesicle aggregation on the
fibers is observed but is likely due to the tendency for UC to cause vesicles to aggregate
prior to spinning through the C-CP fibers.
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While this study did observe GFP and RFP extracellular vesicle aggregates and
vesicles in close proximity through fluorescent microscopy, it is important to note that
single vesicle observation is not possible with a limit of resolution of approximately 150
nm using the Leica SP8 Hyvolution super-resolution imaging system and software.
However, in future studies, the addition of stimulated emission depletion (STED) superresolution to the existing Leica SP8, with resolutions down to 50 nm, may make
individual vesicle imaging of fluorescent sEVs possible and allow samples to be more
easily distinguishable.74, 75 With this in mind, IHOE-CD81-GFP and SKOV-3-CD9-RFP
vesicles, again collected by UC and spun down through PET C-CP fibers, were observed
using super-resolution (~150 nm) fluorescence confocal microscopy. Initial observation
of PBS controls revealed significant autofluorescence from the PET fibers in both the
green (see Figure 3.10c) and red (see Figure 3.10f) channels with RFP emission
wavelengths displaying greater intensity than GFP emission wavelengths. However, after
application of the IHOE-CD81-GFP (see Figure 3.10a) and SKOV-3-CD9-RFP (see
Figure 3.10a) sEVs, groups of fluorescent particles could be observed beyond the fiber
autofluorescence. To verify that the IHOE-CD81-GFP and SKOV-3-CD9-RFP samples
were not emitting significant autofluorescence, non-transduced IHOE (see Figure 3.10b)
and SKOV-3 (see Figure 3.10e) sEVs, collected by UC and spun down through PET CCP fibers were observed under the same fluorescence imaging conditions. Nontransduced IHOE and SKOV-3 sEVs did not display any evidence of additional
fluorescence as compared to the PBS controls. This further demonstrates that the
fluorescent particles observed in the IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV
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sample micrographs are fluorescently-labelled sEVs captured on the PET C-CP fiber
surfaces (Figures 3.10a,c). This observation is further confirmed by SEM images (see
Figure 3.9) and the previous protein and fluorescence analyses of the IHOE-CD81-GFP
and SKOV-3-CD9-RFP sEVs (see Figures 3.2, 3.3, 3.5-3.7). In addition, mixed IHOECD81-GFP and SKOV-3-CD9-RFP sEV samples were spun down on PET C-CP fibers
and imaged under the same conditions as the IHOE-CD81-GFP and SKOV-3-CD9-RFP
samples alone (see Figure 3.11). After overlaying the channels, both GFP and RFP sEVs
can be observed in separate and coinciding locations, suggesting that, while there is
significant overlap, IHOE-CD81-GFP and SKOV-3-CD9-RFP vesicle groupings may be
distinguished from each other on fiber surfaces using super-resolution confocal
microscopy.
As these results show, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs are
captured on the surface of PET C-CP fibers and can be detected and distinguished using
fluorescence microscopy. The addition of the fluorescent labels do not appear to impede
the adherence of the tagged sEVs to the PET C-CP fiber surfaces, therefore, the model
fluorescent sEVs provide a useful tool for validation and optimization of the PET C-CP
fiber-based EV isolation platform. Additionally, the ability to readily distinguish between
non-cancerous and cancerous cell-derived sEVs via green and red fluorescence provides
a means of evaluating the specificity of exosomal biomarker antibodies for use in lateral
flow assay-based ovarian cancer diagnostics.
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Selective immunoaffinity capture of sEVs
Like any complex system, access to a complete dataset would be ideal
when observing the properties of a population. However, as sampling can rarely, if ever,
include every member of a population, statistical analysis is used to look for patterns and
correlations that may explain or predict characteristics and sub-populations based on a
few variables. In lieu of technology capable of selectively identifying the proteome of
individual sEVs and for clinical practicality, only a few parameters are employed to
distinguish cancerous and non-cancerous sEVs. Although the number of parameters is
limited, as OC is a heterogeneous disease with many subtypes and origins, multiple
markers would be more effective for early screening. Here, selective immunoaffinity
capture provides a means to identify sEV sub-populations via multiple biomarker
antibodies with the goal of distinguishing between cancerous and non-cancerous ovarian
cell-derived sEVs and translating that technology to the PET C-CP EV isolation platform.
As only a fraction of an sEV population may express a specific OC tumor-specific
sEV marker, such as CD24 or Her246, 76, sEV capture using only one of these sEV OC
markers may lead to lower numbers of captured sEVs, resulting in low signal and
decreased disease screening success. Generic sEV markers, such as CD9, CD81, and
CD63 are present in a higher proportion of sEVs31, 64, 77 and would likely lead to higher
capture yields. However, ovarian cancer tumor-specific sEV marker capture may allow
for greater sEV population selectivity. The immunocapture experiment described here
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employs strategies from other sEV lateral flow and immunoaffinity blot techniques and
provides a means for validating the model sEV system for use in the development of
immunoaffinity capture and isolation techniques for ovarian cancer diagnostics.78, 79
To provide a means of appropriate comparison and normalization of sEV
immunocapture, dotting of concentrated IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs
on nitrocellulose was used to set a threshold of maximum fluorescence intensity (Figure
3.6). (Of note, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV samples captured on
nitrocellulose were imaged with exposure times of 100 ms and 2 s, respectively. The
discrepancy in these exposure times was appropriated to account for the differences in
documented brightness between copGFP (42 cm-1 M-1)57, 58 and mRFP (12.5 cm-1 M-1)60
molecules and any potential quenching due to the molecular environment in vitro). The
ability to selectively capture GFP- or RFP-expressing sEVs from independent and mixed
IHOE-CD81-GFP and SKOV-3-CD9-RFP sEV (see Figure 3.1 for experimental setup)
samples via a dot blot immunoaffinity assay using rabbit anti-tGFP and rabbit anti-RFP
antibodies was successfully demonstrated These positive controls show that the dot blot
technique can be used to visually confirm the capture of specific sEVs based on their
protein expression.
Once it was demonstrated that selective capture of IHOE-CD81-GFP and SKOV3-CD9-RFP sEVs was possible via rabbit anti-tGFP and rabbit anti-RFP antibodies (see
Figure 3.12, Table 3.2) the next step was to show that specific capture of the cancer and
non-cancer cell-derived sEVs could be performed using antibodies to known ovarian
cancer exosomal biomarkers. In addition to using specific ovarian cancer biomarkers, a
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known universal exosomal biomarker was also investigated as a capture antibody. In this
manner, the capture results from mixed cancer and non-cancer cell-derived sEV samples
may be interpreted in terms of capture specificity. The universal exosomal biomarker,
CD63, was selected as a positive control for the validation of the study dot blot assays.
For the control assays, IHOE-CD81-GFP and SKOV-3-CD9-RFP sEVs were
immunocaptured from both independent (see Figures 3.13-3.16, Table 3.2) and mixed
(see Figures 3.17-3.18 , Table 3.2) samples on dot blots with rabbit anti-CD63 antibody.64
When imaged, the dot blots displayed similar fluorescence intensities for all of the
samples. Although CD63 expression likely differs somewhat between the IHOE-CD81GFP and SKOV-3-CD9-RFP cells, positive fluorescence in both the red and green
channels for the mixed samples indicates that CD-63 can be used as a positive control for
the immunocapture assays. This positive control antibody may be used to show that sEVs
are present and that the capture assay is working properly, just as the positive control line
functions in a lateral flow immunoassay.
The potential to differentiate between IHOE-CD81-GFP and SKOV-3-CD9-RFP
sEVs was assessed using antibodies to various known ovarian cancer tumor-specific
exosomal marker proteins. CD24, Her2, EGFR, and L1CAM molecular markers have all
been identified in previous studies as candidate biomarkers for the diagnosis and
prognosis of ovarian cancer.17, 23, 46, 76, 80-82 Therefore, dot blots using antibodies to these
ovarian cancer exosomal marker proteins were designed to test whether or not
immunoaffinity assays could be used to specifically capture cancer-cell derived sEVs
(see Figures 3.13-3.18, Table 3.2). For these assays, individual and mixed samples of
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IHOE-CD81-GFP (non-cancerous cell-derived) and SKOV-3-CD9-RFP (cancerous cellderived) sEVs were added to the dot blots. Dot blot results for the non-cancer cellderived (IHOE-CD81-GFP) sEVs alone showed no red fluorescence and significant green
fluorescence only for dots containing antibodies to CD63 (control). This indicates that
these non-cancer cell-derived sEVs were captured by the antibody to the generic
exosomal marker tetraspanin protein, CD63, but were not captured by antibodies to any
of the ovarian cancer exosomal marker proteins (CD24, Her2, EGFR, L1CAM).
Conversely, the dot blot results for the cancer cell-derived (SKOV-3-CD9-RFP) sEVs
alone showed no green fluorescence and significant red fluorescence for the dots
containing antibodies to the CD63 control and for all of the dots containing antibodies to
the ovarian cancer exosomal marker proteins (CD24, Her2, EGFR, LICAM). Finally, the
dot blot results of a mixture of the non-cancer and cancer cell-derived sEVs showed
significant green and red fluorescence for the dots containing antibody to CD63, while
significant fluorescence was only seen in the red channel for the dots containing
antibodies to the ovarian cancer marker proteins. These results indicate that sEVs from
the model cell lines may be employed in the future development and optimization of
lateral flow immunocapture assays for rapid, early ovarian cancer diagnostics.
Compared to the utilization of single markers, use of a multiplexed approach to
identify multiple exosomal biomarkers at once may diagnose a greater proportion of
ovarian cancers.16 In this case, a panel of tumor-specific protein markers was successfully
used to differentiate between cancerous and non-cancerous sEVs. Multiple marker “hits”
provides greater assurance that less false negative test results will occur. As cells in the
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tumor environment may undergo changes that can lead to differences in exosomal
biomarker expression83-85, screening for a panel of biomarkers can increase the overall
robustness of an exosomal liquid biopsy-based diagnostic test.9, 22, 38, 40
The impact of IHOE-CD81-GFP and SKOV-3-CD9-RFP cell lines and immunoaffinity
capture on development of a PET C-CP fiber-based EV isolation platform
The IHOE-CD81-GFP and SKOV-3-CD9-RFP cell lines developed in this study
provide an extremely valuable tool for the development, optimization, and proof of
concept testing of the PET C-CP EV isolation platform, and its potential use in a simple,
cost effective, early ovarian cancer diagnostics test. As the Marcus group has previously
shown, antibodies may be grafted onto the surfaces of the PET C-CP fibers or
alternatively to channeled films for selective protein capture.86-90 This study shows that
sEVs expressing biomarker proteins may be selectively captured using immobilized
antibodies. The model system may be used to produce sEVs for laboratory use instead of
having to rely on expensive, limited availability human patient samples. Specifically, the
incorporation of fluorescent markers into sEVs and the proven utility of the tagged sEVs
for self-reporting immunocapture characterization studies provide a framework to further
investigate selective sEV capture parameters, PET C-CP fiber and film-based sEV
selective capture and separation, diagnostic accuracy, and clinical replication. Moreover,
multiplexed immunoaffinity capture using OC tumor-specific EV markers has
demonstrated the potential for these methods to distinguish between malignant and
benign tumor cell-derived sEVs. The IHOE-CD81-GFP and SKOV-3-CD9-RFP cell
model system may also allow for advancement of EV imaging and quantification via
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efficient sample prep, easier live cell imaging, and quantitative fluorescence correlations.
The versatility of the sEVs generated by these cell lines will prove useful as new
applications come to light and the EV community begins to focus more on selective EV
capture and super-resolution microscopy.
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CHAPTER 4
POTENTIAL IMPACTS OF ISOLATION METHOD AND SAMPLE SOURCE ON
SMALL EXTRACELLULAR VESICLE MORPHOLOGY AND BIOMARKER
PROFILING

Abstract
Extracellular vesicles (EVs) have emerged as promising diagnostic, drug delivery,
and therapeutic agents, particularly with regards to cancer. Although research is
progressing quickly, progression of EV applications is hindered by the limitations of EV
isolation and separation technologies. Current EV isolation techniques are in need of
standardization across the industry for translational progression to continue. In particular,
sample source is an important factor that may influence EV isolation choice and outcome.
In this research, urine and cervical mucus are compared as potential sources for EV
isolation and downstream EV analysis for potential ovarian cancer diagnostic and
treatment applications. In addition, a larger study of microRNA (miRNA) content of EVs
isolated from cervical mucus samples from patients with and without ovarian cancer
revealed several potential miRNA biomarkers. In-depth analysis of this miRNA data,
along with corresponding proteomic data, is ongoing in an attempt to reveal pathology
and characteristic-specific miRNA and protein biomarkers for early ovarian cancer
detection. Together, these studies demonstrate that cervical mucus may be useful for
ovarian cancer-specific EV diagnostics. Ultimately, investigations of sample source-
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specific applications, such as this, may lead to more accurate and specific EV diagnostics
and therapeutic outcomes, as well as greater standardization across the EV field.
It should be noted that this is collaborative work and was performed with Dr. Brian Dean
of the Clemson University Biomedical Data Science and Informatics Program. The
bioinformatics work outlined in this chapter was primarily performed by Ms. Paritra
Mandal. All patient samples used in this work were provided by Dr. Larry Puls, who
serves as the Head of Gynecological Oncology at Prisma Health Systems in Greenville,
SC.

Introduction
Extracellular vesicle (EV) and exosome research has quickly developed into an
expansive area of study focusing on vesicle biogenesis, classification, transport, uptake,
dissemination, isolation and separation, biomarker discovery, drug delivery, and
therapeutics.2-6 Broadly, these areas of focus can be divided into basic research and
knowledge discovery and medical application development. Both sides of EV research
are making significant progress but lack a strong base to make definitive and repeatable
claims. Every discovery and development is highly dependent on the source of the
vesicles, the method of separation, and the micro- and macro-environments from which
the vesicles originate. With so many sources and methods of isolating EVs, paired with
the diverse subcategories of EVs, it is both remarkable and encouraging that such
significant progress has been made in the understanding of these bio-nanoparticles.
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However, with each new discovery, the complexities surrounding EVs grow ever more
intricate.
Before investigating either basic research or medical application development, it
is important for the EV community to come to agreement by setting standards in
classification and isolation methods. While Thery et al. and the International Society for
Extracellular Vesicles (ISEV) have made significant progress toward formulating vesicle
classifications and benchmarks of identification, the standards are still continually
debated and evolving.7, 8 There are many commonly used isolation techniques, including
ultracentrifugation (UC), ultrafiltration (UF), chromatography, precipitation, and
immunocapture, but very little agreement upon which technique should be used for
principal comparison.9-11 Perhaps the best way to develop greater consistency and
experimental reproducibility is to develop standards for EV separation and isolation.
Classification of EV isolation strategies into methods better suited for particular
applications may be a good place to start.
Of the most common EV isolation methods, ultracentrifugation is perhaps the
most readily available technique, requiring equipment that is already found at most
biology research institutions.12-14 Although UC output can vary greatly depending on
sample viscosity, sample source, pellet disturbance, and rotor characteristics,15-17 UC has
proven to be a useful starting point for EV research and applications.14 Furthermore,
although other EV separation methods have shown greater promise, UC still holds value
as a tool of comparison when developing new EV isolation methods.12, 16, 18, 19 UC has
demonstrated the ability to isolate EVs from conditioned cell media and most body fluids
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including urine, blood plasma, cerebrospinal fluid, amniotic fluid, saliva, and cervical
mucus.11, 16, 17, 20-25 The flexibility and ease with which UC can be performed make it an
excellent tool for comparison as it serves as an acceptable standard across the industry.
Unlike UC, which relies on vesicle density and molecular weight to separate cell
components and EVs, UF and size exclusion chromatography (SEC) rely on vesicle
diameter.26-28 Stratification based on size allows for greater control of EV subpopulations compared to UC, but struggles to classify larger vesicles. Vesicle size
provides a general picture of vesicle classification, but discounts many key characteristics
including biogenesis, protein, RNA, lipid profiles, density, zeta potential, and
morphology. That said, any EV isolation technique using only one metric of comparison
will likely struggle with classification. Size exclusion EV separation techniques have
demonstrated high throughput, fast isolation, and high yield26-29, but, due to the use of
force, have struggled to limit vesicle deformation and may cause damage to larger
vesicles.9 The use of size limit thresholds and multiple filtration or exclusion steps has
greatly improved the purity and population selection of these techniques.27, 28, 30 With
increased EV purity and population selection, size exclusion techniques may serve best in
applications requiring high through-put and large samples.
Due to the presence and diversity of proteins in EV membranes, immunoaffinity
capture techniques have emerged as popular methods for increasing EV population
specificity and purity. Immunoaffinity steps have been incorporated into microfluidics
devices and combined with other effective EV isolation methods with great success.31-35
For example, Mathivanan et al. identified several colon cancer-related proteins and

179

potential EV diagnostic markers using a combination of UC, UF, and immune-affinity
approaches35, while Ueda et al. coupled antibodies to mass spectroscopy to create an
immuno-assay useful for increasing specificity and quickly identifying proteins for
biomarker discovery.36 With the ability to increase specificity and purity, immunoaffinity
methods are continually being incorporated into EV diagnostic techniques and will likely
play an important role in developing EV isolation methods for specific and unique
applications, particularly disease diagnostics.
From diagnosis of cancer, neurodegenerative diseases, and cardiovascular disease
to treatment of Parkinson’s Disease through drug delivery, EV applications can vary
widely.3, 37-39 In particular, ovarian cancer is a prime candidate for EV-based early
diagnostics due to its propensity for late stage diagnosis and poor 5-year survival rate.40
Each application may require vastly different EV population purity, consistency,
specificity, proteomics, transcriptomics, lipidomics, and morphology. Ideally, different
EV separation methods may be able to control these characteristics with limited vesicle
damage. Additionally, sample source (urine, plasma, etc.) may influence the
effectiveness, efficiency, practicality, and accuracy of EV separation. While consistency
across samples is always important, it is unclear whether it is necessary to calibrate each
EV population characteristic for each application or sample source and whether an EV
separation dominant design will emerge as the most practical method.
While developing individualized EV separation methods for each application may
prove useful, practicality, speed, and ease of use are important considerations that may
push EV isolation research in a different direction. A single consistent isolation, while
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less individualized for applications or sample sources, may ultimately be the most useful
in clinical settings and for vesicle comparison in the EV community. However, just as
immunocapture EV isolation may separate sub-populations of EVs, it is hypothesized that
body fluid samples originating from or near a region of interest may contain more
relevant EV information for specific conditions. For instance, urinary EVs have been
frequently investigated as biomarkers for prostate cancer and kidney diseases as a means
of improving the accuracy and sensitivity of diagnostics.20, 41-46 Additionally, breast milkderived EVs have been shown to directly promote the epithelial-mesenchymal transition
in breast cancer tumor cells and breast milk-derived EVs with high expression of TGFβ2
may be associated with a higher risk of breast cancer.47, 48 Diagnosis via EVs isolated
from plasma may use a more generic EV population and demonstrate lower specific
disease detection accuracy due to low signal to noise ratios. Therefore, establishing a
consistent dominant design for EV isolation, while easier to study and evaluate, may
prove impractical for many applications. Finding a balance between consistency in EV
separation and customization for a given EV application will be required to advance EV
understanding and achieve clinical translation.
Much of the EV community has focused on improving or comparing isolation and
diagnostic methods and has focused very little on comparing EV sample sources.49 While
several studies have compared urine and plasma EV diagnostic potential10, 25, 50, 51,
comparison of region-specific sources, such as cervical mucus, breast milk, amniotic
fluid, tears, semen, and cerebrospinal fluid, is uncommon. The size distributions and
RNA makeup of urine and blood plasma EVs have been shown to vary significantly
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when isolated via ultracentrifugation52 potentially due to the presence of Tamm–Horsfall
protein (THP, one of the most common glycoproteins in urine), albumin, and other
protein contaminants in urine and blood.14, 53 Removal or reduction of THP and other
contaminating agents may decrease the variance in size distribution and biomarker
detection from urine and blood EV samples.54 However, if elimination of contamination
proves difficult, other sample sources may allow EV isolation with reduced or
manageable contaminants. Although no individual study has compared the characteristics
of EVs from different sources (other than urine and blood plasma) under controlled
conditions, sample source comparison across studies reveals variance in EV size
distribution and RNA makeup.24, 52, 55-68
With such variation in EV characteristics and transcriptomics, it is difficult to
determine which body fluid matrix is optimal for each isolation method and downstream
application. Furthermore, it is unclear whether sample proximity to a region of interest
may improve diagnostic accuracy. More analysis and comparison across studies is needed
before any conclusions can be drawn. However, this study aims to compare the
morphology and miRNA content of EVs isolated from urine and cervical mucus samples
of patients with benign or malignant ovarian tumors. In doing so, this study highlights the
differences in morphology and miRNA content between urine and cervical mucus EVs
and may provide evidence for increased use of sample sources near regions of interest
with regard to diagnostic accuracy. Furthermore, this study contributes ovarian cancer
EV miRNA differential expression analysis that can be used to develop more accurate
and potentially earlier EV-based diagnoses for ovarian cancer. Notably, early diagnosis
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(stage 1 or 2) of ovarian cancer, may increase the 5-year survival rate of the disease to
92% from 29% when discovered in stage 3 or 4.40
Due to concerns over the classification and nomenclature of EVs among the EV
community, all EVs discussed in this study will be referred to as small extracellular
vesicles (sEVs) rather than exosomes specifically.

Materials and Methods
Urine, cervical mucus, and plasma collection and storage
Urine, cervical mucus (CM), and blood plasma samples were obtained from
patients through the Prisma Health System (Greenville Campus, Institute for
Translational Oncology Research (ITOR) biorepository responsible for sample
processing and storage). All procedures were approved and performed with adherence to
the Prisma Health Institutional Review Board and Clemson University Institutional
Biosafety Committee safety guidelines. Upon collection, 50 mL urine samples were
supplemented with 1.67 mL of 100 mM sodium azide, 2.5 mL of 2 mg/mL
phenylmethylsulfonyl fluoride (PMSF), and 50 µL of 1 mg/mL Leupeptin. After
supplementation, urine samples were frozen and stored at -80˚C until further processing.
To collect CM samples, the cervical mucus plug and a swab of cervical mucus were
placed in 10 mL of phosphate buffered saline (PBS) supplemented with 334 µL of 100
mM sodium azide, 500 µL of 2 mg/mL PMSF, and 10 µL of 1 mg/mL Leupeptin. After
supplementation, CM samples were placed on ice for 30 minutes, vortexed for 30
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seconds, frozen and stored at -80˚C until further processing. Blood samples were
collected via standard phlebotomy procedures in an ethylenediaminetetraacetic acid
(EDTA) coated tube. Within 30 minutes of sample collection, blood samples were
inverted 8 to 10 times and centrifuged at 1500 x g at 22˚C for at least 15 minutes.
Supernatant of centrifuged blood samples were aliquoted into 1.5 mL cryovials, frozen
and stored at -80˚C.
sEV isolation via ultracentrifugation
Patient urine and cervical mucus were thawed at 22°C prior to sEV isolation.
After thawing completely, urine samples were vortexed for 30 seconds while CM
samples were vortexed for 3 minutes to ensure even mixing, breakup of mucus, and
removal of mucus from the collection swab. After being vortexed, collection swabs were
removed from the CM and scraped into the tube to retain any excess mucus still on the
swab. Briefly, 8 mL of urine or CM was centrifuged at 2,000 x g for 20 minutes at 22˚C
using an Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, Germany). The resultant
supernatant was centrifuged at 10,000 x g for 30 minutes at 4˚C using a Beckman Coulter
Avanti J-26S XPI Centrifuge with a JA-25.50 rotor (Beckman Coulter, Brea, CA). The
resultant supernatant was filtered using a 0.2 µm sterile syringe filter (Thermo Fisher
Scientific, Waltham, MA). After filtration, the supernatant was transferred to a
compatible ultracentrifuge tube (Beckman Coulter, Brea, CA) and centrifuged at 120,000
x g for 60 minutes at 4˚C using a Beckman Coulter Optima XPN-80 Ultracentrifuge and
a Type 45 Ti rotor (Beckman Coulter, Brea, CA). Finally, the resultant pellet was
resuspended in 400 µL of 1x PBS and stored at -80oC for downstream analysis.
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C-CP fiber sEV isolation method
Chemicals used during sEV separation include ammonium sulfate ((NH4)2 SO4)
(VWR, Radnor, PA), 10x PBS (Hyclone Laboratories Inc., Logan, UT), acetonitrile
(ACN) (EMD Millipore, Burlington, MA), glycerol (Fisher Scientific, Waltham, MA),
and ultra-pure water (obtained using a Milli-Q water system, Millipore, Burlington, MA).
Extruded polyethylene terephthalate (PET) capillary-channeled polymer (C-CP) fibers,
produced by the Material Science and Engineering Department at Clemson University,
were wound on a circular frame 8 times (450 fibers) then rinsed with hot water,
acetonitrile, isopropanol, and ultra-pure water. Wound fibers were pulled through a 30
cm length, 0.762 mm internal diameter polyether ether ketone (PEEK)(IDEX Health &
Science LLC, Oak Harbor, WA) tubing using a plastic monofilament. Using a Dionex
Ultimate 3000 HPLC system (LPG-3400SD quaternary pump and MWD-3000 UV–Vis
absorbance detector; Thermo Fisher Scientific, Sunnyvale, CA, USA), packed columns
were washed using ultra-pure water, acetonitrile, and then ultra-pure water at 0.5 mL min1

. Chromatography was performed using the Dionex Ultimate 3000 HPLC system and

controlled by the Chromeleon 7 software system. Samples were injected using a
Rheodyne model 8125 low dispersion injector with a 60 μL injection loop (Rheodyne,
Rohnert Park, CA). The baseline case (no sample, step gradient mobile phase) was
performed with mobile phase flow rate of 0.5 mL min-1 and subtracted from sample
chromatograms. After being flushed with 1X PBS, the column was equilibrated with 2 M
ammonium sulfate solution dissolved in 1X PBS, pH = 7.4. A step gradient mobile phase
of 25% glycerol with 1M (NH4)2 SO4 (0.5 mL min-1) was introduced 3 minutes following
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sample injection. Column elution was initiated by a second step gradient of 50% glycerol
in 1X PBS (0.5 mL min-1) 5 minutes after sample injection. Eluting species (proteins and
sEVs) were detected at 216 nm and recovered using an R1 fraction collector (Teledyne
Isco, Lincoln, NE, USA) based on detector absorbance response.
C-CP Fiber-based film wicking sample preparation
Samples used in the film wicking experiments included patient urine and blood
plasma, obtained through Prisma Health and standard exosomes (HBM-PEU-100,
HansaBioMed, Tallinn, Estonia) diluted in mock urine, reconstituted milk, and mock
saliva to a concentration of 9.3 x 105 particles/mL. Mock urine and saliva were prepared
according to recipes from previous studies69, 70, while reconstituted milk was prepared as
2% non-fat dry milk (Bio-Rad, Hercules, CA) dissolved in DI water. All samples were
supplemented with 1% red food coloring (McCormick, Baltimore, MD) by volume.
C-CP channeled film wicking studies
C-CP channeled films, produced by the Material Science and Engineering
Department at Clemson University, were cut into 5 cm strips and taped down to 1 x 3
inch glass microscope slides, ridges face-up. A micropipette was used to apply 10 µl of
patient urine, patient plasma, 1X PBS diluted standard exosomes, or 1X PBS directly to
the center of the film. The applied drop was allowed to wick along the film for 20
minutes at 22˚C while exposed to air. Following wicking, the films were removed from
the glass slides and the film regions where sample visibly wicked were clipped off using
scissors and prepared for scanning electron microscopy (SEM).
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In a separate experiment, 3 µl of 1X PBS, patient urine, patient plasma, or
standard exosomes diluted in mock urine, mock saliva, reconstituted milk, or 1X PBS
were applied directly to the center of the C-CP films via micropipette and allowed to
wick for 15 minutes at 22˚C while exposed to air and under 5X magnification (Plan APO
1.0X objective, 0.09 numeral aperture, no immersion) stereoscopic observation using a
Leica Thunder Model Organism Imaging System (Leica, Wetzlar, Germany). Images
were captured at a rate of one frame per second and compiled into time-lapse movies.
Tracker Video Analysis and Modeling Tool, available through Open Source Physics
(https://www.compadre.org), was used to track the fluid front in order to determine the
velocity of sample wicking on the films. Any velocities below 2x10-7 m/s (periods of
little to no movement) were not included in the average (n=8) calculations (see Figure
4.4a). Flow rate was calculated as velocity multiplied by the C-CP film cross-sectional
area as measured by SEM.
Sample preparation for scanning electron microscopy
C-CP films being prepared for SEM were fixed in 1% osmium tetroxide for 1
hour with shaking immediately after sample wicking. After removing the osmium
tetroxide, samples were washed in deionized water 3 times for 3-5 minutes per wash.
Next, the samples were washed in an ethanol-water mixture of the following ethanol
percentages for 3 minutes each: 50%, 70%, 80%, 90%, 95%, 100%, 100%. The samples
were then washed in a 50:50 hexamethyldisilazane(HMDS) –ethanol mixture for 3
minutes and then finally washed in 100% HMDS and left to dry at 20˚C in a chemical
fume hood for 2-3 days. After drying was complete, samples were attached to a metal
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stage using adhesive and platinum coated using the Hummer 6.2 Sputtering system
(Anatech, Battle Creek, MI) at 70 millitorr for 2 minutes. Images were captured using a
Hitachi SU5000 Field Emission Scanning Electron Microscope (FE-SEM) (Hitachi,
Tokyo, Japan).
Sample preparation for transmission electron microscopy
To prepare for transmission electron microscopy (TEM), 40 µL of urine or CM
sEVs isolated by UC or C-CP fiber separation were fixed in 4% paraformaldehyde for 30
minutes on ice. All grid adhesion and staining steps were performed by pipetting drops of
sample, stain, or wash onto parafilm and moving 200 mesh copper formvar coated grids
(Electron Microscopy Sciences, Hatfield, PA) from one drop to the next. After sample
fixation, grids were placed coated side down on 5 µL drops of each sample for 5 minutes.
Grids were washed 3 times with DI water for 4 minutes each, stained with 2% uranyl
acetate for 5 minutes, and then washed 3 times with DI water for 4 minutes each. Grids
were air dried in a low-humidity environment and then imaged using a Hitachi H7600
TEM (Hitachi, Tokyo, Japan). SEM measurements were made using ImageJ version 1.48
software (NIH, Bethesda, MD)
RNA sequencing
After isolation via ultracentrifugation, 4 patient urine sEV samples of 200 µL (2
cancerous and 2 non-cancerous) and 4 patient cervical mucus sEV samples of 200 µL (2
cancerous and 2 non-cancerous) were sent to Qiagen (Hilden, Germany) for RNA
isolation, quality control, and differential expression analysis.
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In a second study, 42 patient cervical mucus-derived sEV samples (26 cancerous
and 16 non-cancerous), isolated by ultracentrifugation were sent to Qiagen (Hilden,
Germany) for RNA isolation, quality control, and differential expression analysis. In both
studies, sample quality was assessed via average read quality and average base quality,
prior to next generation sequencing.
miRNA analysis
Analysis, (completed by Qiagen) included adaptor trimming, sequence mapping,
principal component analysis, and miRNA differential expression analysis.
Statistical Analysis
C-CP film sample flow velocity means were presented with ± 1 standard
deviation. A one-tailed t-test with α=0.05, using Microsoft Excel’s data analysis software
(Microsoft, Redmond, WA), was used to analyze film flow velocity numeric values.
Tests with p<0.05 were considered statistically significant. RNAseq data, analyzed using
the EdgeR package in R statistical software (r-project.org), was evaluated using a
statistical test analogous to Fisher’s exact test following a negative binomial
distribution.71
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Results
SEM imaging was performed on the C-CP films following wicking of 1X PBSdiluted standard exosomes, patient urine, and patient plasma (Figure 4.1). The 1X PBSdiluted standard exosomes demonstrated adherence along the length of the films while
wicking and displayed typical vesicular morphology when adhered to the film surface
(Figure 4.1a,b). The patient urine sample, much like the standard exosome sample,
demonstrated sEV adherence along the length of the film surface and demonstrated sEV
morphology similar to the standard exosome sample (Figure 4.1c,d). Finally, the patient
plasma sample, while containing vesicular structures similar in morphology to the
standard exosome sample, also included other plasma components, which were
potentially a mixture of cellular debris and blood clotting proteins (Figure 4.1e,f).
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Figure 4.1. Scanning electron microscopy of C-CP films after wicking of
various media. Film wicking of (a,b) 1X PBS-diluted standard exosomes, (c,d)
patient urine, (e,f) patient plasma, and (g,h) 1X PBS, no sEV control. Images
were captured at 70x magnification (a, c, e, g) and 7,000x magnification (b, d, f,
h).
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Next, the flow rates of patient urine, patient plasma, and standard exosomes
diluted in PBS, mock urine, reconstituted milk, or mock saliva on the films were
measured and calculated using videos of sample wicking under stereoscopic observation.
The average and maximum volumetric flow rates were calculated by multiplying the
velocity of each sample observed during sample movement (see Figure 4.2)(Table 4.1)
and the cross-sectional area of the film as measured from SEM images (see Figure 4.3,
cross-section area: 9,310 µm2). Velocities during periods of minimal movement (velocity
< 2x10-7 m/s)(see Figure 4.4a and Materials and Methods for explanation) were not
included in the average flow calculations. Halting of fluid flow was due to the limited
source pool and uneven sample distribution. PBS control samples demonstrated a
significantly higher flow rate than all other samples. Patient urine average volumetric
flow was significantly higher than mock urine + Std Exo, patient plasma, reconstituted
milk + Std Exo, and mock saliva + Std Exo. Although PBS + Std Exo demonstrated a
significantly lower average volumetric flow rate as compared to PBS, its average
volumetric flow rate was significantly higher than those of patient plasma, mock urine +
Std Exo, reconstituted milk + Std Exo, and mock saliva + Std Exo. Patient urine and PBS
+ Std Exo flow rates were not significantly different. Additionally, the maximum
volumetric flow rates for less viscous samples (PBS, patient urine, PBS + Std Exo, mock
urine + Std Exo, and reconstituted milk + Std Exo) were generally higher than more
viscous matrices (patient plasma and mock saliva + Std Exo)(Table 4.1).
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Figure 4.2. Average volumetric flow rates of C-CP film wicking. Results
demonstrating the average volumetric flow rates for various matrices, including
phosphate buffered saline (PBS), patient urine, patient plasma, PBS + standard
exosomes (Std Exo), mock urine + Std Exo, reconstituted milk + Std Exo, and
mock saliva + Std Exo (* - PBS; significantly different from all samples, p<0.05)
(** - patient urine; significantly different from mock urine +Std Exo, p<0.05, n=8).
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Table 4.1. Average and maximum volumetric flow rates of C-CP film wicking.
Matrices wicked on C-CP films include phosphate buffered saline (PBS), patient
urine, patient plasma, PBS + standard exosomes (Std Exo), mock urine + Std Exo,
reconstituted (Reconst) milk + Std Exo, and mock saliva + Std Exo. Error is
represented by 1 standard deviation from the mean, n=8.

Figure 4.3. SEM of C-CP film cross-section. A cross-sectional image was
captured of a C-CP film using SEM at 315x magnification. Area measurements
(made using ImageJ 1.48) were used to calculate flow rate in the C-CP film
wicking experiments.
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Figure 4.4. Patient urine C-CP fiber-based film wicking velocity and
stereoscopic image. (a) Change in distance over time of patient urine
wicking on C-CP film. Time points with a velocity below 2x10-7 m/s
(periods of little movement, marked by red arrows) were removed from
average velocity and flow calculations. (b) C-CP film stereoscopic image
(5x magnification) of patient urine wicking experiment measured using
Tracker video analysis software.
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When imaged via TEM, patient urine and CM sEVs isolated using a C-CP fiber
column and the glycerol stepwise elution protocol (see Materials & Methods; Figure 4.5)
revealed similar morphologies to those isolated from the same sample type by UC.
Patient urine sEVs isolated by UC (Figure 4.5a) ranged in size from approximately 50200 nm, while the patient urine sEVs isolated by C-CP fiber-based HIC (Figure 4.5b)
were approximately 200 nm in diameter. CM sEVs isolated by UC (Figure 4.5c) ranged
in size from approximately 30-70 nm, while CM sEVs isolated by C-CP fiber-based HIC
(Figure 4.5d) ranged in size from 60-100 nm. Samples derived from patient urine retained
similar staining characteristics regardless of isolation protocol (Figure 4.5a,b), but CM
sEVs isolated by C-CP fiber-based HIC appeared much darker than CM sEVs isolated by
UC.
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Figure 4.5. Transmission electron microscopy of small extracellular
vesicles derived from urine and cervical mucus via UC or C-CP fiber
HIC. Samples include sEVs from a) patient urine, isolated by UC, b)
patient urine, isolated by C-CP fibers using HIC with glycerol elution, c)
cervical mucus, isolated by UC, and d) cervical mucus, isolated by C-CP
fibers using HIC with glycerol elution.
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Initial pilot study sEVs (2 CM-derived – cancerous, 2 CM-derived – benign, 2
urine-derived – cancerous, 2 urine-derived – benign) were run through quality control,
library prepped, sequenced for miRNA, and analyzed for miRNA expression patterns.
Principal component analysis (PCA), which dimensionally reduces and clusters samples
based on the most influential variables (largest coefficient of variation), was used to look
at similarities between samples (Figure 4.6). Principal component 1 is weighed more
heavily than principal component 2, meaning sample proximity within principal
component 1 indicates higher sample similarity than comparable sample proximity within
principal component 2. Cancerous CM-derived sEV miRNA appeared to be grouping
together with cancerous urine-derived sEV miRNA. Benign urine-derived sEV miRNA
appeared to be comparable to cancerous CM- and urine-derived sEV miRNA in one
sample, but not similar in the other sample. Both benign CM-derived sEV miRNA
samples did not appear to group well together, but also differed significantly from
cancerous CM-derived sEV miRNA.
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Figure 4.6. Principal Component Analysis (PCA) plot of benign and
cancerous cervical mucus- or urine-derived sEV miRNA expression (Pilot
Study). Cancerous CM- (n=2), benign CM- (n=2), cancerous urine- (n=2), and
benign urine- (n=2) derived sEV miRNAs were dimensionally reduced and
clustered for easier interpretation. Data was normalized using the weighted
trimmed mean of M-values (TMM) method.1 PCA completed using 50 miRNAs
with the largest coefficient of variation based on TMM. Principal component 1 is
the largest component in the variation and principal component 2 is the second
largest component in the variation.
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Differential expression analysis between pilot study benign (n=2) and cancerous
(n=2) urine-derived sEV miRNA revealed numerous miRNAs that were highly
differentially expressed and statistically different (Figure 4.7). Several cancerous urinederived sEV miRNAs appeared significantly upregulated or downregulated in
comparison to benign counterparts. Specifically, 2 cancerous urine-derived miRNAs
were highly downregulated and statistically significant (log10(p-value)>1.301) and 5
cancerous urine-derived miRNAs were highly upregulated and statistically significant
when compared to benign miRNA counterparts. The maximum log2 fold change
magnitude between benign and cancerous urine-derived sEV miRNA was 3.85. Of those
miRNAs that were highly differentially expressed and statistically significant in the
cancerous urine-derived sEV samples, highly expressed miRNAs (high log of counts per
million – logCPM) with tumor-related published literature were identified as potential
indicators of pathogenesis (Table 4.2).
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Figure 4.7. Volcano plot of miRNA differential expression of benign vs
cancerous urine-derived sEVs (Pilot Study). Benign urine-derived sEV samples
(n = 2) serve as the basis of comparison against cancerous urine-derived sEV
samples (n=2). A log2 fold change > 0 indicates miRNA expression upregulation
while a log2 fold change < 0 indicates miRNA expression downregulation.
Differential expression and statistical significance (p<0.05 or –log10(pvalue)>1.301) determined using the EdgeR package for R and statistical test
analogous to Fisher’s exact test that follows a negative binomial distribution.
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Table 4.2. Differentially expressed miRNAs of interest from benign (n=2) vs
cancerous (n=2) urine-derived sEVs (Pilot Study). Significantly different miRNAs
of interest were selected by looking for a high absolute value log2 fold change (Log2
FC), a high log of counts per million (logCPM), a p-value<0.05, and tumor-related
literature.
miRNA Name

Log2 FC

LogCPM

p-value

Direction

hsa-mir-299-5p

-3.842

4.161

0.0081

Downregulated

hsa-mir-205-5p

3.687

10.807

0.0095

Upregulated

hsa-mir-320d

2.597

4.281

0.018

Upregulated

Differential expression analysis of pilot study benign (n=2) and cancerous (n=2)
CM-derived sEV miRNAs primarily demonstrated high upregulation of miRNAs (Figure
4.8). In the cancerous CM-derived sEV samples, 4 miRNAs were downregulated and
statistically significant and 72 miRNAs were upregulated and statistically significant
compared to benign CM-derived miRNAs. The maximum log2 fold change magnitude
between benign and cancerous CM-derived sEV miRNA observed was 7.34 (Figure 4.8).
Several miRNAs were identified as being highly expressed (high log CPM), highly
differentially expressed (log2 fold change) and statistically significant (p-value <0.05)
(Table 4.3) between benign and cancerous CM-derived sEVs.
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Figure 4.8. Volcano plot of miRNA differential expression of benign vs
cancerous cervical mucus-derived sEVs (Pilot Study). Benign CM-derived sEV
samples (n=2) serve as the basis of comparison against cancerous CM-derived
sEV samples (n=2). Upregulation of miRNA expression (log2 fold change >0),
downregulation of miRNA expression (log2 fold change <0), and statistical
significance (p<0.05 or –log10(p-value)>1.301) determined using the EdgeR
package for R and statistical test analogous to Fisher’s exact test that follows a
negative binomial distribution.

203

Table 4.3. Differentially expressed miRNAs of interest from benign (n=2) vs
cancerous (n=2) cervical mucus-derived sEVs (Pilot Study). Significantly different
miRNAs of interest were selected by looking for a high absolute value log2 fold
change (Log2 FC), a high log of counts per million (logCPM), a p-value<0.05, and
tumor-related literature.
miRNA Name

Log2 FC

LogCPM

p-value

Direction

hsa-mir-95-3p

5.274

5.877

1.53E-17

Upregulated

hsa-mir-184

6.320

7.528

8.01E-14

Upregulated

hsa-mir-429

4.617

9.056

4.88E-16

Upregulated

As part of a larger study, 42 CM-derived sEV (16 benign, 26 cancerous) samples
were sequenced and analyzed (by Qiagen) for miRNA expression. After quality control,
library prep, and sequencing, sample miRNA expression levels were analyzed using
principal component analysis (PCA) to more easily understand clustering and similarities
in expression between samples (Figure 4.9).Visually, cancerous CM-derived sEV
miRNA profiles appeared to cluster closer along the first principal component compared
to benign CM-derived sEV miRNAs. Overall, much of the variance in expression for all
43 miRNAs appear very similar for both cancerous and benign CM-derived sEVs, as
indicated by PCA overlap and close proximity.
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Figure 4.9. Principal Component Analysis (PCA) plot of benign and
cancerous CM-derived sEV miRNA expression. Dimensional reduction and
clustering was used to analyze miRNA expression similarities between benign
CM-derived sEV samples (n=16) and cancerous CM-derived sEV samples (n=26).
Data was normalized using the weighted trimmed mean of M-values (TMM)
method.1 PCA completed using 43 miRNAs with the largest coefficient of
variation based on TMM. Principal component 1 is the largest component in the
variation and principal component 2 is the second largest component in the
variation.
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In a larger analysis, benign (n=16) and cancerous (n=26) CM-derived sEV
miRNAs were analyzed for differential expression based on benign CM-derived sEV
miRNAs (Figure 4.10). Of the miRNAs analyzed, 18 were downregulated and
statistically significant (log10(p-value) >1.301) and 4 were upregulated and statistically
significant in the cancerous CM-derived sEVs. Additionally, the maximum log2 fold
change magnitude observed between benign and cancerous CM-derived sEV miRNA
expression was 3.14. By filtering miRNA expression by high fold change (log2 FC), high
log of counts per million (logCPM), and statistical significance (p-value<0.05) as well as
looking for cancer-related published literature, several potential biomarker candidates
were identified (Table 4.4). Notably, hsa-mir-184 was identified with these qualifications
in both the pilot study (2 benign, 2 cancerous, Figure 4.8, Table 4.3) and larger study (16
benign, 26 cancerous, Figures 4.10, 4.11 Table 4.4) of CM-derived sEV miRNAs.
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Figure 4.10. Volcano plot of miRNA differential expression of benign vs
cancerous cervical mucus-derived sEVs. Benign CM-derived sEV samples
(n=16) serve as the basis of comparison against cancerous CM-derived sEV
samples (n=26). MicroRNA expression upregulation (log2 fold change >0),
downregulation (log2 fold change <0), and statistical significance (p<0.05 or –
log10(p-value)>1.301) determined using the EdgeR package for R and statistical
test analogous to Fisher’s exact test that follows a negative binomial distribution.
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Table 4.4. Differentially expressed miRNAs of interest from benign vs cancerous
cervical mucus-derived sEVs. Differential expression determined using 16 benign
and 26 cancerous CM-derived sEV samples. Significantly different miRNAs of
interest were selected by looking for a high absolute value log2 fold change (Log2
FC), a high log of counts per million (logCPM), a p-value<0.05, and tumor-related
literature.
miRNA Name

Log2 FC

LogCPM

p-value

Direction

hsa-mir-142-3p

-1.500

12.628

0.0013

Downregulated

hsa-mir-34c-3p

-1.718

8.530

0.0154

Downregulated

hsa-mir-184

1.694

10.170

0.0191

Upregulated

hsa-mir-223-3p

-1.288

15.523

0.0500

Downregulated

Figure 4.11. Re-clustering of cervical mucus miRNA expression data. Ongoing
research has observed clustering of samples into high-grade (G1) and lowgrade/benign (G2) rather than cancerous and non-cancerous. Top differentially
expressed miRNAs between correctly grouping samples (n=42).
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Discussion
The impact that EVs may have on disease diagnostics and therapies is becoming
more apparent. As EV biogenesis and classifications become clearer, more efficient, and
effective EV isolations emerge, and EV technology moves closer to clinical translation.2,
72

Specifically, EV isolation maintains a great deal of promise for early cancer

detection.46 Due to frequent late stage discovery and severity, ovarian cancer (OC) is a
prime candidate for EV-based diagnostics. According to a recent epidemiology review,
patients diagnosed with OC at stages 3 or 4 have a 5-year survival rate of 29% and a 5year survival rate of 92% when diagnosed at stages 1 or 2.40, 73 As most OC patients are
diagnosed in stages 3 or 474, early stage discovery via EV-based diagnosis may be used to
greatly improve OC survival rates. Clinical routine screening for cancer cell-derived EVs
is plausible, practical, inexpensive, and could substantially reduce instances of cancerrelated deaths.
Although EVs have demonstrated promising and powerful therapeutic and
diagnostic abilities in vitro, only a handful of clinical trials have reported results from
phase 1-3 (dosage, safety, and efficacy)75-79 studies. The trials reporting results have
demonstrated that therapeutic EV dosing has been well-tolerated in most instances with
only a few cases of moderate adverse events.80 To date, no clinical trials regarding EV
diagnostic ability have reported results. While these trials are promising, the number of
trial applications has been limited primarily due to EV isolation inconsistencies, changing
EV characterization definitions, and mutable good manufacturing practices (GMP). For
EV technology to be translated to the clinic, it is vitally important that the EV community
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establish greater consistency within EV isolation, classification, characterization, and
sample source selection. The International Society of Extracellular Vesicles (ISEV) has
thus far done an excellent job establishing standards of classification and
characterization8, but much more research and discussion will be required to fully
understand the complexities surrounding EV biogenesis and classification.
A large hurdle impeding consistency across EV research is choice of EV source.
The majority of EVs used in clinical trials come from either autologous or allogeneic
dendritic cells (DCs), mesenchymal stem cells (MSCs) or patient body fluids.80 Sources
of EVs investigated in vitro may include human, plant, or other eukaryotic cell lines and
numerous human body fluids.2, 3, 52, 80-89 Sample source can greatly impact the results of a
study and should be carefully chosen for each application. By defining isolation strategies
starting with sample source, the EV community may be able to improve EV diagnostic
consistency, precision, and accuracy needed to progress toward clinical translation. While
several studies have demonstrated diagnostic correlations using urine or plasma, more
body fluids are worth investigating for region-specific diagnostic potential. For instance,
hypothetically speaking, urine may provide the most accurate diagnosis for renal cell or
bladder carcinomas, while breast milk may provide the most accurate diagnosis for breast
cancer. Moreover, the strategies employed to isolate EVs should largely depend on the
sample source and application desired. By investigating how EV separation techniques
using various sample sources impacts downstream EV applications, the EV community
may find correlations that help develop improved guidelines and standards for EV
isolation and diagnostics.
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When choosing an EV isolation design, both physical characteristics and potential
application should be considered. Vesicle properties including size, morphology,
concentration, and protein, nucleotide, and lipid content can influence EV separation
parameters.12, 15, 30, 48, 90, 91 Furthermore, the EV source fluid viscosity, protein profile,
volume, and contaminants can affect process efficiency or resulting sample purity. For
instance, a highly viscous source, such as blood plasma or cervical mucus, may not flow
through microfluidics devices under the same conditions as urine, thus potentially
influencing capture efficiency. As applications are considered, it is important to
understand the EV sub-populations and contaminants present in each EV source. For
instance, blood sample EV separations have demonstrated the highest level of
contamination (proteins, non-vesicular membranous species, lipoproteins), which may
influence downstream proteomics, lipidomics, or therapies.92, 93 Even while considering
the EV physical characteristics, source, and application, with the lack of comparison of
EV isolation techniques and sources, it can be difficult to ascertain the optimal approach.
This study aims to compare the effects of separation method and sEV source (urine or
cervical mucus), on recovered sEV morphology, and RNA sequencing (miRNA) results.
In particular, this study provides important preliminary data for the study of ovarian
cancer diagnostic potential of urine- and cervical mucus-derived sEV miRNA. The
ultimate aim of these investigations and those of the cohort is to determine which EV
source is optimal for downstream predictive ovarian cancer diagnostics and to optimize
EV separation for that source.
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The Case for Urine-derived EVs
Urine was chosen first for EV investigation as it has become a popular choice for
EV study due to its availability and ease of collection. Urine-derived EVs have been
characterized by morphology, proteome, and miRNA content numerous times, providing
an abundance of information for comparison.42, 52, 94 Furthermore, ultracentrifugation,
size exclusion, microfluidics, polymer precipitation, and immunoaffinity separation
approaches have been used to isolate urine-derived EVs.20, 52, 56, 95, 96 Given the lack of
standards within the EV community, size characterization and quantification of urinary
EVs appears heavily dependent on isolation protocol, purification steps, sample
preparation, and characterization method. However, when developed under identical
protocols, different size distribution and concentrations of urinary EVs could indicate
underlying disease states.42 Urinary EVs may be particularly useful for downstream
miRNA analysis as the abundant protein content in urine does not prohibit RNA
extraction43 and extravesicular RNA does not tend to co-precipitate with urinary EVs.43, 97
Moreover, publications have identified more than 5,000 urinary EV proteins (many of
which can be analyzed online at EVpedia and Vesiclepedia) that researchers can
investigate further as potential biomarkers.42 Compared to other body fluids, urine and
blood have amassed the most EV-related literature and, given the large amount of data
available and ease of access, may be ideal for biomarker discovery and disease
diagnostics.
Since plasma EVs cannot easily cross the glomerular filtration apparatus, the
majority of urinary EVs are derived from the kidneys.58 Based on the premise that EV
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sources in close proximity to diseased tissue may allow for better diagnostic accuracy,
most studies of urinary EV diagnostic potential have focused on urinary tract diseases.20,
44, 45, 55, 97, 98

However, proteomics analysis of urinary EVs has demonstrated significant

diagnostic potential for urogenital tract diseases, metastatic cancers, and non-urologic
diseases. For instance, Wang et al found that SNAP23 and calbindin were elevated in
Parkinson’s Disease urinary EVs and predicted disease 86% of the time.57 The suggestion
that urinary EVs can be used to diagnose urogenital tract diseases is valid, but, likely due
to glomerular filtration of proteins, urinary EVs may also have the potential to diagnose
distant diseases or injuries, such as neurodegenerative diseases, cardiovascular diseases,
liver injury, and cancers.35, 57, 92, 95, 99, 100
The early results of this study suggest that urine may be an excellent EV source
for isolation techniques involving wicking or capillary movement. Initial TEM images of
sample wicking on C-CP fiber-based films (Figure 4.1) demonstrated high similarity in
EV capture and morphology between PBS-diluted standard exosomes (Figure 4.1a,b) and
patient urine (Figure 4.1c,d) samples. Vesicles in both PBS-diluted standard exosomes
and patient urine samples appeared to adhere to the film surface in large aggregates.
Although, it remains to be seen if capturing vesicles in aggregates or with even surface
distribution is more or less beneficial for easy vesicle detection. When compared to
patient plasma wicked on C-CP films (Figure 4.1e,f), urine presented clearer and cleaner
capture of EVs, suggesting that urine may be more compatible with wicking-based EV
separation and capture. Plasma samples may require further purification or
supplementation (to reduce protein contamination or viscosity) in this format in order to
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wick and separate plasma sEVs. Analysis of the flow rates of the various matrices on CCP films (see Figure 4.2) revealed that PBS-diluted standard exosomes and urine flow at
significantly lower rates than PBS, but significantly higher rates than patient plasma and
standard exosomes diluted in mock urine, reconstituted milk, or mock saliva. The
presence of standard exosomes in PBS appeared to decrease the sample flow rate
compared to PBS alone. The significant difference in flow rates of patient urine and
mock urine suggests that the samples have significantly different composition. As the
mock urine is not capable of representing the large range and variation of patient urine
(especially in regard to water content and solute concentrations), the difference in flow
rates is not surprising. Additionally, it seems unlikely that the urine collection
preservatives (protease inhibitors and a bacteriostatic) may be altering the sample surface
tension, viscosity, or interaction with the fiber surface. However, as urine samples can
vary widely from patient to patient, more sample replicates would be required to make
substantial claims.
Due to its widespread use, availability of proteomic information , compatibility
with wicking and capillary flow applications, and diverse EV population, urine may act
as an optimal EV source in most situations. However, as one of the primary goals of these
investigations is to determine which EV source is optimal for downstream predictive
ovarian cancer diagnosis, body fluids more closely associated with the female
reproductive tract needed to be explored. While urine may provide heterogenous EV
populations useful for a variety of applications, greater homogeneity in EV population
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may provide enhanced diagnostic sensitivity for certain diseases. Hence, the next logical
step was to investigate a body fluid with greater proximity to the ovaries.
The Case for Cervical Mucus-derived EVs
Recently, cervical mucus (CM) has generated interest as an EV source for
diagnosis of diseases or injury in the female reproductive tract. Like urine, CM proximity
to potential diseased areas (cervix, endometrial lining, ovaries, fallopian tubes, etc.) may
allow for greater diagnostic specificity. While blood-derived EV disease diagnosis is
promising, low specificity, heterogeneous EV populations, and EV sub-population
masking by other EV populations may affect diagnostic accuracy in certain applications.
In the case of ovarian cancer, the potential of CM specificity may outweigh diagnostic
potential of more heterogenous EV population sources, such as blood and urine.
Although CM may be an appealing source of EVs for diagnosis, there has been
very little investigation into CM-derived EVs by researchers. Since EVs are found in
most body fluids6, 101, are heavily involved in placental barrier communication during
pregnancy102, 103, and Flori et al. found that cervical mucus from pregnant and nonpregnant women contain membranous vesicles having exosome-like structure,24 there is
reasonable evidence that CM contains EVs. However, the CM-derived vesicle
concentrations and characteristics are not well documented. With so little available
information, it can be challenging to develop new protocols that produce consistent EV
populations and downstream results from CM. However, the lack of CM-derived EV
research offers an opportunity to expand understanding of EV separation, morphology,
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and downstream analysis of CM. The practicality or ease of collection of CM may also
generate concern, especially compared to urine; however, CM can be easily obtained
during routine gynecological examinations.
In this study, initial analysis suggests that sEVs may be separated from CM in a
similar fashion to urine. TEM imaging of urine and CM samples subjected to UC and
glycerol elution (see Figure 4.5) all revealed small dimpled vesicles meeting the
description of sEVs. The similarity in morphology between UC and glycerol elution
samples for each sample type suggests that the glycerol elution method may provide an
alternative to UC isolation. Furthermore, the similarity in morphology across CM UC and
glycerol elution samples suggests that CM may be compatible with chromatography
techniques despite high sample viscosity.
After literature investigation and experimental demonstration of CM sEV
separation, the potential of CM sEV downstream analysis needed to be investigated. With
an eye toward comparison of urine and CM downstream analyses and ensuing OC
diagnostics investigations, an sEV miRNA sequencing pilot study was designed to
examine miRNA differential expression of cancerous and benign urine and CM sEV
samples.
Comparison of urine- and CM-derived EV miRNA sequencing
Urine and CM-derived EV samples were prepared via UC prior to miRNA
isolation, sequencing, and analysis. The pilot study consisted of 2 cancerous urinederived, 2 non-cancerous urine-derived, 2 cancerous CM-derived, and 2 non-cancerous
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CM-derived EV samples with all 4 urine-derived and 4 CM-derived EV samples sourced
from the same 4 patients (one urine and one CM sample from each patient). Although the
sample sizes were not large enough to make conclusive statements, the pilot study
allowed for assessment of sample source compatibility with the given protocol and
provided small insights into the miRNA differential expression of urine- and CM-derived
EVs.
Initial completion of quality control and observation of the PCA (see Figure 4.6)
suggests that the UC method used here can produce viable urine- and CM-derived EVs
for downstream miRNA analysis. A more thorough analysis of the quality and
differential expression of miRNA may be required when developing or comparing new
isolation methods. In this case, UC is already a well-established EV isolation protocol
with many studies demonstrating viable miRNA analysis.16, 19, 59, 65, 104 For this study, as
CM-derived EVs have never been sequenced for miRNA, it was very important to verify
miRNA quality in the CM-derived EV samples.
The pilot study PCA of benign and cancerous cervical mucus- or urine-derived
sEV miRNA expression (see Figure 4.6), although based on small sample size, suggested
that CM-derived EV miRNAs may cluster better into benign and cancerous groups than
urine-derived EV miRNAs. Both urine- (Figure 4.7) and CM-derived (Figure 4.8) sEV
miRNA profiles demonstrated several miRNAs that were highly differentially expressed
and statistically different; however, the number of miRNAs meeting this criteria was
much greater for CM-derived sEVs than urine-derived sEVs (CM-derived: 4
downregulated, 72 upregulated; Urine-derived: 2 downregulated, 5 upregulated).
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Moreover, the maximum log2 fold change for CM-derived sEV miRNAs was 7.34 while
the maximum log2 fold change for urine-derived sEV miRNAs was 3.85. It is unclear
why the differentially expressed CM-derived sEV miRNAs are skewed toward
upregulation, but a larger sample size would provide more extensive data and possible
insights. It is notable that several of the miRNAs identified as highly expressed and
highly differentially expressed in urine- and CM-derived sEVs were found in tumorrelated literature (see Table 4.2 and Table 4.3). This suggests that both urine- and CMderived sEVs may facilitate diagnosis of cancerous tumors using specific miRNA
markers. However, the greater number of differentially expressed and statistically
different miRNAs, and the greater maximum log2 fold change suggests that CM-derived
sEVs may provide clearer demonstrations of benign and cancerous sEV miRNA
differential expression. Thus, CM-derived sEV-identified miRNA markers may enable
more accurate and specific downstream OC diagnoses than urine-derived sEV miRNA
markers.
After discussion and comparison of urine- and CM-derived sEVs, CM-derived
sEVs were chosen for a subsequent, more comprehensive miRNA study. The larger study
group was comprised of 16 benign CM-derived sEV and 26 cancerous CM-derived sEV
samples. Ideally, the control benign patient samples would comprise half of the group;
however, the total number of potential benign CM samples were difficult to predict ahead
of time as patients who were asked to supply samples were undergoing hysterectomies
because they had ovarian tumors were not biopsied until after surgery. PCA of all 42
samples (see Figure 4.9) did not reveal distinct groupings between benign and cancerous.
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Although this is concerning, especially regarding differential expression, more in-depth
analysis of groupings based on cancer type, stage, and physical characteristics revealed
more representative clustering. Early bioinformatics indicates that high-grade tumor
sample cluster together, while low-grade tumor and benign samples are more similar in
expression (see Figure 4.11). This may be an indication that low-grade tumors and benign
samples may be more difficult to distinguish based on these parameters. As ovarian
cancer is a highly heterogeneous disease, this is not surprising, and additional
categorization beyond these simplistic cancerous and non-cancerous groupings will likely
be required to fully characterize the complexities of the data. Concerning this
observation, more research is ongoing to classify and discriminate characteristics
between these groups to better analyze biomarker candidates. However, differential
expression analysis of the 42 samples (see Figure 4.10) based on simple benign and
cancerous groupings still provided insightful patterns and demonstrated significant
miRNA upregulation (4 miRNAs) and downregulation (18 miRNAs). Significant
differential expression, even with simple benign and cancerous groupings, is evidence
that specific miRNA markers may be used either in single or multiplexed formats to
identify ovarian cancer CM-derived sEVs. Similar to the pilot study, these 22
significantly differentially expressed miRNAs were cross-referenced with tumor-related
literature and the markers that were highly differentially expressed and relevant to
ovarian cancer were identified (see Table 4.4).
Of the markers identified, hsa-miR-184 was of particular interest as it was highly
upregulated in both the pilot and 42-sample miRNA studies and early indications from
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ongoing research suggest that it is also highly upregulated in the clustered high-grade
tumor samples as compared to the low-grade tumor and benign samples. Further
investigation into published research revealed that hsa-miR-184 has been identified as a
potential prognostic marker in epithelial ovarian cancer.105 Functionally, hsa-miR-184
has been categorized as a tumor suppressor for renal cell carcinoma, colorectal cancer,
retinoblastoma, and epithelial ovarian cancer and, accordingly, is typically downregulated
in these tumor environments.105-107 While the exact mechanism is unclear, hsa-miR-184
appears to regulate cell proliferation, apoptosis, and inflammation.105 However, this study
suggests that hsa-miR-184 is highly upregulated in ovarian tumor sEVs, a marked
difference from most investigations. This appears puzzling at first, but there are several
rationales that may explain the disparity. First, no study has used sEV-derived miRNA to
link hsa-miR-184 to a tumor environment. While sEV contents are derived from the cell
cytoplasm, specific molecules are often selectively packaged into sEVs to direct exact
cell communication.4, 108, 109 Second, while most investigations have found that hsa-miR184 is downregulated in tumor tissues, Chen et al.106 found that tongue squamous cell
carcinoma had upregulated levels of hsa-miR-184 compared to corresponding nontumorous tissue and that upregulation of hsa-miR-184 may promote tongue squamous
cell carcinoma migration and metastasis. Therefore, since sEVs are a mode of
microenvironmental communication and are known to be involved in tumor
microenvironment progression and metastasis, it is possible that hsa-miR-184, a potential
promoter of cell migration and metastasis, may be released into the microenvironment
where it could serve to promote disease spread. Lastly, the variety of types and stages of
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ovarian cancer involved in this study may influence hsa-miR-184 expression. For
instance, late stage (III/IV) epithelial ovarian cancer tissues have demonstrated lower hsamiR-184 expression,105 which may skew the differential expression results if samples are
not more specifically categorized for analysis. While the intracellular mechanisms of hsamiR-184 require further investigation, especially for therapeutic applications, hsa-miR184 differential expression and its known involvement in ovarian cancer mechanisms
may prove to be a useful biomarker for diagnostic or disease progression monitoring
applications. It is hoped that more insight into this possible biomarker and the discovery
of others may be realized during an ongoing Phase II patient study that focuses on
patients who have identified BRCA1 mutations.
Frequently denoted as BRCA1 “positive,” a mutation in the BRCA1 tumor
suppressor gene is associated with a much higher risk of developing ovarian, breast,
fallopian tube, peritoneal, and pancreatic cancer.110 As a result of a BRCA1 mutation, the
homologous recombination system responsible for repairing double strand DNA breaks
may fail and cell cycle arrest may be impaired with consequence of a higher risk of tumor
development.111 For women with a BRCA1 mutation, the lifetime risk of developing OC
is 40% and late stage OC discovery survival rates remain low.110 In the currently ongoing
study, cervical mucus samples from patients undergoing prophylactic surgery as well as
those with tumors, both cancerous and non-cancerous, will be processed for EV isolation
for subsequent characterization via RNA sequencing and proteomics. The resulting
miRNA expression and protein data from these samples will be used to identify novel
protein biomarkers for early stage OC. Moreover, machine learning algorithms are being
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constructed that will be used to correlate miRNA and protein expression data to uncover
specific biological pathways involved in tumor initiation and progression. In this manner,
intermediary proteins may be identified that may prove to be diagnostically useful
biomarkers or potential cancer therapy targets.
Sample source selection and OC sEV diagnostic potential
These investigations have compared the resultant sEV morphology and miRNA
profiles for different sEV separation methodologies and sample sources (urine and
cervical mucus). The apparent distinctions between urine and CM-derived sEVs,
particularly concerning miRNA expression, highlight the need to consider sample source
when selecting sEV separation method, downstream analysis, and biomarker discovery.
Both urine- and CM-based diagnostic approaches have great potential and are worthy of
consideration for downstream sEV analysis. However, for these investigations, CM was
chosen based on proximity to the cancer origin and preliminary results. Resulting sEV
miRNA data suggests that CM-derived sEV miRNA sequencing can be used to construct
a panel of OC diagnostic biomarkers. With the correct sEV isolation methods, CMderived sEV miRNA may deliver a simple test that could be seamlessly integrated into
routine gynecological examinations. Such a test would greatly increase the number of
early-stage OC diagnoses and potentially increase the average 5-year survival rate of OC
patients. While the lofty aims of this assay are still far from accomplished, future
investigations are being designed to address the diagnostic accuracy of specific
biomarkers. These investigations should include more CM-derived sEV miRNA
sequencing and analysis, CM-derived sEV proteomics analysis, CM-derived sEV C-CP
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film-based separation, and colorimetric assay development. Continued development of CCP film-based sEV isolation could benefit from even sample application and increased
wicking capacity using sample and absorption pads (similar to standard lateral flow
assays, e.g. pregnancy test strips). Uniform sample application and wicking would
improve the consistency of C-CP film-based sEV separation and elucidate the prospects
of the sEV isolation strategy for use in diagnostics. Further transcriptomics and
proteomics investigations should focus on clustering patients based on carcinoma subtype
or underlying pathophysiology and analyzing data using bioinformatic machine learning
algorithms to reveal expression patterns. These expression patterns may then be used to
develop a panel of diagnostic biomarkers to predict OC occurrence. Paired with the
appropriate sEV isolation, predictive OC biomarkers could lead to more accurate, easier
to perform, and inexpensive OC detection assays. Clinical translation of this technology
has the potential to reach clinical or home settings and would truly revolutionize early
cancer detection and improve cancer survival rates for one of the deadliest cancers for
women.
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CHAPTER 5:
CONCLUSIONS
The primary goal of these studies is to ultimately create a “liquid biopsy” system
for exosome-based diagnosis of ovarian cancer. Exosomes are an excellent “liquid
biopsy” candidate species as they are found in a variety of body fluids, making invasive
or surgical diagnostic procedures unnecessary. In addition, they are inherently more
stable than other liquid biopsy targets, such as free DNA, RNA, and proteins. While
promising, exosome applications have been limited by inconsistent, expensive and timeconsuming isolation techniques. To alleviate this problem, we have developed a PET CCP fiber-based EV isolation method that is quick and inexpensive and have compared it
to standard EV isolation protocols.
For ovarian cancer diagnostics to be possible using this new isolation platform,
we must devise methods of selective EV isolation based on specific EV-associated
ovarian cancer biomarkers. These efforts will require the use of model sEVs derived from
normal and malignant ovarian cells. To this end, we have engineered a model system
consisting of two ovarian cell lines, one normal and one cancerous, to produce green and
red fluorescent sEVs, respectively, that may be employed in the testing and optimization
of the PET C-CP EV isolation platform for specific sEV capture. The model sEVs can be
easily visualized via fluorescence microscopy and provide a simple, cost-effective,
consistent system to verify specificity and sensitivity of antibodies to OC biomarker
proteins grafted to the PET C-CP fiber surfaces for use in lateral flow-based diagnostics
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for OC. In order to ensure selective capture potential and imaging compatibility, the
model EVs were generically captured on the PET C-CP fibers and selectively captured on
nitrocellulose using ovarian cancer marker-specific antibodies.
With future experiments in mind, we demonstrated that urine or cervical mucus
can be used as a sample source for EV isolation and for EV miRNA differential
expression analysis. The miRNA data collected during these investigations and in
ongoing proteomics investigation will be used to identify novel ovarian cancer EV
biomarkers. Additionally, a new clinical investigation of BRCA1 mutation patients with
or without ovarian cancer of varying stages will continue to bolster biomarker discovery.
Newly discovered ovarian cancer biomarkers will be incorporated into the new PET CCP platform selective EV capture method to improve early ovarian cancer detection. To
support clinical translation of the PET C-CP fiber technology, a PET C-CP fiber-based
film is being refined to capture and detect ovarian cancer EVs as a colorimetric lateral
flow assay, similar to a pregnancy test. With a new EV isolation method, model sEVs
designed to test it, a protocol for ovarian cancer biomarker identification and
incorporation, we have a clear path toward clinical translation. Future work will focus on
the development of a prototype for a quick, inexpensive, and easy-to-use colorimetric
ovarian cancer diagnostic test that can be routinely performed in the clinical or home
setting.
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APPENDIX A:
EXTRACELLULAR VESICLE CHARACTERIZATION IN BUFFERS
Materials and Methods
Extracellular Vesicles (EV) isolation
Caov-3 cells were grown to 80% confluency, refreshed with new media, and
incubated for 3 days. Conditioned media was then aspirated from the culture flask and
processed using an ultracentrifugation protocol. Briefly, conditioned culture media was
centrifuged at 700 x g for 5 minutes at 22˚C using an Eppendorf Centrifuge 5430R
(Eppendorf, Hamburg, Germany). The resulting supernatant was centrifuged at 2,000 x g
for 10 minutes at 22˚C using an Eppendorf Centrifuge 5430R (Eppendorf, Hamburg,
Germany). Again, the resultant supernatant was centrifuged at 10,000 x g for 30 minutes
at 4˚C using a Beckman Coulter Avanti J-26S XPI Centrifuge with a JA-25.50 rotor
(Beckman Coulter, Brea, CA). Lastly, the supernatant resulting after centrifugation at
10,000 x g was centrifuged at 120,000 x g for 60 minutes at 4˚C using a Beckman
Coulter Optima XPN-80 Ultracentrifuge and a Type 45 Ti rotor (Beckman Coulter, Brea,
CA). Finally, 400 µL of 1x PBS was used to resuspend and store the resultant pellet for
downstream analysis.

236

EV buffer characterization
Caov-3 ultracentrifugation EV samples in PBS were mixed with several buffers at
a ratio of 1:1. Mixing buffer working concentrstions included 1X PBS, 5%,10%, 20%,
and 30% glycerol, 25 mM trehalose, 20% acetonitrile, mixed 20% acetonitrile and 25
mM trehalose,, 1 M ammonium sulfate, and mixed 1 M ammonium sulfate and 20%
acetonitrile diluted in PBS. EVs were mixed with each buffer and stored briefly on ice
prior to fixation and staining for transmission electron microscopy (TEM) imaging.
Sample preparation for transmission electron microscopycaov-3 EVs isolated by UC
were fixed in 4% paraformaldehyde for 30 minutes on ice. All grid adhesion and staining
steps were performed by pipetting drops of sample, stain, or wash onto parafilm and
moving 200 mesh copper formvar coated grids (Electron Microscopy Sciences, Hatfield,
PA) from one drop to the next. After sample fixation, grids were placed coated side down
on 5 µL drops of each sample for 5 minutes. Grids were washed 3 times with DI water
for 4 minutes each, stained with 2% uranyl acetate for 5 minutes, and then washed 3
times with DI water for 4 minutes each. Grids were air dried in a low-humidity
environment and then imaged using a Hitachi H7600 TEM (Hitachi, Tokyo, Japan).
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Results
Caov-3 small EVs (sEVs) isolated by UC were subjected to a various buffers and
imaged using TEM to assess morphological structure and damage. Caov-3 sEVs in PBS
(see Figure A1b) demonstrated sEV characteristics under this staining methodology.
Caov-3 sEVs in PBS maintain a “dimpled” structure with a slight shadow surrounding
the vesicle and are within 30-150 nm in diameter as compared to the negative control.
Caov-3 sEVs diluted in 5%, 10%, 20%, and 30% glycerol (see Figure A1c-f)
demonstrated similar morphology to Caov-3 sEVs in PBS and displayed no evidence of
structural damage. Glycerol samples demonstrated significant non-vesicular imaging
artifacts compared to the positive and negative controls. Next, Caov-3 sEVs diluted in 25
mM trehalose (see Figure A1g) demonstrated morphology similar to Caov-3 sEVs in
PBS, but appeared in a smaller size range and stained much darker. Samples diluted in 25
mM trehalose also displayed significant non-vesicular imaging artifacts compared to the
positive and negative controls. Caov-3 sEVs diluted in 20% acetonitrile (see Figure A1h)
demonstrated very little morphological similarities to Caov-3 sEVs in PBS and contained
large amounts of organic debris while Caov-3 sEVs diluted in 20% acetonitrile with
addition of 25 mM trehalose (see Figure A1i) saw some retention of sEV morphological
structure in addition to altered staining and organic debris. Addition of 1M ammonium
sulfate to Caov-3 UC samples (see Figure A1j) resulted in morphological change and
possible crenation of vesicles as well as altered staining and non-vesicular artifacts.
Finally, addition of 1M ammonium sulfate and 20% acetonitrile to Caov-3 UC samples
(see Figure A1k) resulted in morphological change, possible crenation or vesicles, altered
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Figure A1. Scanning electron microscopy of Caov-3 small extracellular
vesicles isolated by UC and diluted in various buffers. PBS negative control
containing a) no sEVs and Caov-3 sEVs diluted in b) PBS, c) 5% glycerol, d)
10% glycerol, e) 20% glycerol, f) 30% glycerol, g) 25 mM trehalose, h) 20%
acetonitrile, i) 20% acetonitrile and 25 mM trehalose, j) 1 M ammonium sulfate,
and k) 1 M ammonium sulfate and 20% acetonitrile.
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staining, and non-vesicular imaging artifacts, similar to Caov-3 vesicles subjected to 1M
ammonium sulfate alone.
Discussion
As the parameters surrounding binding affinity of sEVs to poly(ethylene
terephthalate) capillary-channeled polymer (C-CP) fibers are being further investigated, it
is important to determine which media components may work best for eventual elution
and separation of sEVs from the PET C-CP fibers. Ideally, all reagents used during the
separation process should be compatible with the technical aspects of the
chromatography process, while also retaining the morphology, structure, and informatic
components of the sEVs. Damage to the vesicles could result in misinterpretation of
downstream results. Therefore, TEM imaging was used to look at morphology and
potential damage to vesicles in various buffers. As discussed before, intact sEVs
observed under TEM tend to flatten out slightly, showing a circular structure with a
“dimpled” interior.1, 2 Additionally, vesicles in this format tend to show a darker ring or
shadow around the circular structure due to the uranyl acetate employed while staining.3
Of note, observed differences in the intensity of staining may be due in part to slight
variation within the staining process. Any significant structural variation or lack thereof
may indicate significant damage to or lysing of the vesicles.
Caov-3 sEVs collected via UC and diluted in 5%, 10%, 20%, and 30% glycerol
(see Figure A1c-f) appeared to maintain normal sEV morphology within this description
when compared to Caov-3 sEVs diluted in PBS. Glycerol, frequently used as a cryoprotectant in biological laboratories4, is an organic osmolyte that helps maintain cell
integrity and protein structure through reduction of intracellular non-organic ions.5-7
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Furthermore, because it is a highly polar protic solvent, glycerol has been used as a
solvent in hydrophobic interaction chromatography.8, 9 Dilution of sEVs in 5-30%
glycerol revealed conserved sEV morphology under TEM (see Figure A1c-f). Small EV
protectant and organic solvent properties make glycerol an ideal candidate for further
biological liquid chromatography investigations.
Caov-3 sEVs diluted in 25 mM trehalose showed limited damage based on
morphology but appeared in much lower concentrations and smaller vesicle diameters,
suggesting that damage or vesicle lysing may be occurring (see Figure A1g). Small EVs
in 20% acetonitrile alone appeared to be severely damaged, lysed, and fragmented (see
Figure A1h). While addition of 25 mM trehalose to 20% acetonitrile appeared to protect
sEVs from some of the effects of 20% acetonitrile, there remained significant changes in
vesicle staining and morphology among most vesicles (see Figure A1i). Addition of 25
mM trehalose to storage buffers has been shown to prevent aggregation and cryodamage
in exosomes while narrowing the size distribution of the vesicles.10 In this study, sEVs
diluted in or supplemented with 25 mM trehalose demonstrated conserved morphology
and structure (see Figure A1g,i). Therefore, 25 mM trehalose may be worth further
investigation as a stabilizing agent for downstream sEV analysis and sEVs undergoing
liquid chromatography separation.
As sEVs are comprised of a semi-permeable phospholipid bilayer, they are
susceptible to disruption with organic solvents and small changes to osmotic pressure.
Acetonitrile is a polar aprotic organic solvent that is particularly useful for
chromatographic separations. However, its organic dissolution properties may severely
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disrupt the phospholipid bilayer of sEVs, even in low concentrations.11 This is clearly
demonstrated in Figure A1h, where only organic fragments remain after application of
20% acetonitrile to sEVs and in Figure A1i where the vesicles are disfigured. Dilution of
Caov-3 sEVs in 1 M ammonium sulfate demonstrated significant changes in vesicle
shape and staining, but did not fragment the vesicles to the same degree as 20%
acetonitrile (see Figure A1j). Finally, sEVs diluted in a solution of 20% acetonitrile and 1
M ammonium sulfate demonstrated significant changes in vesicle shape and staining, but,
again, did not fragment the vesicles to the same degree as 20% acetonitrile alone (see
Figure A1k). Ammonium sulfate is an inorganic salt commonly used in chromatographic
separations that reduces protein solubility without denaturing the proteins.12, 13 However,
semipermeable phospholipid bilayers are highly susceptible to variations in salt
concentrations in solution. For example, human osmoregulation maintains NaCl in the
blood at 0.9 % w/v and any variations can lead to changes in osmotic pressure and
crenation or lysing of cells.14 Ammonium sulfate, while not frequently tested with living
cells due to toxicity concerns, has demonstrated inhibitory effects toward C. Albicans
with a concentration greater than 0.3 g/L.15 In perspective, 1 M ammonium sulfate is
equivalent to 132.14 g/L and, for these reasons, will likely affect the stability of the
phospholipid bilayer of sEVs.
Together, these results indicate that glycerol in moderate concentrations ranging
from 5-30% may help protect sEV morphology if used as a diluting reagent. Furthermore,
addition of 25 mM trehalose, while results are not as conclusive, may help retain EV
morphology as well. However, 20% acetonitrile and 1 M ammonium sulfate, when
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applied separately and in conjunction may severely alter sEV structure and would likely
influence potential downstream sEV analysis.
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APPENDIX B:
EXOSOME UPTAKE EXPERIMENT
Materials and Methods
Passage of Dictyostelium discoideum
Dictyostelium discoideum AX2 cell culture flasks were passaged when cells
reached at least 70-90% confluency. Media from the old 25 cm2 flask was replaced with 7
mL of fresh HL5 (Recipe on DictyBase.org) and the flask was vigorously beaten against
the palm 5-7 times to detach the amoeba in solution. Next, 7 mL of fresh HL5 was added
to each new culture flask and supplemented with 7 µL of 1000X Ampicillin (or
appropriate selection). Finally, 0.1- 0.3 mL of the cell culture media from the old flask
was added to any new flasks. Passage of cells into 75 cm2 culture flasks follows the same
protocol with exception of using 15 mL of fresh HL5 and 15 µL of 1000x Ampicillin (or
appropriate selection) instead.
Exosome isolation
All centrifugation steps performed below 12,000Xg were performed using an
Eppendorf Centrifuge 5430R (Eppendorf, Hamburg, Germany). Centrifugations of
12,000Xg or more were performed using a Beckman Coulter Avanti J-26S XPI
Centrifuge with a JA-25.50 rotor (Beckman Coulter, Brea, CA). The first centrifugation
step was performed at 700Xg (5 min., 22˚C) in a full 50 mL conical centrifuge tube.
After centrifugation, 45 mL of the supernatant was transferred to a new 50 mL conical
centrifuge tube for further centrifugation, with the remaining 5 mL of supernatant saved
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for exosome isolation via the C-CP HIC method. The second centrifugation was
performed at 2,000Xg (10 min., 22oC.) The final centrifugation step was performed at
12,000Xg (30 min., 4oC.) The supernatant was carefully removed and the final pellet was
re-suspended in 400 µL of PBS and stored at 4oC.
GFP-Vacuolin-β AX2 transfection
Escherichia coli containing GFP-Vacuolin-β plasmid were obtained from Dr.
Marcus Maniak, University of Kassel, Germany. GFP-Vacuolin-β presence in E. coli was
verified via Polymerase Chain Reaction (PCR) with primers matching the GFP-Vacuolinβ nucleotide sequence. A Plasmid Maxi Kit (QIAGEN, Hilden, Germany) was used to
isolate the GFP-Vacuolin-β plasmid followed by gel electrophoresis and PCR to verify
the presence of the plasmid. AX2 Dictyostelium discoideum cells were transfected with
the GFP-Vacuolin- β plasmid by electroporation. D. discoideum cells were centrifuged
for 5 minutes at 500Xg and 4˚C, washed in 1 mL of H50 solution (Recipe on
DictyBase.org) twice and resuspended to a concentration of 2x107 cells/mL. After
washing, 100µl of the cells in H50 were added to a pre-chilled 1 mm gap cuvette. Next, 2
µg of GFP-Vacuolin-β plasmid DNA was added to the cuvette and allowed to incubate
on ice for 5 minutes. The cuvette underwent two consecutive pulses of 0.85 kV and
capacitance 25 µF with 5 seconds recovery between pulses. Electroporated cells sat on
ice for 5 minutes before being transferred to culture flasks with 7 mL of HL5 media.
G418 selection was added to the culture flask the next day. Upon sufficient growth, GFPVacuolin-β AX2 cells were sorted using a BIORAD S3e cell sorter to obtain a higher
percentage of high intensity fluorescent cells.
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Exosome uptake experiment
GFP-Vacuolin- β AX2 cells were centrifuged for 5 minutes at 500Xg and 22˚C
and then resuspended in HL5 media to a concentration of 1x106 cells/mL. Next, 400 µL
of the cell solution was added to live cell imaging well plates and cells attached to the
dish for 1 hour. Exosomes isolated from normal AX2 cells were stained for 90 minutes at
37 ˚C using Cell Mask Orange (Thermo Fisher Scientific Inc, Waltham, MA) at a
concentration of 5 µg/mL. Following staining, exosomes were filtered using a 30 kDa
cutoff (Amicon Ultra-0.5 Centrifugal Filter unit, MilliporeSigma, Burlington, MA) to
remove excess stain following manufacturer instructions. Prior to imaging, GFPVacuolin-β AX2 cell nuclei were stained with Hoechst 33342 at a concentration of 5
µg/mL for 5 minutes followed by washing and covering cells with PBS. Stained AX2
exosomes were added to the GFP-Vacuolin-β AX2 cell wells (5, 10, or 20 µL) and
imaged every 60 seconds for 30 minutes.
Imaging conditions
Confocal fluorescent images were captured using a Leica SP8 confocal
microscope with Hyvolution super-resolution (Leica, Wetzlar, Germany). All images
were captured using an HC PL APO CS2 63x/1.40 oil immersion objective. Hoechst
images were obtained using 405 nm excitation (15% power; gain=50), and a HyD
detector (411-449 nm detection;). GFP images were obtained using 488 nm excitation
(15% power; gain=100), and a HyD detector (512-564 nm detection). RFP images were
obtained using 558 nm excitation (25% power; gain=300), and a HyD detector (575-650
nm detection). Images were captured every 60 seconds for a total of 30 minutes.
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Results

Figure B1. Exosome uptake experiment. GFP-Vacuolin Dictyostelium discoideum
cells (Green) with Hoechst stain (cyan) exposed to cellMask Orange stained D.
discoideum exosomes (Red) time lapse, Leica SP8 confocal microscope 63x
magnification over a 30-minute period.
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Discussion
The purpose of this experiment was to investigate exosome uptake mechanisms
within a recipient cell using fluorescence microscopy. With little knowledge of the
uptake and dissemination mechanisms surrounding exosomes in recipient cells, further
investigation is required. Knowledge of these mechanisms will be particularly important
for future exosome drug delivery investigations. The recipient cells used during the
uptake experiment were engineered to express a GFP tag on Vacuolin-β, a protein
expressed within the endocytic pathway of D. discoideum. Any overlap of fluorescent
exosomes and GFP-Vacuolin-β expression may suggest that exosome dissemination is
occurring throughout the endocytic pathway. Although this experiment likely needs
refinement to obtain clearer results, exosomes (red, Figure B1) were observed entering
the GFP-Vacuolin-β AX2 cells (green, Figure B1). Further investigation may be required
to determine if the cellMask orange stain is remaining adhered to the exosome surface
and whether the exosome lipid bilayer is mixing with the cell plasma membrane. It is
unclear why the GFP expression disappeared around 8-12 minutes during exosome
incubation. Furthermore, Hoechst staining of the GFP-Vacuolin-β AX2 cell was
inconsistent likely due to D. discoideum tendency to expel foreign stains. Although this
experiment produced very interesting images, it should be performed again with adjusted
staining and uptake parameters. Investigators revisiting this experiment may look to
adjust the live/dead cell imaging choice, resolution of the microscope used, stain
concentrations, Hoechst and cellMask Orange stain choices, incubation time, cell
concentrations, or exosome isolation technique. Alternatively, a similar experiment can
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be performed using the IHOE-CD81-GFP or SKOV-3-CD9-RFP cells developed in
chapter 2.
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APPENDIX C:
EXTRACELLULAR VESICLE DRUG DELIVERY PROPOSAL
Hypothesis and Specific Aims
Exosomes are a class of extracellular vesicles, typically 30-100 nm in diameter,
that facilitate cell-to-cell communication via paracrine and autocrine signal transduction.1,
2

Exosome research has quickly developed into a flourishing research topic over the last

15 years and we are only now discovering the numerous roles of exosomes within regular
homeostasis and the metastasis of cancers. To date, the scientific community has
envisioned multitudes of exosome applications from cancer diagnosis to treatment of
neurodegenerative diseases, some of which are coming to fruition.3-5
Exosomes are emerging as a potential Drug Delivery System (DDS) due to their
size, encapsulating ability, natural biocompatibility, and potential for membranous
marker manipulation.6-8 Specifically, exosomes have been shown to cross the blood-brain
barrier (BBB), which may allow for drug delivery to specific portions of the brain, a
significant advantage over many other DDSs.9 Our long term goal is to continue
examining the potential for an exosome DDS that will deliver pharmaceutical or gene
modifying agents past the BBB to specific regions of the brain for treatment of
neurodegenerative diseases.
However, as exosome research is still in its early stages, there is a significant
problem with isolating exosomes quickly, efficiently, and with sufficient purity in order
to implement effective down-stream analysis and applications.10 In previous research, our
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cohort has developed a method of exosome isolation via Capillary-Channeled Polymer
(C-CP) fibers using Hydrophobic Interaction Chromatography (HIC) for small-scale
disease diagnostic purposes.11-20 We plan to convert to and test this method of exosome
isolation on a larger scale using batches of allogeneic cells grown in a bioreactor and
modified to contain specific targeting moieties.
Specifically, our research group has imagined mass-producing exosomes to be
used for drug delivery of catalase as a treatment for Parkinson’s disease. We hypothesize
that exosomes isolated via Capillary-Channeled Polymer fibers using Hydrophobic
Interaction Chromatography, modified to express a rabies virus glycoprotein (RVG)targeting peptide, and loaded with catalase will decrease brain inflammation in
Parkinson’s disease model mice. In order to assess this hypothesis, we will investigate
these three specific aims.
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Specific Aims:
Aim 1:
Investigate the capability of Capillary-Channeled Polymer fibers using
Hydrophobic Interaction Chromatography to isolate exosomes from mammalian cell
culture grown on large scales.
Aim 2:
Genetically modify mammalian cells to include modified exosomal membrane
protein RVG-targeting peptides and investigate the loading capacity of catalase into
RVG-targeted exosomes.
Aim 3:
Evaluate the effects of RVG-targeted and catalase loaded exosomes on cell
cytotoxicity and brain inflammation in Parkinson’s disease model mice using Intravenous
injection.
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Research Strategy
A. Significance
Parkinson’s disease (PD) is among the most common neurodegenerative disease
affecting adults worldwide. In the United States, 680,000 adults of over the age of 45
have developed this physically and mentally debilitating disorder and an increasingly
older population and increased lifespan will likely escalate the number of
neurodegenerative cases seen every year.21 PD is characterized by degeneration of the
dopaminergic neurons of the substantia nigra region of the brain. The degeneration of
these neurons leads to decreased downstream production of dopamine, a neurotransmitter
involved in significant pathways controlling reward-motivated behavior and motor
function. As a result, patients with PD exhibit symptoms including loss or disruption of
motor control and mental cognition.22, 23 Most clinical treatments for PD still focus on
replacement of the missing dopamine by administering pharmaceutical precursors that
can be converted into dopamine. For example, levodopa is a precursor to dopamine that
can cross the BBB, where it is converted to dopamine by DOPA decarboxylase.24 Despite
the alleviation of symptoms, dopamine replacement therapies do not significantly slow
the degeneration of dopaminergic neurons or the development of PD.25
The pathology and development of PD is still a topic that is poorly understood,
but evidence suggests that a variety of pathways may lead to a final common pathway of
neuronal cell death. Altered mitochondrial activity, inflammatory changes, proteolysis
modifications, and the formation of reactive oxygen species (ROS) have all been
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implicated in the pathogenesis of neuronal cell death. Specifically, oxidative stress due to
the formation of ROS is considered a cornerstone of the ideas surrounding dopaminergic
cell death and has been implicated to contribute to a variety of neurodegenerative
diseases. As such, PD has been associated with a reduction of redox enzymes including
catalase, glutathione, superoxide dismutase, and others.23, 26 Therefore, replacement or
supplementation of redox enzymes has been theorized to slow the pathogenesis of
dopaminergic cell death.27 Furthermore, catalase, a powerful antioxidant capable of
eliminating 1 million ROS per second per molecule, has been implicated as a potential
treatment for PD.6
Unfortunately, 98% of drugs suspected to remedy various disease states of the
central nervous system (CNS) cannot cross the BBB efficiently, catalase included.6
Therefore, a DDS capable of crossing the BBB may be required to deliver catalase to the
CNS for treatment of PD. Exosomes, a class of extracellular vesicles involved in cell-tocell communication, have demonstrated drug delivery capabilities with increased
biocompatibility and are able to cross the BBB.6-9 Furthermore, Haney et al.6 have
specifically demonstrated the ability of exosomes to deliver catalase to the CNS. Taken a
step further, to improve the capacity of exosomes targeting the CNS, several research
groups have engineered cell cultures to secrete exosomes that express RVG peptide on
their surface.8, 28, 29 RVG peptide targeting has shown to improve CNS drug uptake and
delivery across many DDSs, including exosomes.30
Previously, we have developed a method of exosome isolation using C-CP fibers
and HIC that is quicker, more efficient, and cheaper than conventional methods.
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Furthermore, HIC can be scaled up to process much larger volumes of cell culture media
that may prove ideal for downstream analysis.14 The major goals of this proposal are to
investigate the ability of C-CP fibers and HIC to isolate exosomes on a large scale and
investigate the ability of RVG-peptide expressing exosomes loaded with catalase to target
the CNS and affect brain inflammation in Parkinson’s disease model mice. We believe
that this proposed research is significant because it will help develop a promising
exosome isolation method capable for use in clinical settings and investigate the
capability of exosomes as a DDS and the ability of catalase to treat Parkinson’s disease.
A1) Our proposal investigates a method of exosome isolation via C-CP fibers and
HIC on large scales: We have shown previously that C-CP fibers and HIC can be used to
isolate exosomes on small scales for diagnostic purposes. Conventional methods of
exosome isolation, ultracentrifugation, ultrafiltration, and others, have been proven to
isolate exosomes, but with high inefficiency, cost, and time requirements. Furthermore,
current methods of exosome isolation do not always produce high purity exosomes that
are viable and consistent enough for clinical use.10, 31, 32 Our technology, which we
believe is capable of processing large volumes of media, provides a faster, cheaper, and
more efficient method of isolating exosomes in clinical settings.
A2) Our proposal aims to create an allogeneic dendritic cell line engineered to
express RVG-peptide targeted exosomes: A considerable hurdle to employing
engineered exosomes in a clinic is the need to use autologous cells. Exosomes must be
isolated after autologous cells are harvested, engineered, and grown from each individual
patient. Exosomes derived from autologous sources are likely to produce a smaller
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immune reaction. However, evidence suggests that allogeneic exosomes may avoid
significant detection by the innate and adaptive immune systems due to the size of the
vesicles.33-36 An allogeneic exosome source could allow for pre-production,
concentration, and lyophilization of exosomes for faster clinical application and more
consistent drug development.
A3) Our proposal investigates the ability of catalase to treat Parkinson’s disease
with an enhanced RVG-peptide targeted exosome DDS: The absence or reduction of
redox enzymes in PD is a potential target point for drug therapeutics. Catalase, a
powerful antioxidant, could potentially mitigate or slow down the effects that ROS have
on degeneration of dopaminergic neurons and reduce inflammation in the brain.6 An
RVG-targeted exosome DDS could allow for enhanced delivery of catalase across the
BBB into the central and peripheral nervous systems for treatment and prevention of
various neurodegenerative disorders.8, 29, 30, 37

B) Innovation
B1) Our method of exosome isolation is unique and may contribute to
translational exosome research: Standard methods of exosome isolation lack the qualities
to be consistently used in small clinical settings and on large scales for drug
development. Ultracentrifugation, perhaps the most common method of exosome
isolation, is too costly, time consuming, and difficult for most translational applications.4,
10, 32, 38-40

Our method of exosome isolation using C-CP fibers and HIC is extremely cost
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effective, quick, and easy to use. These C-CP fibers, developed by the Marcus research
group at Clemson University, has been previously used to isolate other small molecules
and proteins from solution.13-16 Our exosome isolation method has the potential to
transform exosome translational applications and galvanize clinical exosome research.
B2) Allogeneic, engineered exosomes will allow for more consistency and quality
control in drug development: Consistency and quality control in regards to DDS
development and drug treatment are essential for pharmaceutical approval and
advancement to clinical trials. Autologous exosomes have been used in clinical trials due
to identical DNA expression and histocompatibility.7, 41, 42 However, allogeneic
exosomes, if shown to be hypo-immunogenic or engineered to have reduced
immunogenicity, could allow for greater, more specific manipulation and massproduction for pharmaceutical DDS development. We will engineer and modify a cell
line that produces biocompatible allogeneic exosomes ideal for immune system
avoidance and eventual clinical approval.
B3) Our methodology integrates an innovative exosome isolation technique with a
unique targeted DDS to realize a translational treatment: We have partnered with experts
in high performance liquid chromatography and bioengineering to implement techniques
suitable for our goals including HIC, mass-production of cell lines in bioreactors, and
DDS development. A multidisciplinary approach encompassing innovative strategies and
complementary experts will allow us to investigate the feasibility of our technology and
push it toward clinical application and relevance.
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C) Approach
Our cohort has previously demonstrated the capability of C-CP fibers and HIC to
isolate exosomes on small scales for diagnostic purposes (Figure C1). As it has been done
previously with protein isolation, we believe that we can scale up our exosome isolation
procedure using C-CP fibers and HIC to separate exosomes from larger volumes of
milieu. Furthermore, based on previous experiments performed by other research
groups43-45, we believe we can engineer a cell line appropriate for allogeneic exosome
separation and subsequently develop an exosome DDS for alleviation of Parkinson’s
disease degeneration and symptoms. Specifically, we hope to: (Aim 1) evaluate the
ability of C-CP fibers and HIC to isolate exosomes from large volumes of human induced
pluripotent stem cell (HiPSC)-derived dendritic cell (DC) culture milieu; (Aim 2)
engineer and modify HiPSC-derived DCs to release RVG-peptide targeted exosomes and
investigate the loading capacity of catalase into RVG-targeted exosomes; (Aim 3)
investigate the effects of RVG-peptide targeted exosomes loaded with catalase on
Parkinson’s disease brain inflammation.
C1) Introduction
Exosomes are extracellular vesicles, approximately 30-100 nm in diameter,
involved in various methods of autocrine and paracrine cell communication. Fortuitously,
the messages carried by exosomes can potentially be traced back to the originating cell,
allowing for many biomedical applications, such as disease diagnostics. Furthermore, the
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ability of exosomes to load and pass cargo to many portions of the body, including the
central nervous system, has led to investigation into exosome drug delivery applications.1,
4, 10, 32, 46, 47

With so many potential applications and encouraging studies, exosome

research has exploded onto the scene and has become a hot topic over the past 5 years. As
a result, early progress has made toward developing exosomes as potential disease
diagnostic biomarkers. Ideally, by identifying either the internal or external makeup of
patient exosomes, clinicians may be able to provide a cancer diagnosis without the need
to perform an invasive biopsy. Investigation into exosome origins has revealed several
proteins and steps involved in the biogenesis of exosomes, but exosome uptake
mechanisms, despite several investigations, still remain elusive.1, 47, 48 Remarkably,
Alvarez et al.8 have demonstrated the ability of exosomes to perform as an efficient DDS
for neurodegenerative diseases using modified RVG peptide exosomes, which may
further the development of a translatable exosome DDS.
However, despite the promising advancements, the methods with which most
investigators isolate exosomes are inefficient, time consuming, and costly. The “goldstandard” of exosome isolation, ultracentrifugation, is a proven method, but is expensive,
time-consuming, results in low purity samples, and most importantly, is not easily
translatable to the clinic.31, 32, 38, 49, 50 With greater development of these exosome
applications comes a greater need to improve exosome isolation methods. Using HIC in
conjunction with C-CP fibers provides a promising alternative to standard exosome
isolation procedures. Hydrophobic interaction chromatography and packed C-CP
columns use innate hydrophobicity properties to isolate exosomes from the surrounding
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environment. Particles of varying hydrophobicity will attach to and elute from the
column at different salt concentrations, allowing for easy separation. This technique,
especially when using solid phase extraction spin down columns, is extremely quick,
cheap, easy, and suitable for clinical translation. Modification and scaling of this
procedure could potentially result in a process that could mass-produce exosomes for
other down-stream applications, including drug delivery.
Several clinical trials have used exosomes derived from dendritic cells for
immunostimulatory purposes to prime the host immune system to target cancer cells
producing neoantigens.36 Down the line, dendritic-derived exosomes could be loaded
with cancer therapeutics and be used to stimulate the immune system to target cancer
cells and, in conjunction, deliver cancer drugs to the desired target. However, most
exosome trials involve exosomes derived from autologous sources, which limits the
replicability and quality control of the biological treatment.41, 42 Allogeneic-derived
exosomes have demonstrated hypo-immunogenic properties and could increase the
quality, consistency, and replicability of an exosome biological treatment.34, 51
Development of exosomes from an allogeneic dendritic cell line could result in a DDS
that can be used to treat any number of cancers and neurological disorders and stimulate
the immune system for enhanced outcomes.
Specifically, PD, which results in dopaminergic neurodegeneration in the
subtantia nigra, has been pinned as a potential target for an exosome DDS. Although the
pathology of PD is poorly understood, several factors, including excess ROS, have been
implicated in the disease development. Therefore, treatment with powerful antioxidants
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may help remediate or slow down the neurodegeneration associated with PD.22, 23
Specifically, catalase, a powerful antioxidant, has shown promise in alleviation of PD,
but, like most drugs, cannot cross the BBB.6 An exosome DDS, capable of crossing the
BBB and targeting the CNS, may allow for specific delivery of catalase to the CNS.
Furthermore, exosomes engineered to contain an RVG-peptide targeting system may
allow for increased efficiency and efficacy of delivery to the CNS.
C2) Preliminary Studies

Figure C1. Average exosome concentration and particle size
distribution measured by NTA. Exosomes isolated sequentially by
differential centrifugation and HIC with Poly(ethylene terephthalate)
C-CP fibers.
Previously, Marcus et al.52 have demonstrated the potential for fast protein
separation using C-CP fibers. Using C-CP fibers developed by the Marcus lab, we have
used hydrophobic interaction chromatography to separate cell culture media components
from dictyostelium Discoideum and Caov-3 cell lines. Specifically, we have demonstrated
the ability to separate extracellular vesicles from cell culture after cells have been
removed by either centrifugation or filtration. Nanoparticle Tracking Analysis (NTA)
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allows for characterization of nanoparticle size distributions and concentrations using
light scattering and Brownian motion properties. Using NTA (Figure C1), we have shown

Figure C2. SEM and Fluorescent images of extracellular vesicles adhered
to C-CP fiber surfaces. (a) SEM image of Caov-3 ultracentrifuge derived
extracellular vesicles and (b) fluorescent image of Caov-3 cellMask orange
stained ultracentrifuge derived extracellular vesicles.
that the separation technique we have developed isolates extracellular vesicles of
approximately 100-200 nm. Furthermore, we have demonstrated that the extracellular
vesicles are adhering to the solid-phase component of the HIC method via scanning
electron microscopy (SEM) and fluorescent microscopy (Figure C2).
C3) Research Plan
Aim 1: Investigate the capability of Capillary-Channeled Polymer fibers using
Hydrophobic Interaction Chromatography to isolate exosomes from mammalian cell
culture grown on large scales. The goal of this aim is to determine whether scaled up CCP fiber columns using HIC can isolate exosomes of high purity, quality, and quantity.
To do this we will perform a number of chemical and physical verification steps to ensure
effective total quality management of the separation method.
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Aim 1.1: Verify the presence of exosome-associated markers in the C-CP fiber
and HIC elution. Rationale: Although there is no “gold standard” to characterize
exosomes, according to the International Society of Extracellular Vesicles, extracellular
vesicles must be characterized by both protein composition and physical traits.53 Samples
must be characterized not only to determine the presence of exosomes, but also to
determine the quality, quantity, and purity of the exosome samples. Our method of
exosome isolation has demonstrated the ability to isolate well-characterized exosomes for
diagnostic purposes. Therefore, we hypothesize that large-scale exosome isolation via CCP fibers and HIC will produce high purity exosome samples with typical exosomeenriched proteins.
Experimental Design: In order to investigate the protein composition of C-CP
fiber and HIC isolated exosomes, we will perform standard protein Bradford assays and
western blots of exosome-enriched proteins. Specifically, using a western blot, we will
look for the presence of CD9, CD81, CD63, TSG101, calnexin, and Grp94 to
characterize the presence and purity of exosomes.
Expected Outcomes: As there are many types of extracellular vesicles, exosomes
included, it is important for us to be able to first, verify the presence of extracellular
vesicles and then second, verify that the sample is exosome-enriched. Since extracellular
vesicles are derived from the phospholipid bilayer membrane of cells, transmembrane
proteins are typically used to characterize their presence. Therefore, we would expect
samples to contain the transmembrane proteins CD9, CD81, and CD63, all of which are
typically used to characterize extracellular vesicles. Furthermore, cytosolic proteins that
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are involved in extracellular vesicle biogenesis can be used to identify exosomes. In this
instance, we will use TSG101, which is involved in the development of multivesicular
bodies that generate exosomes, as a positive marker. A positive appearance of TSG101
further verifies the existence of extracellular vesicles and further suggests that the sample
may be exosome-enriched. Additionally, to further characterize our samples as exosomeenriched, we will look for microvesicle markers calnexin and Grp94. These two markers
are typically found enriched in the endoplasmic reticulum, a common place of origin for
microvesicles. Therefore, we would expect our isolated exosome samples to contain little
to no amounts of calnexin and Grp94. Lower amounts of calnexin and Grp94 would
indicate that our exosome samples do not contain other types of extracellular vesicles
including microvesicles, ectosomes, and apoptotic bodies.53 If we can detect at least one
transmembrane protein marker, one cytosolic protein marker and minimize the amount of
negative exosome marker detected for each sample, we will have found chemical
evidence that our sample contains exosomes and not another type of extracellular vesicle.
Furthermore, we would expect a Bradford assay to find higher amounts of protein in each
sample as compared to our previous research of exosome isolation on a small scale.
Potential Pitfalls and Alternatives: We do not expect to encounter significant difficulties
with the western blot process as it is a very well developed technology and commonplace
procedure in our lab. Furthermore, we have previously found that C-CP fiber and HIC
exosome isolation produces samples with exosome-enriched markers, so we would
anticipate to find these markers again. However, upon scaling up the procedure and using
larger chromatography columns we may not encounter exosome isolation using the same
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properties and framework. Mass isolation of exosomes may shift the expected adsorption
and elution values of the columns due to oversaturation or vesicle aggregation. Although,
with some adjustment and saturation analysis we should be able to overcome any
alteration to the HIC procedure. Additionally, with a larger column, we might expect the
concentration of exosomes isolated to scale linearly based on the size of the column or
the amount of media injected through the column. We will test many column sizes and
injection volumes to find the most efficient and effective procedure for producing pure,
high concentration exosomes for down-stream analysis.
It is well known that western blot analysis is not a terribly quick procedure and
performing protein analysis with this method on many samples may require a significant
amount of resources and time. Furthermore, western blot analysis only detects the
proteins of interest and ignores the presence of any other potentially important proteins.
Therefore, we may consider using protein mass-spectrometry to identify the entire protein
spectrum of each sample. Complete protein analysis would allow us to further analyze
each sample and potentially differentiate between different types of exosomes for downstream application.
Aim 1.2: Further characterize the presence, quality, and quantity of exosomes in
the C-CP and HIC elution by physical properties. Rationale: As mentioned in aim 1.1,
although there is no perfect process, exosomes can be reasonably characterized and
identified using both protein composition and physical traits. Physical trait analysis can
be used to further investigate the quality, quantity, and purity of the samples. Therefore,
we hypothesize that large-scale exosome isolation via C-CP fibers and HIC will produce
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exosomes with uniform size and density, high and consistent concentration, and sufficient
purity.
Experimental Design: In order to investigate this aim we will inject cellular milieu
samples into the scaled up C-CP fiber columns, perform HIC, and analyze the elution
using nanoparticle tracking analysis (NTA), scanning electron microscope (SEM)
imaging, transmission electron microscope (TEM) imaging and fluorescent imaging.
Performing each of these techniques will allow us to verify the presence, quality, purity,
and concentration of exosomes in each eluted sample. Furthermore, these techniques will
also allow us to analyze the solid-phase surface interactions of the exosomes and C-CP
fibers.
Expected Outcomes: By using several techniques to characterize the physical
traits of our samples, we would expect a complete and replicated profile for each sample.
Each of these procedures unveils information about the sample from a slightly different
perspective. Specifically, from NTA, we would expect a size distribution similar to our
previous research with the highest concentration of nanoparticles at approximately 100
nm. As we will be working with much larger volumes of media, we would also expect a
nanoparticle concentration much higher than our previous research and on par with other
standard exosome isolation methods. SEM imaging of the vesicles attached to the C-CP
fibers pre- and post-elution will reveal information about the surface interactions between
the vesicles and solid-phase C-CP fibers. We would expect similar images as compared
to our previous research (Figure C2). Specifically, vesicles should be evenly distributed
across the surface of the fiber with little aggregation, should be free of any visible
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damage or deformity, and should no longer be present after elution from the fiber. TEM
imaging will be used to further characterize the general shape, size, and structure of the
eluted vesicles post-elution. We would expect TEM imaging to display highly
concentrated vesicles of approximately 30-100 nm in diameter with the highly
characteristic ‘dimple’ or ‘cupped’ appearance of exosomes. We would not expect to see
broken, damaged, or deformed vesicles with TEM imaging due to the moderate nature of
our exosome isolation. Finally, fluorescent imaging will be used to further verify vesicle
and C-CP fiber interaction. Cellular stains CellMask and CellTracker will be used to
fluorescently stain exosome samples prior to incubation with C-CP fibers and imaging.
Similar to SEM, we would expect fluorescent images obtained using Leica SP8 with
HyVolution, a super resolution software enhancement, to show vesicles evenly
distributed across the fiber with little aggregation and the absence of vesicles postelution.
Potential Pitfalls and Alternatives: As we have performed all of these techniques
in previous research with C-CP fibers, we would expect fewer hurdles in collecting this
information. NTA is commonly used to quantitatively and qualitatively assess exosome
properties, but admittedly is not a perfect method. Many articles have addressed this
issue54, 55, but few better quantitative methods have emerged. Alternatively, to quantify
exosome samples, we could use dynamic light scattering (DLS) or a newer technique
such as tunable resistive pulse sensing (TRPS). Both DLS and TRPS have advantages
and disadvantages, but the main point is that there is no perfect single method to analyze
exosome properties. Therefore, it is best to assess the quality and quantity of our samples
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using several techniques. SEM and TEM are very robust and informative techniques that
will help assess the size and deformity of vesicles, but are limited to single vesicle
analysis and do not incorporate the entire sample. As SEM and TEM imaging quality is
almost entirely dependent on sample preparation, poor fixation and staining protocols
may need to be adjusted based on the needs of the sample. If required, we may consider
using cryogenic electron microscopy if TEM and SEM imaging do not produce adequate
or quality results. Fluorescent imaging using Leica SP8 with HyVolution has a limit a
resolution of approximately 140 nm, which is larger than the diameter of exosomes.
Therefore, collecting images of individual vesicles via this method is very difficult, but
possible when observing juxtaposed or collections of vesicles. Alternatively, as our lab is
highly ingrained in the light microscopy community, we could send fiber and elution
samples for super resolution imaging with a lower limit of resolution.
Aim 2: Genetically modify mammalian cells to include modified exosomal
membrane protein RVG-targeting peptides and investigate the loading capacity of
catalase into RVG-targeted exosomes. The goal of this aim is to generate a modified
HiPSC-derived dendritic cell line to further investigate exosomes as a DDS. Specifically,
we will modify the targeting moiety of the exosomes and investigate the loading capacity
of catalase into exosomes.
Aim 2.1: Manipulate HiPSCs to differentiate into dendritic cells. Rationale: Production of
an allogeneic cell line will allow for down-stream production of allogeneic exosomes.
Presently, several clinical exosome studies have used exosomes derived from autologous
dendritic cells, but allogeneic exosomes have demonstrated hypo-immunogenic
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properties.34, 41, 42, 51 Therefore, we are aiming to develop an allogeneic dendritic cell line
for exosome production. We hypothesize that HiPSC expression manipulation will result
in fully functional allogeneic dendritic cells capable of producing allogeneic exosomes.
Experimental Design: Specifically, we will follow previously well-developed
protocols to differentiate HiPSCs into DCs similar to the CD141+ subtype.45 Doing so
involves a number of additions and removals of specific growth factors at certain time
points. Formation of embryoid bodies (EBs) through differentiation of HiPSCs, as a first
step toward differentiation of HiPSCs into DCs, has been demonstrated using several
types of bioreactors with reduced mixing.56 In this instance, we will use structured and
scheduled treatments of HiPSCs with pre-determined growth and differentiation factors
using a high throughput bioreactor to initiate and complete the differentiation process of
HiPSCs into DCs. Specifically, cells will be cultured over a 30 day period with gradual
removal of growth factors including Bone Morphogenetic Protein 4 (BMP4), Vascular
Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF), and Granulocyte
Macrophage Colony-Stimulating Factor (GM-CSF). Finally, the culture will be
supplemented with Interleukin 4 to support final differentiation.45
Expected Outcomes: Forced differentiation is a highly controlled and structured
process that is more easily accomplished using a high throughput bioreactor. Several well
developed published protocols have demonstrated the expected outcomes of each
differentiation step during the process that we will follow. We would expect to observe a
step-wise transformation of HiPSCs into hematopoietic stem cells, common myeloid
progenitors, DC precursors, immature DCs, and finally mature DCs. Quality management
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along each step of the differentiation process will be critical to achieve the expected
outcomes. The final outcome should be a variety of DCs presenting qualities similar to
the CD141+ subtype as detailed in published protocols.43, 45, 57
Potential Pitfalls and Alternatives: Forcing differentiation of stem cells is a very
structured and difficult process and meticulous monitoring will be required to complete
an accurate differentiation into DCs. Therefore, there may be certain difficulties in
finding the exact environmental variables, growth factors, and timing for the process. We
would expect that if the initial HiPSCs are slightly different than in previous studies that
the differentiation process may vary slightly. By using a high throughput bioreactor we
will be able monitor the environmental variables and test several cell culture preparations
at one time to ensure an adequate final product of suitable quality and expression. If the
differentiation procedure from HiPSCs to DCs is not fully accomplished with satisfactory
expression and quality we could consider completing the remaining goals using
allogeneic HiPSCs. As exosomes have demonstrated hypo-immunogenic properties, a
different source of allogeneic exosomes may be worth investigating. Furthermore, since
even allogeneic cells may contain epigenetic variation depending on the source, we could
investigate the epigenetic expression of the cells and the impact of epigenetic expression
on exosome variation.
Aim 2.2: Engineer HiPSC-derived dendritic cells to display RVG-targeting
peptide on exosome surface membranes. Rationale: Exosomes are capable of crossing the
BBB, but are not specifically targeted to remain in the brain and could disperse
throughout the remaining blood. Ideally, exosomes engineered to target the brain

272

specifically will increase the fraction of injected exosomes in the central nervous system
and are more likely to meet the designed target. We aim to create a DDS that is more
accurate for drugs being delivered to the central nervous system via exosome transport.
Therefore, we hypothesize that HiPSC-derived dendritic cell exosomes can be engineered
to display RVG-targeting peptides on the outside phospholipid bilayer surface.
Experimental Design: RVG-peptide targeted exosomes have been engineered
from murine cells, but have yet to be developed in human cells.8 We will clone the RVG
peptide into the human Lamp2b gene, an exosome-enriched transmembrane protein,
using plasmid cDNA. Specifically, Lamp2b plasmid cDNA will be isolated from storage
Escherichia coli and engineered to contain the RVG codon sequence using DNA
fragments, restriction sites, and restriction and ligation enzymes. The resulting RVGLamp2b plasmid will be transformed into E. coli for plasmid verification and storage.
After isolating the engineered plasmid from E. coli, RVG-Lamp2b cDNA will be
transfected into HiPSC-derived DCs and cultured using the Lipofectamine 3000
transfection kit. Subsequently, we will verify the presence of RVG-peptide in both the
DCs and DC exosomes via anti-RVG western blot.
Expected Outcomes: The HiPSC-derived cell line that we are developing will be
stably transfected with a human cDNA plasmid. As part of cloning procedure, we will
verify that RVG is inserted into the Lamp2b cDNA in the correct location using selection
agents. After isolation of the cDNA and transfection into HiPSC-derived DCs, we would
expect successfully transfected cells to express the positive selection trait (gaining
resistance to a drug) inserted into the plasmid cDNA. An anti-RVG western blot of the
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transfected DCs and subsequent exosomes will further verify the expression of RVGLamp2b in the transfected cells and exosomes.
Potential Pitfalls and Alternatives: Stable plasmid cDNA transfection in
mammalian cells is not a terribly efficient process and as such, we may run into
difficulties while performing the transfection. Furthermore, transfection with RVGLamp2b cDNA is no guarantee that the transfected DC exosomes will contain RVGLamp2b protein. Transient plasmid transfection is much more efficient and easier than
stable transfection and has previously been used for mass production of proteins in
mammalian cells.58 Thus, as an alternative, we could transiently transfect the DCs to
express RVG-Lamp2b and then isolate the exosomes within 24-48 hours posttransfection. Furthermore, as there are many transmembrane proteins typically enriched
on the surface of exosomes, we could use other peptides such as CD9, CD81, or CD63 to
develop an RVG-targeted exosome.
Aim 2.3: Investigate loading capacity of catalase into various modified exosomes.
Rationale: Catalase is a powerful antioxidant that may help mitigate neuronal degradation
in PD and other neurodegenerative diseases by limiting ROS. Like many drugs, catalase
cannot cross the BBB and requires transport to reach the central nervous system.6 We
believe that exosomes can be used as an efficient DDS for catalase due to their natural
ability to cross the BBB and hypo-immunogenicity.7, 9 Therefore, we hypothesize that
catalase can be loaded into RVG-targeted and normal exosomes with high efficiency for
downstream drug delivery.
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Experimental Design: There are a number of different approaches to loading
enzymes, RNAs, and other pharmaceuticals into exosomes, yet no one technique has
emerged as the standard option.59 Therefore, we will investigate several exosome loading
techniques with our specific cell line and exosomes. Specifically, we will investigate the
loading efficiency of electroporation, sonication, saponin permeabilization, and room
temperature incubation of exosomes with catalase. NTA, DLS, and TEM will be used to
examine the physical structure and integrity of the vesicles after loading. To effectively
measure the amount of catalase or antioxidant in a sample, we will measure the rate at
which hydrogen peroxide decomposes. Hydrogen peroxide decomposes at a very slow
rate when no antioxidants are present. This hydrogen peroxide decomposition assay and
western blot will be used to demonstrate the loading capacity and stability of exosomes
loaded with catalase.
Expected Outcomes: Exosome properties can vary based on cell type origin,
environmental factors, and biochemical purpose. As such, we would expect exosomes
derived from HiPSC-derived DCs to have different size, integrity, loading capacity,
proteins, makeup, and internal content than any exosomes studied previously. Therefore,
it is difficult to predict which method of exosome loading will ultimately demonstrate the
most efficient loading. Electroporation, sonication, saponin permeabilization, and room
temperature incubation have all demonstrated loading capability in exosomes from
multiple sources.6, 8, 59, 60 However, sonication has demonstrated high loading efficiency
and sustained release with exosome and catalase formulations, so we would expect the
highest efficiency with sonication.6 Each loading procedure applies very different
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physical stresses to the exosomes and therefore, will likely cause disruption, collapse, or
deformation of the vesicles in varying amounts. NTA, DLS, and TEM will clarify the
physical exosome disturbances of each loading technique. Furthermore, we would expect
the hydrogen peroxide decomposition assay and western blot to reveal a high loading
capacity and retention time for each of the techniques with room temperature incubation
likely having the lowest efficiency.
Potential Pitfalls and Alternatives: Since each of the exosome loading techniques
can potentially damage or deform the exosome membrane, we may run into problems
with catalase loaded exosome downstream applications. To help mitigate these potential
problems we will assess the physical quality, loading capacity, and retention time of each
of the loading techniques. With the most promising loading techniques, we can further
assess the uptake and delivery of the exosome-catalase formulations in cell culture. If
none of the proposed techniques offer an appropriate efficiency we could also investigate
exosome extrusion, freeze/thaw, and optically reversible protein-protein interactions as
potential alternative methods for loading.
Aim 3: Evaluate the effects of RVG-targeted and catalase loaded exosomes on
cell cytotoxicity and brain inflammation in Parkinson’s disease model mice using
Intravenous injection. The goal of this aim is to measure brain inflammation in
Parkinson’s disease model mice after treatment with catalase loaded and RVG-targeted
exosomes. We will use various histological techniques and fluorescent techniques to
evaluate the level of inflammation in the mice brain samples.
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Aim 3.1: Evaluate the cytotoxicity of RVG-targeted exosomes loaded with
catalase using cell cytotoxicity and proliferation assays. Rationale: Exosomes have not
typically been found to have cytotoxic properties, but any material introduced into a cell
environment, especially with engineered modifications, could potentially introduce some
form of toxicity. Therefore, especially with RVG modification, it is important to assess
the cytotoxicity and proliferation of cell lines in vitro prior to performing any animal
studies. We hypothesize that RVG-targeted exosomes from HiPSC-derived DCs will not
be toxic to or alter the proliferation of in vitro cell cultures.
Experimental Design: Using Neuro2a (murine neuronal cells) and C2C12 (murine
muscle cells) cell lines, we will perform a Trypan Blue exclusion viability assay and an
MTT cell toxicity and proliferation assay to determine the cytotoxicity of catalase alone
and RVG-targeted and normal exosomes loaded with catalase. Furthermore, we will use
the same two cell lines to perform a mixed lymphocyte reaction using CD3+ T cell
proliferation to determine the immunogenicity of catalase alone and the RVG-targeted
and normal exosomes loaded with catalase.
Expected Outcomes: As previously mentioned, exosomes have demonstrated
hypo-immunogenic qualities and specifically, RVG-targeted exosomes have shown low
immunogenicity in mice.8, 51 Specifically, Trypan Blue exclusion can be used to
determine cell viability and an MTT assay measures the level of cell metabolic activity,
which can be used to quantify cell viability and proliferation. From these two assays, we
would expect high viability and proliferation of cells treated with RVG-targeted
exosomes loaded with catalase. Furthermore, to assess the immunogenicity of the
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produced catalase loaded exosomes, we will use a mixed lymphocyte reaction using
CD3+ T cell proliferation. After treatment with RVG-targeted exosomes loaded with
catalase, we would expect low T cell proliferation, indicating low immunogenicity.
Potential Pitfalls and Alternatives: Cell viability, proliferation, and
immunogenicity assays are standard and custom procedures for any substance being
introduced as a novel drug or pharmaceutical agent. An exosome DDS, as an engineered
pharmaceutical component, will require cell viability, proliferation, and immunogenicity
assessment. We would not expect significant difficulties performing the assays, as they
are very standard practice and well developed. However, if we find that any assay does
not produce appropriate or sufficient results, we will perform subsequent additional
experiments such as colorimetric tetrazolium assays, luminogenic ATP assays, or DNA
synthesis assays. If we find that RVG-targeted exosomes loaded with catalase generate
unacceptable levels of cell viability, proliferation, or immunogenicity, we will readdress
the engineering and source of the exosomes. We could potentially engineer the exosomes
to be less immunogenic by disrupting beta-2-microglobulin and C2TA genes, which have
been shown to affect MHC-I and MHC-II generation and immunogenicity, using
CRISPR/cas9.57 Cells modified to not express MHC-I and MHC-II molecules will in turn
release exosomes without MHC-I and MHC-II molecules. Both MHC-I and MHC-II are
involved in histocompatibility and immune response of foreign materials. If the MHC
molecule does not match the unique MHC molecules of the host, then an immune
response will be triggered. Removal of the MHC molecules will help increase
histocompatibility and decrease immune response in the host.
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Aim 3.2: Use histology and fluorescence techniques to stain and quantify
inflammation and evaluate biodistribution in Parkinson’s disease model mice brain
sections treated with RVG-targeted exosomes loaded with catalase. Rationale:
Parkinson’s disease and other neurodegenerative diseases are often associated with brain
inflammation in addition to physical and cognitive degeneration.22, 23 Histological and
fluorescent imaging techniques can be used to quantify the amount of inflammation in
brain sections and help determine the level of neurodegeneration in the affected subject.
Treatment with RVG-targeted exosomes loaded with catalase, which aims to eliminate or
reduce ROS in the central nervous system, could reduce the downstream effects of
Parkinson’s disease, including inflammation. Therefore, we hypothesize that RVGtargeted exosomes loaded with catalase will reduce inflammation in Parkinson’s disease
model mice.
Experimental Design: We will use both intranasal (i.n.) and intravenous (i.v.)
injection to assess the effects of RVG-targeted exosomes loaded with catalase on
Parkinson’s disease model mice. All exosome samples will be stained with fluorescent
dye prior to injection to help assess biodistribution using fluorescent microscopy. After
injection with either RVG-targeted catalase exosomes, normal catalase exosomes,
unloaded exosomes, or catalase alone, mice will be sacrificed and perfused at several
time points ranging from 4 to 48 hours. After fixation, mice brains will be sectioned and
prepared for staining. To assess the general cell composition and level of inflammation
we will stain the sections with hematoxylin and eosin (H&E) and observe the tissue using
standard wide-field light microscopy. Additionally, we will perform anti-CD11b
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immunohistochemistry (IHC) to further assess the level of inflammation in the brain
sections.
Expected Outcomes: Given that catalase has previously been shown to reduce
brain inflammation when loaded into exosomes, we would expect the RVG-targeted
exosomes loaded with catalase to achieve similar or better reduction in inflammation and
targeting.6 With H&E staining, we would expect to observe an array of neuronal and
microglial cells in addition to other immune cells. In general, higher concentrations of
immune cells in the tissue indicate greater levels of inflammation. Various amounts of
neutrophils, basophils, eosinophils, monocytes, lymphocytes, or macrophages could help
determine the stage of inflammation, type of inflammation, or other potential causes of
inflammation. For instance, a high level of eosinophils and basophils is typically
associated with anaphylactic reaction.61 CD11b antibody is typically used as a marker for
microglial cells, macrophages, and other granulocytes within nervous tissue.6 We would
expect Immunohistochemistry using CD11b to show moderate, but reduced
concentrations of immune cells and activated microglial cells in mice brain sections with
RVG-targeted catalase exosomes as compared to normal catalase exosomes and untreated
mice.
Potential Pitfalls and Alternatives: H&E and IHC are very common and
established staining techniques, so we don’t expect any significant hurdles. Furthermore,
we work with cell staining and imaging experts that will help improve and expedite the
process. With both imaging techniques, we would expect to see inflammation in the brain
sections. Furthermore, we would expect to see targeted biodistribution of exosomes.
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However, the inflammation may vary depending on the region of the brain that is imaged.
We must be careful to identify and document each region of the brain and compare and
contrast the inflammation. As Parkinson’s disease develops in the substantia nigra, we
may expect higher levels of inflammation in the areas surrounding the substantia nigra. If
H&E or IHC fail to produce accurate or consistent images, then we may consider
immunophenotyping spleen tissue derived from the subject mice to get a sense of the
overall immune reaction to the treatments.
Conclusion
We believe that with further development of exosome isolation via C-CP fibers and HIC
we will be able to create a clinically translatable technique that can be applied to any
number of exosome applications. Further development of this technique, coupled with
development of an allogeneic cell line for exosome isolation, could have a large impact
on the development of an exosome DDS. Many ailments, including cancers and
neurodegenerative diseases, could benefit from more specific and capable drug delivery
system. With the methods we have outlined here, we hope to achieve our goal of
contributing to exosome research and the development of an exosome DDS.

281

Timeline
Aims

Year 1

Year 2

Year 3

1
2
3
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Year 4

Year 5

Vertebrate Animals
The animals and protocols used in this study will be approved by the Clemson University
Institutional Animal Care and Use Committee (IACUC). Clemson University follows
strict guidelines to maintain adherence to the protocols and procedures laid out by the
IACUC. Specific designated areas within the Godley-Snell Research Center will be used
to maintain and treat the mice used in this proposal.
This study will require the use of mice in Aim 3. Both Parkinson’s disease model mice
(Nrf2-) and wild type mice (C57BL) will be used to assess the effects of the developed
DDS. A total of 160 Nrf2- and 160 C57LB mice will be required for completion of this
portion of the study.

Aim 3: Evaluate the effects of RVG-targeted and catalase loaded exosomes on cell
cytotoxicity and brain inflammation in Parkinson’s disease model mice using Intravenous
injection.
Aim 3.2: Use histology and fluorescence techniques to stain and quantify
inflammation and evaluate biodistribution in Parkinson’s disease model mice brain
sections treated with RVG-targeted exosomes loaded with catalase
80 Nrf2- mice for dose inflammation quantification = 5 mice per group x 4 groups
(PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/ catalase
dose) x 4 dosages.
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80 C57LB mice for dose inflammation quantification = 5 mice per group x 4
groups (PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/
catalase dose) x 4 dosages.
80 Nrf2- mice for time point inflammation quantification = 5 mice per group x 4
groups (PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/
catalase dose) x 4 time points.
80 C57LB mice for time point inflammation quantification = 5 mice per group x 4
groups (PBS injection, no treatment, RVG-exosome dose, and RVG-exosome w/
catalase dose) x 4 time points.
Use of a mouse model in exosome research is essential prior to human clinical
trials due to the young age of the potential therapies. Particularly, testing treatment of
RVG-exosomes loaded with catalase will require investigation in a mouse model. Nrf2mice are useful for studying oxidative stress in the pathogenesis of Parkinson’s disease.
All mice will be housed at the Godley-Snell Research Center and handled and cared for
by experienced technicians and veterinarians.
All procedures and experiments on mice will be performed in a manner such as to
minimize discomfort, distress, pain, and injury. All mice exhibiting excessive pain or
discomfort will be euthanized. Euthanasia will be performed by CO2 asphyxiation.
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Biohazards
Engineered or innate exosomes are not known to be infections to humans or
animals. Direct exposure or ingestion of exosome samples may cause mild cellular level
inflammation. All experiments will be performed in a laboratory meeting the biosafety
level 2 requirements.
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Resources and Environment
All fluorescent microscopy equipment and BSL2 lab space will be provided by
the Clemson Light Imaging Facility. Procedures requiring the use of bioreactors and
BSL2 lab space is available through the Clemson department of Bioengineering. The
Clemson Electron Microscopy facility will assist in the staining and gathering of SEM
and TEM images. Finally, all procedures requiring the use of mice will be performed at
the Godley Snell Research Center, which is a Clemson University approved location for
research using vertebrate animals.
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